WO2016069906A1 - Efficient delivery of therapeutic molecules to cells of the inner ear - Google Patents
Efficient delivery of therapeutic molecules to cells of the inner ear Download PDFInfo
- Publication number
- WO2016069906A1 WO2016069906A1 PCT/US2015/058081 US2015058081W WO2016069906A1 WO 2016069906 A1 WO2016069906 A1 WO 2016069906A1 US 2015058081 W US2015058081 W US 2015058081W WO 2016069906 A1 WO2016069906 A1 WO 2016069906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- notch
- myc
- protein
- cells
- Prior art date
Links
- 210000003027 ear inner Anatomy 0.000 title claims abstract description 194
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 456
- 108010070047 Notch Receptors Proteins 0.000 claims abstract description 270
- 102000005650 Notch Receptors Human genes 0.000 claims abstract description 270
- 230000000694 effects Effects 0.000 claims abstract description 176
- 210000002768 hair cell Anatomy 0.000 claims abstract description 175
- 230000008093 supporting effect Effects 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 157
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 238000011282 treatment Methods 0.000 claims abstract description 49
- 230000022131 cell cycle Effects 0.000 claims abstract description 48
- 230000004913 activation Effects 0.000 claims abstract description 18
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 358
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 350
- 102000004169 proteins and genes Human genes 0.000 claims description 300
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 299
- 101800001628 Notch 1 intracellular domain Proteins 0.000 claims description 225
- 102400000552 Notch 1 intracellular domain Human genes 0.000 claims description 225
- 101150039798 MYC gene Proteins 0.000 claims description 208
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 207
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims description 207
- 239000012190 activator Substances 0.000 claims description 85
- 150000007523 nucleic acids Chemical class 0.000 claims description 69
- 229920001184 polypeptide Polymers 0.000 claims description 67
- 101710150912 Myc protein Proteins 0.000 claims description 63
- 239000003795 chemical substances by application Substances 0.000 claims description 61
- 230000035755 proliferation Effects 0.000 claims description 61
- 239000012528 membrane Substances 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 54
- 102000053602 DNA Human genes 0.000 claims description 53
- 206010011878 Deafness Diseases 0.000 claims description 45
- 230000000368 destabilizing effect Effects 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 208000016354 hearing loss disease Diseases 0.000 claims description 44
- 108091034117 Oligonucleotide Proteins 0.000 claims description 43
- 125000000129 anionic group Chemical group 0.000 claims description 41
- 230000000845 anti-microbial effect Effects 0.000 claims description 41
- 239000003112 inhibitor Substances 0.000 claims description 41
- 102000040945 Transcription factor Human genes 0.000 claims description 40
- 108091023040 Transcription factor Proteins 0.000 claims description 40
- 230000001965 increasing effect Effects 0.000 claims description 40
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 238000001727 in vivo Methods 0.000 claims description 39
- 102000040430 polynucleotide Human genes 0.000 claims description 38
- 108091033319 polynucleotide Proteins 0.000 claims description 38
- 229920002477 rna polymer Polymers 0.000 claims description 38
- -1 cationic lipid Chemical class 0.000 claims description 36
- 230000014509 gene expression Effects 0.000 claims description 36
- 238000000338 in vitro Methods 0.000 claims description 36
- 239000005090 green fluorescent protein Substances 0.000 claims description 35
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 34
- 238000013518 transcription Methods 0.000 claims description 34
- 230000035897 transcription Effects 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 230000006870 function Effects 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 231100000888 hearing loss Toxicity 0.000 claims description 23
- 230000010370 hearing loss Effects 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 22
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 21
- 108020004635 Complementary DNA Proteins 0.000 claims description 20
- 238000010804 cDNA synthesis Methods 0.000 claims description 20
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 238000010362 genome editing Methods 0.000 claims description 20
- 239000004599 antimicrobial Substances 0.000 claims description 19
- 231100000895 deafness Toxicity 0.000 claims description 17
- 230000003247 decreasing effect Effects 0.000 claims description 17
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 15
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 15
- 108020001507 fusion proteins Proteins 0.000 claims description 15
- 102000037865 fusion proteins Human genes 0.000 claims description 15
- HKODIGSRFALUTA-RCDLFFMESA-N (1R,4Z,6S,7R,17R)-4-ethylidene-7-hydroxy-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione Chemical compound O1C(=O)C(=C/C)\C[C@H](C)[C@@](C)(O)C(=O)OCC2=CCN3[C@H]2[C@H]1CC3 HKODIGSRFALUTA-RCDLFFMESA-N 0.000 claims description 13
- NYBBAADJGSCXPS-UHFFFAOYSA-N Aurein+ Natural products COC1=C(OC)C(OC)=CC(CC(C)C=2C=C(OC)C(OCC=C)=C(OC)C=2)=C1 NYBBAADJGSCXPS-UHFFFAOYSA-N 0.000 claims description 13
- 229930184528 aurein Natural products 0.000 claims description 13
- 125000002091 cationic group Chemical group 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000001172 regenerating effect Effects 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 10
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 8
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 8
- 108020005004 Guide RNA Proteins 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 108091006106 transcriptional activators Proteins 0.000 claims description 7
- 230000004568 DNA-binding Effects 0.000 claims description 6
- 108010091086 Recombinases Proteins 0.000 claims description 6
- 102000018120 Recombinases Human genes 0.000 claims description 6
- 108091008324 binding proteins Proteins 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 108091006107 transcriptional repressors Proteins 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 230000014511 neuron projection development Effects 0.000 claims description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 230000001323 posttranslational effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 231
- 150000001413 amino acids Chemical group 0.000 description 31
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 210000003477 cochlea Anatomy 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 22
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 20
- 230000001720 vestibular Effects 0.000 description 20
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 18
- 230000008929 regeneration Effects 0.000 description 18
- 238000011069 regeneration method Methods 0.000 description 18
- 241000124008 Mammalia Species 0.000 description 17
- 230000004071 biological effect Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 16
- 238000013459 approach Methods 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 14
- 239000003540 gamma secretase inhibitor Substances 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 230000001953 sensory effect Effects 0.000 description 11
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 10
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 10
- 108091061960 Naked DNA Proteins 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 210000002241 neurite Anatomy 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 230000006727 cell loss Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000001687 destabilization Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 210000001445 inner phalangeal cell Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 102000015735 Beta-catenin Human genes 0.000 description 5
- 108060000903 Beta-catenin Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 210000000243 deiters cell Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000001323 spiral ganglion Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 4
- XCGJIFAKUZNNOR-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]propanoic acid Chemical compound C1CC(CCC(=O)O)CCC1(S(=O)(=O)C=1C=CC(Cl)=CC=1)C1=CC(F)=CC=C1F XCGJIFAKUZNNOR-UHFFFAOYSA-N 0.000 description 4
- IZAOBRWCUGOKNH-OAHLLOKOSA-N 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](C)C=1C(=CC(F)=CC=1)CCCC(O)=O)C1=CC(F)=CC=C1F IZAOBRWCUGOKNH-OAHLLOKOSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 4
- AMDGKLWVCUXONP-UHFFFAOYSA-N 7-amino-4-chloro-3-methoxy-2-benzopyran-1-one Chemical compound NC1=CC=C2C(Cl)=C(OC)OC(=O)C2=C1 AMDGKLWVCUXONP-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 4
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 4
- 101150029234 Hes5 gene Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 4
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000012076 audiometry Methods 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- PKXWXXPNHIWQHW-RCBQFDQVSA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(5S)-3-methyl-4-oxo-2,5-dihydro-1H-3-benzazepin-5-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C2=CC=CC=C21 PKXWXXPNHIWQHW-RCBQFDQVSA-N 0.000 description 3
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 3
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 3
- 208000032041 Hearing impaired Diseases 0.000 description 3
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 208000027601 Inner ear disease Diseases 0.000 description 3
- MURCDOXDAHPNRQ-ZJKZPDEISA-N L-685,458 Chemical compound C([C@@H]([C@H](O)C[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-ZJKZPDEISA-N 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 3
- 108091057508 Myc family Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- OJPLJFIFUQPSJR-INIZCTEOSA-N RO4929097 Chemical compound N1C(=O)[C@@H](NC(=O)C(C)(C(=O)NCC(F)(F)C(F)(F)F)C)C2=CC=CC=C2C2=CC=CC=C21 OJPLJFIFUQPSJR-INIZCTEOSA-N 0.000 description 3
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 108050003627 Wnt Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 210000000262 cochlear duct Anatomy 0.000 description 3
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011977 dual antiplatelet therapy Methods 0.000 description 3
- 210000000883 ear external Anatomy 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000000630 fibrocyte Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003990 interdental cell Anatomy 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002985 organ of corti Anatomy 0.000 description 3
- 231100000199 ototoxic Toxicity 0.000 description 3
- 230000002970 ototoxic effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SVXDHPADAXBMFB-JXMROGBWSA-N (5e)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(CC)=CC=C1\C=C\1C(=O)NC(=S)S/1 SVXDHPADAXBMFB-JXMROGBWSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- RUJZRLFQRAMGNM-UHFFFAOYSA-N 2,4-dibenzyl-3-sulfanylidene-1,2,4-thiadiazolidin-5-one Chemical compound S=C1N(CC=2C=CC=CC=2)C(=O)SN1CC1=CC=CC=C1 RUJZRLFQRAMGNM-UHFFFAOYSA-N 0.000 description 2
- ZRHRPGSSSVYBRG-UHFFFAOYSA-N 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole Chemical compound IC1=CC=CC(CSC=2OC(=NN=2)C=2C=CN=CC=2)=C1 ZRHRPGSSSVYBRG-UHFFFAOYSA-N 0.000 description 2
- KYVDGDMQERQKOY-UHFFFAOYSA-N 2-chloro-1-(4,5-dibromo-2-thiophenyl)ethanone Chemical compound ClCC(=O)C1=CC(Br)=C(Br)S1 KYVDGDMQERQKOY-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- NIYGGGHYMHMOBP-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-(5h-pyrimido[5,4-b]indol-4-yl)pyrazol-3-amine Chemical compound NC1=NN(C=2C=3NC4=CC=CC=C4C=3N=CN=2)C=C1C1=CC=C(Cl)C=C1 NIYGGGHYMHMOBP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 2
- PSXOKXJMVRSARX-SCSAIBSYSA-N 5-chloro-n-[(2s)-4,4,4-trifluoro-1-hydroxy-3-(trifluoromethyl)butan-2-yl]thiophene-2-sulfonamide Chemical compound FC(F)(F)C(C(F)(F)F)[C@@H](CO)NS(=O)(=O)C1=CC=C(Cl)S1 PSXOKXJMVRSARX-SCSAIBSYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- QNOXYUNHIGOWNY-UHFFFAOYSA-N 6,7-dimethoxy-2-phenylquinoxaline Chemical compound N1=C2C=C(OC)C(OC)=CC2=NC=C1C1=CC=CC=C1 QNOXYUNHIGOWNY-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000008122 Casein Kinase I Human genes 0.000 description 2
- 108010049812 Casein Kinase I Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 2
- 108010055179 EphA4 Receptor Proteins 0.000 description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102100031809 Espin Human genes 0.000 description 2
- 101710118108 Espin Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 2
- 101710146275 Hemagglutinin 2 Proteins 0.000 description 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020559 Hyperacusis Diseases 0.000 description 2
- 206010048865 Hypoacusis Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 108700003486 Jagged-1 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 208000008719 Mixed Conductive-Sensorineural Hearing Loss Diseases 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100032702 Protein jagged-1 Human genes 0.000 description 2
- 108700037966 Protein jagged-1 Proteins 0.000 description 2
- 102100032733 Protein jagged-2 Human genes 0.000 description 2
- 101710170213 Protein jagged-2 Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- RNPDUXVFGTULLP-VABKMULXSA-N benzyl n-[(2s)-4-methyl-1-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxohexan-2-yl]amino]pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 RNPDUXVFGTULLP-VABKMULXSA-N 0.000 description 2
- WJQLUFQGNVGLKR-SZMVWBNQSA-N benzyl n-[(2s,3s)-3-methyl-1-[[(2s)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)OCC1=CC=CC=C1 WJQLUFQGNVGLKR-SZMVWBNQSA-N 0.000 description 2
- 108010008526 benzyloxycarbonyl-leucyl-leucyl-norleucinal Proteins 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000238 cell of claudius Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 2
- 210000000860 cochlear nerve Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 210000004307 hair cells vestibular Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012074 hearing test Methods 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000000067 inner hair cell Anatomy 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- XAPDRNSTUYCSQC-SGTLLEGYSA-N methyl (2s)-2-[[(2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]propanoyl]amino]-2-phenylacetate Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 XAPDRNSTUYCSQC-SGTLLEGYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007433 nerve pathway Effects 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 108010058731 nopaline synthase Proteins 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 102000044158 nucleic acid binding protein Human genes 0.000 description 2
- 108700020942 nucleic acid binding protein Proteins 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- VHWJSJBTUWUEAL-UHFFFAOYSA-N propanamide;hydrochloride Chemical compound Cl.CCC(N)=O VHWJSJBTUWUEAL-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002205 spiral ligament of cochlea Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000000645 stria vascularis Anatomy 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 108010061506 tau-protein kinase Proteins 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 208000027491 vestibular disease Diseases 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AEYISOCIPZEJJJ-HRWMIKOJSA-N (2S)-2-fluoro-3-methyl-N-[(2S)-1-[(1-methyl-2-oxo-5-phenyl-3H-azepin-3-yl)amino]-1-oxopropan-2-yl]butanamide Chemical compound F[C@H](C(=O)N[C@@H](C)C(NC1C(N(C=CC(=C1)C1=CC=CC=C1)C)=O)=O)C(C)C AEYISOCIPZEJJJ-HRWMIKOJSA-N 0.000 description 1
- PNICFAZEOPSEKZ-JDLVMGNASA-N (2S)-2-hydroxy-3-methyl-N-[(2S)-1-[(1-methyl-2-oxo-5-propan-2-yl-3H-azepin-3-yl)amino]-1-oxopropan-2-yl]butanamide Chemical compound O[C@H](C(=O)N[C@@H](C)C(NC1C(N(C=CC(=C1)C(C)C)C)=O)=O)C(C)C PNICFAZEOPSEKZ-JDLVMGNASA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- VFCRKLWBYMDAED-REWPJTCUSA-N (2s)-2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-n-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide Chemical compound O=C([C@@H](N[C@@H]1CC2=C(F)C=C(F)C=C2CC1)CCC)NC1=CN(C(C)(C)CNCC(C)(C)C)C=N1 VFCRKLWBYMDAED-REWPJTCUSA-N 0.000 description 1
- OQZBHCUFLVCXCE-ZSOXZCCMSA-N (2s)-2-amino-n-(1-methyl-2-oxo-5-phenyl-3h-azepin-3-yl)propanamide Chemical compound C1=CN(C)C(=O)C(NC(=O)[C@@H](N)C)C=C1C1=CC=CC=C1 OQZBHCUFLVCXCE-ZSOXZCCMSA-N 0.000 description 1
- DPPSUGSPUHMWEH-BYPYZUCNSA-N (2s)-2-fluoro-3-methylbutanoic acid Chemical compound CC(C)[C@H](F)C(O)=O DPPSUGSPUHMWEH-BYPYZUCNSA-N 0.000 description 1
- NAJCWWPWHKQQDL-WBAXXEDZSA-N (2s)-2-hydroxy-3-methyl-n-[(2s)-1-[[(3s)-1-methyl-2-oxo-5-phenyl-3h-azepin-3-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound C1=CN(C)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](O)C(C)C)C=C1C1=CC=CC=C1 NAJCWWPWHKQQDL-WBAXXEDZSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
- JLHWBVQBEGDSEZ-LFOOZZFTSA-N (4s)-5-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-5-amino-1-[[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phosphonooxypropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]p Chemical compound CCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H](C)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](COP(O)(O)=O)C(=O)N2[C@@H](CCC2)C(N)=O)CCC1 JLHWBVQBEGDSEZ-LFOOZZFTSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ATNKUORYLJHRKS-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridine-3-carbonitrile Chemical compound N#CC1CNC=CC1 ATNKUORYLJHRKS-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- GJGROPRLXDXIAN-UHFFFAOYSA-N 1,3-thiazol-4-one Chemical class O=C1CSC=N1 GJGROPRLXDXIAN-UHFFFAOYSA-N 0.000 description 1
- HASUWNAFLUMMFI-UHFFFAOYSA-N 1,7-dihydropyrrolo[2,3-d]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)NC2=C1C=CN2 HASUWNAFLUMMFI-UHFFFAOYSA-N 0.000 description 1
- GBHXISDJTKHBFA-UHFFFAOYSA-N 1-(2-phenylethyl)benzotriazole Chemical compound N1=NC2=CC=CC=C2N1CCC1=CC=CC=C1 GBHXISDJTKHBFA-UHFFFAOYSA-N 0.000 description 1
- RRYJSZIRNLXJPC-UHFFFAOYSA-N 1-(phenylsulfanylmethyl)benzimidazole Chemical compound C1=NC2=CC=CC=C2N1CSC1=CC=CC=C1 RRYJSZIRNLXJPC-UHFFFAOYSA-N 0.000 description 1
- MPPKSGHRQXQDSK-UHFFFAOYSA-N 1-[(2-chlorobenzoyl)amino]-3-(4-fluorophenyl)thiourea Chemical compound C1=CC(F)=CC=C1NC(=S)NNC(=O)C1=CC=CC=C1Cl MPPKSGHRQXQDSK-UHFFFAOYSA-N 0.000 description 1
- BYFBFHALNZEKSR-UHFFFAOYSA-N 1-[(4-methylphenyl)methoxy]-6-nitro-2-phenylbenzimidazole Chemical compound C1=CC(C)=CC=C1CON1C2=CC([N+]([O-])=O)=CC=C2N=C1C1=CC=CC=C1 BYFBFHALNZEKSR-UHFFFAOYSA-N 0.000 description 1
- LBMUGOKSTFDDNF-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)-1-phenylethyl]benzimidazole Chemical compound COC1=CC=C(C=C1)CC(C1=CC=CC=C1)N1C=NC2=C1C=CC=C2 LBMUGOKSTFDDNF-UHFFFAOYSA-N 0.000 description 1
- HOQOBNCJEIGGEO-UHFFFAOYSA-N 1-[3-amino-5-(4-tert-butylphenyl)thiophen-2-yl]ethanone Chemical compound NC1=C(C(=O)C)SC(C=2C=CC(=CC=2)C(C)(C)C)=C1 HOQOBNCJEIGGEO-UHFFFAOYSA-N 0.000 description 1
- LIYLTQQDABRNRX-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(C=2C=C(Cl)C(Cl)=CC=2)C(F)=CC=1C1(C(=O)O)CC1 LIYLTQQDABRNRX-UHFFFAOYSA-N 0.000 description 1
- ZQMZRHDICAIAPU-UHFFFAOYSA-N 2,5-dichloro-n-[(1-methylbenzimidazol-2-yl)methyl]aniline Chemical compound N=1C2=CC=CC=C2N(C)C=1CNC1=CC(Cl)=CC=C1Cl ZQMZRHDICAIAPU-UHFFFAOYSA-N 0.000 description 1
- MICKUPVNNWGVFH-UHFFFAOYSA-N 2,5-dimethyl-n-phenyl-1-(thiophen-2-ylmethyl)pyrrole-3-carboxamide Chemical compound CC=1N(CC=2SC=CC=2)C(C)=CC=1C(=O)NC1=CC=CC=C1 MICKUPVNNWGVFH-UHFFFAOYSA-N 0.000 description 1
- NZZHRBQXFHVPBE-UHFFFAOYSA-N 2-(1,3-benzoxazol-2-ylsulfanyl)-n-(2-chlorophenyl)acetamide Chemical compound ClC1=CC=CC=C1NC(=O)CSC1=NC2=CC=CC=C2O1 NZZHRBQXFHVPBE-UHFFFAOYSA-N 0.000 description 1
- AJYKLFYVMCSPOL-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)quinoxaline Chemical compound C1=C(C)C(C)=CC=C1C1=CN=C(C=CC=C2)C2=N1 AJYKLFYVMCSPOL-UHFFFAOYSA-N 0.000 description 1
- VMJUIVQZAGBLOF-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-2-hydroxyacetamide Chemical compound NC(=O)C(O)C1=CC(F)=CC(F)=C1 VMJUIVQZAGBLOF-UHFFFAOYSA-N 0.000 description 1
- GLNAHCOBHVPDPM-UHFFFAOYSA-N 2-(3-methylphenyl)quinoline Chemical compound CC1=CC=CC(C=2N=C3C=CC=CC3=CC=2)=C1 GLNAHCOBHVPDPM-UHFFFAOYSA-N 0.000 description 1
- CEOFYVGCBDRXCN-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-n-(1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NC1=NC=CS1 CEOFYVGCBDRXCN-UHFFFAOYSA-N 0.000 description 1
- QDLVHIXBWKCXDP-UHFFFAOYSA-N 2-(methylamino)-n-(2-phenylethyl)benzamide Chemical compound CNC1=CC=CC=C1C(=O)NCCC1=CC=CC=C1 QDLVHIXBWKCXDP-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
- MWKOUPJMMYDGLH-UHFFFAOYSA-N 2-[(2-methoxyphenoxy)methyl]-1H-benzimidazole Chemical compound COC1=CC=CC=C1OCC1=NC2=CC=CC=C2N1 MWKOUPJMMYDGLH-UHFFFAOYSA-N 0.000 description 1
- BNZRNEVZOMLBKN-UHFFFAOYSA-N 2-[(2-methylphenoxy)methyl]-1h-benzimidazole Chemical compound CC1=CC=CC=C1OCC1=NC2=CC=CC=C2N1 BNZRNEVZOMLBKN-UHFFFAOYSA-N 0.000 description 1
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 1
- UELQPMYVOWTTFY-UHFFFAOYSA-N 2-[(4-fluorophenoxy)methyl]-1-methylbenzimidazole Chemical compound N=1C2=CC=CC=C2N(C)C=1COC1=CC=C(F)C=C1 UELQPMYVOWTTFY-UHFFFAOYSA-N 0.000 description 1
- PSHBGHWQWXFLKT-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfanyl]-1,3-benzothiazole Chemical compound C1=CC(F)=CC=C1CSC1=NC2=CC=CC=C2S1 PSHBGHWQWXFLKT-UHFFFAOYSA-N 0.000 description 1
- CBDGMLPLXGYCIV-UHFFFAOYSA-N 2-[(4-methylphenyl)methylsulfanyl]-[1,3]oxazolo[4,5-b]pyridine Chemical compound C1=CC(C)=CC=C1CSC1=NC2=NC=CC=C2O1 CBDGMLPLXGYCIV-UHFFFAOYSA-N 0.000 description 1
- RNHMYCVIMDJTRN-UHFFFAOYSA-N 2-[4-(2-methylpropoxy)phenyl]-3-naphthalen-2-yl-1,2-dihydroquinazolin-4-one Chemical compound C1=CC(OCC(C)C)=CC=C1C1N(C=2C=C3C=CC=CC3=CC=2)C(=O)C2=CC=CC=C2N1 RNHMYCVIMDJTRN-UHFFFAOYSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- WRTCBNZTJXPLNV-UHFFFAOYSA-N 2-butoxy-5-phenyl-3h-azepine Chemical compound C1C(OCCCC)=NC=CC(C=2C=CC=CC=2)=C1 WRTCBNZTJXPLNV-UHFFFAOYSA-N 0.000 description 1
- QVEMWYGBLHQEAK-UHFFFAOYSA-N 2-ethylbutanamide Chemical compound CCC(CC)C(N)=O QVEMWYGBLHQEAK-UHFFFAOYSA-N 0.000 description 1
- HLGBFFRWIHAYNE-NNGSBXSVSA-N 2-hydroxy-3-methyl-N-[(2S)-1-[(1-methyl-2-oxo-4-phenyl-3H-azepin-3-yl)amino]-1-oxopropan-2-yl]butanamide Chemical compound OC(C(=O)N[C@@H](C)C(NC1C(N(C=CC=C1C1=CC=CC=C1)C)=O)=O)C(C)C HLGBFFRWIHAYNE-NNGSBXSVSA-N 0.000 description 1
- DPSHJKZKKFYEHL-UHFFFAOYSA-N 2-hydroxypentanamide Chemical class CCCC(O)C(N)=O DPSHJKZKKFYEHL-UHFFFAOYSA-N 0.000 description 1
- PFRYFZZSECNQOL-UHFFFAOYSA-N 2-methyl-4-[(2-methylphenyl)diazenyl]aniline Chemical compound C1=C(N)C(C)=CC(N=NC=2C(=CC=CC=2)C)=C1 PFRYFZZSECNQOL-UHFFFAOYSA-N 0.000 description 1
- YNFSUOFXEVCDTC-UHFFFAOYSA-N 2-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=C2NC=NC2=N1 YNFSUOFXEVCDTC-UHFFFAOYSA-N 0.000 description 1
- CACDYUNTCMPDMI-UHFFFAOYSA-N 2-naphthalen-2-yl-1h-indole Chemical compound C1=CC=CC2=CC(C3=CC4=CC=CC=C4N3)=CC=C21 CACDYUNTCMPDMI-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- PGOGFFNZPDGPGC-UHFFFAOYSA-N 2-phenylbutanoic acid 4-phenylbutanoic acid Chemical compound C1(=CC=CC=C1)CCCC(=O)O.C1(=CC=CC=C1)C(C(=O)O)CC PGOGFFNZPDGPGC-UHFFFAOYSA-N 0.000 description 1
- OLGGLCIDAMICTA-UHFFFAOYSA-N 2-pyridin-2-yl-1h-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=N1 OLGGLCIDAMICTA-UHFFFAOYSA-N 0.000 description 1
- NIPYQLPZPLBOLF-GBLLEDPASA-N 3'-hydroxy-6'-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C3(C4=CC=CC=C4C(=O)O3)C3=CC=C(O)C=C3OC2=C1 NIPYQLPZPLBOLF-GBLLEDPASA-N 0.000 description 1
- JOSXKPZXMVHRKU-UHFFFAOYSA-N 3,5-bis(4-nitrophenoxy)benzoic acid Chemical compound C=1C(OC=2C=CC(=CC=2)[N+]([O-])=O)=CC(C(=O)O)=CC=1OC1=CC=C([N+]([O-])=O)C=C1 JOSXKPZXMVHRKU-UHFFFAOYSA-N 0.000 description 1
- RMHDNTKNCCMULG-UHFFFAOYSA-N 3-(6-methyl-1h-benzimidazol-2-yl)chromen-2-imine Chemical compound C1=CC=C2OC(=N)C(C3=NC4=CC=C(C=C4N3)C)=CC2=C1 RMHDNTKNCCMULG-UHFFFAOYSA-N 0.000 description 1
- VPNIQGRFZCTBEZ-UHFFFAOYSA-N 3-N-[4-(cyclopropylamino)-3-hydroxy-1-phenylbutan-2-yl]-5-[methyl(methylsulfonyl)amino]-1-N-(1-phenylethyl)benzene-1,3-dicarboxamide Chemical compound C=1C=CC=CC=1C(C)NC(=O)C(C=1)=CC(N(C)S(C)(=O)=O)=CC=1C(=O)NC(C(O)CNC1CC1)CC1=CC=CC=C1 VPNIQGRFZCTBEZ-UHFFFAOYSA-N 0.000 description 1
- UXGATWLUBVVVJC-UHFFFAOYSA-N 3-chloro-n-(5-chloropyridin-2-yl)-1-benzothiophene-2-carboxamide Chemical compound S1C2=CC=CC=C2C(Cl)=C1C(=O)NC1=CC=C(Cl)C=N1 UXGATWLUBVVVJC-UHFFFAOYSA-N 0.000 description 1
- WXPHQFQCOBBPIO-UHFFFAOYSA-N 3-chloro-n-(oxolan-2-ylmethyl)-1-benzothiophene-2-carboxamide Chemical compound S1C2=CC=CC=C2C(Cl)=C1C(=O)NCC1CCCO1 WXPHQFQCOBBPIO-UHFFFAOYSA-N 0.000 description 1
- 102220531551 39S ribosomal protein L4, mitochondrial_S12A_mutation Human genes 0.000 description 1
- YBRVSVVVWCFQMG-UHFFFAOYSA-N 4,4'-diaminodiphenylmethane Chemical compound C1=CC(N)=CC=C1CC1=CC=C(N)C=C1 YBRVSVVVWCFQMG-UHFFFAOYSA-N 0.000 description 1
- RZYSPXGJWXYPRK-UHFFFAOYSA-N 4-(4-methoxyphenyl)-n-(3-methylpyridin-2-yl)-1,3-thiazol-2-amine Chemical compound C1=CC(OC)=CC=C1C1=CSC(NC=2C(=CC=CN=2)C)=N1 RZYSPXGJWXYPRK-UHFFFAOYSA-N 0.000 description 1
- HTAUVJPDFDVVHV-UHFFFAOYSA-N 4-(4-phenylphenyl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 HTAUVJPDFDVVHV-UHFFFAOYSA-N 0.000 description 1
- UYYUYDDKLNGZQL-UHFFFAOYSA-N 4-[2-(1-methyl-2-benzimidazolyl)ethyl]aniline Chemical compound N=1C2=CC=CC=C2N(C)C=1CCC1=CC=C(N)C=C1 UYYUYDDKLNGZQL-UHFFFAOYSA-N 0.000 description 1
- LJGMQDMQXJTEGM-UHFFFAOYSA-N 4-bromo-n-(5-chloropyridin-2-yl)benzamide Chemical compound N1=CC(Cl)=CC=C1NC(=O)C1=CC=C(Br)C=C1 LJGMQDMQXJTEGM-UHFFFAOYSA-N 0.000 description 1
- CUJBDMOLECMFKQ-UHFFFAOYSA-N 4-chloro-1-methyl-n-phenacylpyrazole-3-carboxamide Chemical compound CN1C=C(Cl)C(C(=O)NCC(=O)C=2C=CC=CC=2)=N1 CUJBDMOLECMFKQ-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- TWORYSIVMSFUFY-UHFFFAOYSA-N 4-tert-butyl-n-(oxolan-2-ylmethyl)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NCC1OCCC1 TWORYSIVMSFUFY-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- MWZTVVRRGYNIJF-UHFFFAOYSA-N 5-[5-(2,4-difluorophenyl)furan-2-yl]-1-methylsulfonylpyrazole Chemical compound CS(=O)(=O)N1N=CC=C1C1=CC=C(C=2C(=CC(F)=CC=2)F)O1 MWZTVVRRGYNIJF-UHFFFAOYSA-N 0.000 description 1
- UVIBAJPAVLHXIC-UHFFFAOYSA-N 5-chloro-2-phenyl-1,3-benzoxazole Chemical compound N=1C2=CC(Cl)=CC=C2OC=1C1=CC=CC=C1 UVIBAJPAVLHXIC-UHFFFAOYSA-N 0.000 description 1
- ZIYKFNBOSWDWSJ-UHFFFAOYSA-N 5-chloro-n-methyl-1,3-benzothiazol-2-amine Chemical compound ClC1=CC=C2SC(NC)=NC2=C1 ZIYKFNBOSWDWSJ-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- BNIGTUNMSKIXBQ-UHFFFAOYSA-N 5-methyl-2-(3-methylphenyl)-1,3-benzoxazole Chemical compound CC1=CC=CC(C=2OC3=CC=C(C)C=C3N=2)=C1 BNIGTUNMSKIXBQ-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- PLUDYDNNASPOEE-UHFFFAOYSA-N 6-(aziridin-1-yl)-1h-pyrimidin-2-one Chemical compound C1=CNC(=O)N=C1N1CC1 PLUDYDNNASPOEE-UHFFFAOYSA-N 0.000 description 1
- SXQMWXNOYLLRBY-UHFFFAOYSA-N 6-(methylamino)purin-8-one Chemical compound CNC1=NC=NC2=NC(=O)N=C12 SXQMWXNOYLLRBY-UHFFFAOYSA-N 0.000 description 1
- KDIBYEXYKOOOBI-UHFFFAOYSA-N 6-chloro-1-[(2-chlorophenyl)methoxy]-2-(4-methoxyphenyl)benzimidazole Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(Cl)C=C2N1OCC1=CC=CC=C1Cl KDIBYEXYKOOOBI-UHFFFAOYSA-N 0.000 description 1
- VZQOMOTXZJPWTG-UHFFFAOYSA-N 6-chloro-1-[(2-chlorophenyl)methoxy]-2-phenylbenzimidazole Chemical compound C=1C=CC=C(Cl)C=1CON1C2=CC(Cl)=CC=C2N=C1C1=CC=CC=C1 VZQOMOTXZJPWTG-UHFFFAOYSA-N 0.000 description 1
- GGIZNSCZQDNNIP-UHFFFAOYSA-N 6-chloro-1-[(3,5-dimethylphenyl)methoxy]-2-(4-methoxyphenyl)benzimidazole Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(Cl)C=C2N1OCC1=CC(C)=CC(C)=C1 GGIZNSCZQDNNIP-UHFFFAOYSA-N 0.000 description 1
- BFSUBYRXVTYOQI-UHFFFAOYSA-N 6-chloro-2-(4-methoxyphenyl)-1-[(4-methoxyphenyl)methoxy]benzimidazole Chemical compound C1=CC(OC)=CC=C1CON1C2=CC(Cl)=CC=C2N=C1C1=CC=C(OC)C=C1 BFSUBYRXVTYOQI-UHFFFAOYSA-N 0.000 description 1
- MSHNCNCMADMAGG-UHFFFAOYSA-N 6-chloro-2-(4-methoxyphenyl)-1-[(4-methylphenyl)methoxy]benzimidazole Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(Cl)C=C2N1OCC1=CC=C(C)C=C1 MSHNCNCMADMAGG-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- SKQACDXEJFEWQP-UHFFFAOYSA-N 7-[(4-fluorophenyl)methoxy]chromen-2-one Chemical compound C1=CC(F)=CC=C1COC1=CC=C(C=CC(=O)O2)C2=C1 SKQACDXEJFEWQP-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- WMGKBJPKUZMADQ-UHFFFAOYSA-N 7-methoxy-2-(4-methoxyphenyl)spiro[1,10b-dihydropyrazolo[1,5-c][1,3]benzoxazine-5,1'-cyclohexane] Chemical compound C1=CC(OC)=CC=C1C1=NN2C3(CCCCC3)OC3=C(OC)C=CC=C3C2C1 WMGKBJPKUZMADQ-UHFFFAOYSA-N 0.000 description 1
- JETSDIPTVSZMLI-UHFFFAOYSA-N 7-methoxy-5-methyl-2-phenyl-1-benzopyran-4-one Chemical compound C=1C(OC)=CC(C)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 JETSDIPTVSZMLI-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 101710117251 Aurein-1.2 Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100021411 C-terminal-binding protein 2 Human genes 0.000 description 1
- 101710178053 C-terminal-binding protein 2 Proteins 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 108010028326 Calbindin 2 Proteins 0.000 description 1
- 102000016843 Calbindin 2 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000833010 Claudius Species 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
- 206010010280 Conductive deafness Diseases 0.000 description 1
- 108010069156 Connexin 26 Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010011882 Deafness congenital Diseases 0.000 description 1
- 206010011894 Deafness permanent Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102100023721 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 102100023733 Ephrin-B3 Human genes 0.000 description 1
- 108010044085 Ephrin-B3 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000331546 Grubea cochlear Species 0.000 description 1
- 241000644555 Guppy reovirus Species 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000918352 Homo sapiens Coagulation factor XIII A chain Proteins 0.000 description 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101100403718 Homo sapiens MYC gene Proteins 0.000 description 1
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 description 1
- 101000867413 Homo sapiens Segment polarity protein dishevelled homolog DVL-1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000018422 Jagged/Serrate proteins Human genes 0.000 description 1
- 108050007523 Jagged/Serrate proteins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 108700042694 Lhx3 Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710189714 Major cell-binding factor Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 241000122159 Modiolus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 101100443626 Mus musculus Dner gene Proteins 0.000 description 1
- 101100518992 Mus musculus Pax2 gene Proteins 0.000 description 1
- 229940124160 Myc inhibitor Drugs 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- OXODSZPOYQHMPS-UHFFFAOYSA-N N-(5-methyl-3-isoxazolyl)-1,3-benzodioxole-5-carboxamide Chemical compound O1C(C)=CC(NC(=O)C=2C=C3OCOC3=CC=2)=N1 OXODSZPOYQHMPS-UHFFFAOYSA-N 0.000 description 1
- WXVLIIDDWFGYCV-UHFFFAOYSA-N N-benzoylanthranilic acid Chemical compound OC(=O)C1=CC=CC=C1NC(=O)C1=CC=CC=C1 WXVLIIDDWFGYCV-UHFFFAOYSA-N 0.000 description 1
- 108010063250 N-myristoyl-glycyl-lysyl-glutamyl-alanyl-prolyl-prolyl-alanyl-prolyl-prolyl-glutaminyl-phosphoseryl-proline Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 101800000017 Notch 4 intracellular domain Proteins 0.000 description 1
- 102400000544 Notch 4 intracellular domain Human genes 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- UQVKZNNCIHJZLS-UHFFFAOYSA-N PhIP Chemical compound C1=C2N(C)C(N)=NC2=NC=C1C1=CC=CC=C1 UQVKZNNCIHJZLS-UHFFFAOYSA-N 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108050001617 Prestin Proteins 0.000 description 1
- 102000011383 Prestin Human genes 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102100030128 Protein L-Myc Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 101150079271 RPS6 gene Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 102100032758 Segment polarity protein dishevelled homolog DVL-1 Human genes 0.000 description 1
- 102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
- 108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102100029373 Transcription factor ATOH1 Human genes 0.000 description 1
- 101710133186 Transcription factor Atoh1 Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 102000044880 Wnt3A Human genes 0.000 description 1
- 108700013515 Wnt3A Proteins 0.000 description 1
- NGBKFLTYGSREKK-PMACEKPBSA-N Z-Val-Phe-H Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 NGBKFLTYGSREKK-PMACEKPBSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- CZXYTEYPIOIKOG-UHFFFAOYSA-N [3-(4-bromophenyl)-1-phenylpyrazol-4-yl]methanol Chemical compound OCC1=CN(C=2C=CC=CC=2)N=C1C1=CC=C(Br)C=C1 CZXYTEYPIOIKOG-UHFFFAOYSA-N 0.000 description 1
- CVPGDDRZFCAIGF-UHFFFAOYSA-N [5-(4-bromophenyl)-1,2-oxazol-3-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(Br)=CC=C1C1=CC(C(=O)N2CCOCC2)=NO1 CVPGDDRZFCAIGF-UHFFFAOYSA-N 0.000 description 1
- CCARLZYJBQFBOH-UHFFFAOYSA-N [[amino-(3-methylphenyl)methylidene]amino] pyridine-3-carboxylate Chemical compound CC1=CC=CC(C(N)=NOC(=O)C=2C=NC=CC=2)=C1 CCARLZYJBQFBOH-UHFFFAOYSA-N 0.000 description 1
- QARIOAFKWVRWIH-UHFFFAOYSA-N [[amino-(4-bromophenyl)methylidene]amino] furan-2-carboxylate Chemical compound C=1C=C(Br)C=CC=1C(N)=NOC(=O)C1=CC=CO1 QARIOAFKWVRWIH-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- RBLRFRHHEGBJAJ-UHFFFAOYSA-N ac1m3byw Chemical compound C1CCCCC2=C1N=C1SC(C(=O)N)=C(N)C1=C2 RBLRFRHHEGBJAJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- OLUKILHGKRVDCT-UHFFFAOYSA-N alsterpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC([N+](=O)[O-])=CC=C1N2 OLUKILHGKRVDCT-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000002982 auditory neuropathy Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 229950008567 avagacestat Drugs 0.000 description 1
- HYGWNUKOUCZBND-UHFFFAOYSA-N azanide Chemical compound [NH2-] HYGWNUKOUCZBND-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 229950008971 begacestat Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OWCDMRFUFMERMZ-UHFFFAOYSA-N benzenesulfonamide;hydrochloride Chemical compound Cl.NS(=O)(=O)C1=CC=CC=C1 OWCDMRFUFMERMZ-UHFFFAOYSA-N 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- CSKGFHNQMOIAFM-SFTDATJTSA-N benzyl n-[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C(=O)OCC1=CC=CC=C1 CSKGFHNQMOIAFM-SFTDATJTSA-N 0.000 description 1
- RNPDUXVFGTULLP-UHFFFAOYSA-N benzyl n-[4-methyl-1-[[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate Chemical compound CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 RNPDUXVFGTULLP-UHFFFAOYSA-N 0.000 description 1
- 108010079329 benzyloxycarbonyl-isoleucyl-leucinal Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- 229960005539 bryostatin 1 Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 108010007877 calpain inhibitor III Proteins 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- AOHZJKSTSDMBIZ-UHFFFAOYSA-N chembl111433 Chemical compound C1=CC=C2C(=O)C(C3=C(O)NC4=CC=C(C=C43)C)=NC2=C1 AOHZJKSTSDMBIZ-UHFFFAOYSA-N 0.000 description 1
- MPNWPWDNLZRGBV-UHFFFAOYSA-N chembl1561348 Chemical compound OC1=CC(OC)=CC=C1C1=NNC(C=2C=CC=CC=2)=C1 MPNWPWDNLZRGBV-UHFFFAOYSA-N 0.000 description 1
- XMPHNZMDLSUDQI-UHFFFAOYSA-N chembl173682 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC(Br)=CC=C4NC=3O)=NC2=C1 XMPHNZMDLSUDQI-UHFFFAOYSA-N 0.000 description 1
- NKHUILHBYOOZDF-NCOIWELASA-N chembl196215 Chemical compound N1S(=O)(=O)N(CC(F)(F)F)C[C@]21[C@@H]1CC[C@H]2CC2=CC=C(\C=C\CN3CCC(CC3)C(F)(F)F)C=C2C1 NKHUILHBYOOZDF-NCOIWELASA-N 0.000 description 1
- WCCYEJYTLNWYCC-UHFFFAOYSA-N chembl337300 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=C(I)C=C21 WCCYEJYTLNWYCC-UHFFFAOYSA-N 0.000 description 1
- REOGMBVECOGANJ-UHFFFAOYSA-N chembl377740 Chemical compound C1=CC(O)=CC=C1C1=NC2=CC=CC=C2N1 REOGMBVECOGANJ-UHFFFAOYSA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 108010045512 cohesins Proteins 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000023563 conductive hearing loss disease Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 108700041286 delta Proteins 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000013028 emission testing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- UIWYJDYFSGRHKR-AHCXROLUSA-N gadolinium-153 Chemical compound [153Gd] UIWYJDYFSGRHKR-AHCXROLUSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- HBDSHCUSXQATPO-BGBJRWHRSA-N indirubin-3'-monoxime Chemical compound O=C/1NC2=CC=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 HBDSHCUSXQATPO-BGBJRWHRSA-N 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000032575 lytic viral release Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- DINAVFJXFRFCRE-ZXYZSCNASA-N methyl (2s)-2-[[(2s)-2-[[benzyl-[(2r,3s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutyl]carbamoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoate Chemical compound C([C@@H]([C@H](O)CN(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)OC)C(C)C)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 DINAVFJXFRFCRE-ZXYZSCNASA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091056924 miR-124 stem-loop Proteins 0.000 description 1
- 108091042879 miR-326 stem-loop Proteins 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- LCYUOKAAYGHPHR-UHFFFAOYSA-N n'-(2,2,3,3,3-pentafluoropropyl)propanediamide Chemical compound NC(=O)CC(=O)NCC(F)(F)C(F)(F)F LCYUOKAAYGHPHR-UHFFFAOYSA-N 0.000 description 1
- GZCNJTFELNTSAB-UHFFFAOYSA-N n'-(7h-purin-6-yl)hexane-1,6-diamine Chemical compound NCCCCCCNC1=NC=NC2=C1NC=N2 GZCNJTFELNTSAB-UHFFFAOYSA-N 0.000 description 1
- LCURRAIGMWCTJY-UHFFFAOYSA-N n,n-diethyl-5-phenyl-3h-azepin-2-amine Chemical compound C1C(N(CC)CC)=NC=CC(C=2C=CC=CC=2)=C1 LCURRAIGMWCTJY-UHFFFAOYSA-N 0.000 description 1
- MKMPBIAEJINDEO-UHFFFAOYSA-N n,n-diethyl-6-methoxythieno[2,3-b]quinoline-2-carboxamide Chemical compound COC1=CC=C2N=C(SC(C(=O)N(CC)CC)=C3)C3=CC2=C1 MKMPBIAEJINDEO-UHFFFAOYSA-N 0.000 description 1
- IQPSRWPYTFZOCI-UHFFFAOYSA-N n,n-diethyl-6-phenyl-3h-azepin-2-amine Chemical compound C1=CCC(N(CC)CC)=NC=C1C1=CC=CC=C1 IQPSRWPYTFZOCI-UHFFFAOYSA-N 0.000 description 1
- UJDPJWCVFVUTAR-UHFFFAOYSA-N n-(1,3-benzothiazol-2-yl)-2-methylpyrazole-3-carboxamide Chemical compound CN1N=CC=C1C(=O)NC1=NC2=CC=CC=C2S1 UJDPJWCVFVUTAR-UHFFFAOYSA-N 0.000 description 1
- BBENHWDGQNOFKV-UHFFFAOYSA-N n-(2,4-dichlorophenyl)-8-methoxy-2h-chromene-3-carboxamide Chemical compound C1OC=2C(OC)=CC=CC=2C=C1C(=O)NC1=CC=C(Cl)C=C1Cl BBENHWDGQNOFKV-UHFFFAOYSA-N 0.000 description 1
- JFHGEZKEAMGUNV-UHFFFAOYSA-N n-(2,5-dichlorophenyl)-1-ethylpyrazole-3-carboxamide Chemical compound CCN1C=CC(C(=O)NC=2C(=CC=C(Cl)C=2)Cl)=N1 JFHGEZKEAMGUNV-UHFFFAOYSA-N 0.000 description 1
- NLYRDFJCBHZFBC-UHFFFAOYSA-N n-(2-chlorophenyl)-2-(1h-indol-3-yl)-2-oxoacetamide Chemical compound ClC1=CC=CC=C1NC(=O)C(=O)C1=CNC2=CC=CC=C12 NLYRDFJCBHZFBC-UHFFFAOYSA-N 0.000 description 1
- XFLWEBGMTHKYGN-UHFFFAOYSA-N n-(2-methoxyethyl)-5-(4-methylphenyl)pyrimidin-2-amine Chemical compound C1=NC(NCCOC)=NC=C1C1=CC=C(C)C=C1 XFLWEBGMTHKYGN-UHFFFAOYSA-N 0.000 description 1
- KCBJKFUEZACDSD-UHFFFAOYSA-N n-(2-methoxyphenyl)-4-phenyl-1,3-thiazol-2-amine Chemical compound COC1=CC=CC=C1NC1=NC(C=2C=CC=CC=2)=CS1 KCBJKFUEZACDSD-UHFFFAOYSA-N 0.000 description 1
- BEDOWVBPFLCOBB-UHFFFAOYSA-N n-(3-carbamoyl-5,6-dihydro-4h-cyclopenta[b]thiophen-2-yl)-1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)NC3=C(C=4CCCC=4S3)C(=O)N)=CC2=C1 BEDOWVBPFLCOBB-UHFFFAOYSA-N 0.000 description 1
- ZKGTZNMQTBERCA-UHFFFAOYSA-N n-(3-cyanothiophen-2-yl)-4-propan-2-yloxybenzamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NC1=C(C#N)C=CS1 ZKGTZNMQTBERCA-UHFFFAOYSA-N 0.000 description 1
- AXPCHVXFDHPTBW-UHFFFAOYSA-N n-(3-methoxyphenyl)-7h-purin-6-amine Chemical compound COC1=CC=CC(NC=2C=3NC=NC=3N=CN=2)=C1 AXPCHVXFDHPTBW-UHFFFAOYSA-N 0.000 description 1
- FMMITHNLRZRVCC-UHFFFAOYSA-N n-(4-bromo-3-methylphenyl)quinazolin-4-amine Chemical compound C1=C(Br)C(C)=CC(NC=2C3=CC=CC=C3N=CN=2)=C1 FMMITHNLRZRVCC-UHFFFAOYSA-N 0.000 description 1
- QDQOLKXVSCFWKW-UHFFFAOYSA-N n-(4-bromophenyl)-5-propan-2-yl-1,2-oxazole-3-carboxamide Chemical compound O1C(C(C)C)=CC(C(=O)NC=2C=CC(Br)=CC=2)=N1 QDQOLKXVSCFWKW-UHFFFAOYSA-N 0.000 description 1
- SZULKQKLXQZPCZ-UHFFFAOYSA-N n-(4-iodophenyl)furan-2-carboxamide Chemical compound C1=CC(I)=CC=C1NC(=O)C1=CC=CO1 SZULKQKLXQZPCZ-UHFFFAOYSA-N 0.000 description 1
- NSUJCDDALMMGFW-UHFFFAOYSA-N n-(4-methoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=CC=CC=C12 NSUJCDDALMMGFW-UHFFFAOYSA-N 0.000 description 1
- QQYQSNYBWJLLOW-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)thiophene-2-carboxamide Chemical compound N1=CC(Cl)=CC=C1NC(=O)C1=CC=CS1 QQYQSNYBWJLLOW-UHFFFAOYSA-N 0.000 description 1
- FLISPZKWFXOOAI-UHFFFAOYSA-N n-(6-acetamido-1,3-benzothiazol-2-yl)furan-2-carboxamide Chemical compound S1C2=CC(NC(=O)C)=CC=C2N=C1NC(=O)C1=CC=CO1 FLISPZKWFXOOAI-UHFFFAOYSA-N 0.000 description 1
- PBTDVLHIEJPHGQ-UHFFFAOYSA-N n-(6-bromo-1,3-benzothiazol-2-yl)thiophene-2-carboxamide Chemical compound S1C2=CC(Br)=CC=C2N=C1NC(=O)C1=CC=CS1 PBTDVLHIEJPHGQ-UHFFFAOYSA-N 0.000 description 1
- HCSQOCQSLRYMCE-UHFFFAOYSA-N n-(6-fluoro-1,3-benzothiazol-2-yl)-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NC=2SC3=CC(F)=CC=C3N=2)=C1 HCSQOCQSLRYMCE-UHFFFAOYSA-N 0.000 description 1
- OLGMRMJENRKJRP-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 OLGMRMJENRKJRP-UHFFFAOYSA-N 0.000 description 1
- MKKJQCYETACFQM-UHFFFAOYSA-N n-[2-(4-fluorophenoxy)ethyl]thiophene-2-carboxamide Chemical compound C1=CC(F)=CC=C1OCCNC(=O)C1=CC=CS1 MKKJQCYETACFQM-UHFFFAOYSA-N 0.000 description 1
- YIRSNFPPORDIPG-UHFFFAOYSA-N n-[2-[2-(4-fluorophenyl)-2-oxoethyl]sulfanyl-4-oxoquinazolin-3-yl]benzamide Chemical compound C1=CC(F)=CC=C1C(=O)CSC1=NC2=CC=CC=C2C(=O)N1NC(=O)C1=CC=CC=C1 YIRSNFPPORDIPG-UHFFFAOYSA-N 0.000 description 1
- WDZVWDXOIGQJIO-UHFFFAOYSA-N n-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC1=CC=C(F)C(C2(CCC(CC2)NS(=O)(=O)C(F)(F)F)S(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 WDZVWDXOIGQJIO-UHFFFAOYSA-N 0.000 description 1
- RPEWYPOGZDRQLY-UHFFFAOYSA-N n-[5-(5-tert-butyl-2-methylfuran-3-yl)-1h-pyrazol-3-yl]benzamide Chemical compound O1C(C(C)(C)C)=CC(C=2NN=C(NC(=O)C=3C=CC=CC=3)C=2)=C1C RPEWYPOGZDRQLY-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- GTVPOLSIJWJJNY-UHFFFAOYSA-N olomoucine Chemical compound N1=C(NCCO)N=C2N(C)C=NC2=C1NCC1=CC=CC=C1 GTVPOLSIJWJJNY-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 231100000763 ototoxin Toxicity 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- HLEKYJVHEBHTMR-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O.CCCCC(N)=O HLEKYJVHEBHTMR-UHFFFAOYSA-N 0.000 description 1
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 1
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 101150016977 pou4f3 gene Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- WOQIDNWTQOYDLF-RPWUZVMVSA-N quarfloxin Chemical compound CN1CCC[C@H]1CCNC(=O)C(C1=O)=CN2C3=C1C=C(F)C(N1C[C@@H](CC1)C=1N=CC=NC=1)=C3OC1=CC3=CC=CC=C3C=C12 WOQIDNWTQOYDLF-RPWUZVMVSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 210000001079 scala tympani Anatomy 0.000 description 1
- 229950001900 semagacestat Drugs 0.000 description 1
- 210000002480 semicircular canal Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- LFWHFZJPXXOYNR-MFOYZWKCSA-N sulindac sulfide Chemical compound C1=CC(SC)=CC=C1\C=C\1C2=CC=C(F)C=C2C(CC(O)=O)=C/1C LFWHFZJPXXOYNR-MFOYZWKCSA-N 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229950005628 tarenflurbil Drugs 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QOBRBYUDKRECNM-NBFOIZRFSA-N tert-butyl n-[(2s)-1-[(1-methyl-2-oxo-5-propan-2-yl-3h-azepin-3-yl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CC(C)C1=CC(NC(=O)[C@H](C)NC(=O)OC(C)(C)C)C(=O)N(C)C=C1 QOBRBYUDKRECNM-NBFOIZRFSA-N 0.000 description 1
- CUQROTVQPOWJCY-MBIQTGHCSA-N tert-butyl n-[(2s)-1-[(1-methyl-2-oxo-6-phenyl-3h-azepin-3-yl)amino]-1-oxopropan-2-yl]carbamate Chemical compound CN1C(=O)C(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C)C=CC(C=2C=CC=CC=2)=C1 CUQROTVQPOWJCY-MBIQTGHCSA-N 0.000 description 1
- MURCDOXDAHPNRQ-PJRHAEEISA-N tert-butyl n-[(2s,3r,5s)-6-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-PJRHAEEISA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003412 trans-golgi network Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 101150068520 wnt3a gene Proteins 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
Definitions
- the present invention relates to protein therapeutics including compositions, methods of treatment and delivery of the therapeutic molecules for inducing inner ear cells to reenter the cell cycle and to proliferate.
- Hair cells are sensory cells in the cochlea responsible for transduction of sound into an electrical signal.
- the human inner ear contains only about 15,000 hair cells per cochlea at birth, and, although these cells can be lost as a result of various genetic or environmental factors (e.g., noise exposure, ototoxic drug toxicity, viral infection, aging, and genetic defects), the lost or damaged cells cannot be replaced.
- Hair cells also are found in the utricle of the vestibule, an organ which regulates balance. Therefore, hair cell regeneration is an important approach to restoring hearing and vestibular function.
- Supporting cells underlie, at least partially surround, and physically support sensory hair cells within the inner ear.
- Examples of supporting cells include inner rod (pillar cells), outer rod (pillar cells), inner phalangeal cells, outer phalangeal cells (of Deiters), cells of Held, cells of Hensen, cells of Claudius, cells of Boettcher, interdental cells and auditory teeth (of Huschke).
- Transdifferentiation of supporting cells to hair cells by overexpression or activation of Atonal Homolog 1 (Atohl) in supporting cells or by exposure of supporting cells to Atohl agonists is one such approach to generating new hair cells.
- transdifferentiation of supporting cells to hair cells diminishes the existing population of supporting cells, which can impair inner ear function.
- overexpression of Atohl in aged inner ear or flat epithelium, which lacks supporting cells is not sufficient to induce hair cells.
- Other studies of hair cell regeneration have examined cell cycle reentry for hair cells in embryonic or neonatal mice by, for example, blocking Rb 1 and p27kip 1. However similar manipulations in the adult inner ear have not induced cell cycle reentry.
- the hair cells in embryonic and neonatal mice that reenter the cell cycle in general, subsequently die.
- Over 150 types of genetic deafness are due to mutations in genes that affect both hair cells and supporting cells. For example, mutations in Myosin Vila (Myo7a) cause hair cell stereocilia abnormalities that lead to permanent deafness. Mutations in GJB2 (connexin 26) cause damage to supporting cells that lead to the most common form of genetic deafness.
- inner ear non-sensory cells e.g., fibrocytes in the ligament
- inner ear non-sensory cells can be damaged by factors such as noise and aging, which contribute to hearing loss.
- These cell types like many of those in the inner ear, lack the capacity to regenerate spontaneously after damage. Because spontaneous regeneration does not occur in the mammalian inner ear, recovery from hearing loss requires intervention to replace any inner ear cell types that are lost or degenerated. Therefore, there is an ongoing need to regenerate hair and/or supporting cells within the mammalian ear, in particular in the inner ear, to replace those lost, for example, by genetic or environmental factors.
- the regenerated hair and supporting cells may be used to slow the loss of hearing and/or vestibular function and/or partially or fully to restore loss of hearing and/or vestibular function.
- Embodiments of the invention are directed, inter alia, to therapeutic compositions and delivery of these compositions to the inner ear of patients.
- These compositions activate Myc and Notch in inner ear cells, the hair cells and/or supporting cells which results in the induction of hair cell and/or supporting cell proliferation.
- Inhibition of Myc and/or Notch in the supporting cells induces transdifferentiation of supporting cells to hair cells.
- activating Atohl induces transdifferentiation of supporting cells to hair cells.
- the proliferation and the subsequent differentiation of the cell into hair and/or supporting cells can restore or improve hearing and/or vestibular function.
- embodiments of the invention include all cells and cell types associated with hearing and hearing loss, including neural cells, such as for example, neurites.
- a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear.
- a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell,
- the method may also include the step of inhibiting Myc and/or Notch expression or activity after proliferation of the hair or supporting cell to induce differentiation or transdifferentiation of the cell and/or at least one of its daughter cells into a hair cell.
- the method may also further include the step of activating Atohl to induce transdifferentiation of the supporting cells to hair cells.
- the Myc activity in the hair and/or supporting cells is increased by administering an effective amount of Myc protein, Myc peptides or Myc activators linked to supercharged proteins, such as, for example, green fluorescent proteins (s-GFP) or variants thereof.
- s-GFP green fluorescent proteins
- the Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
- Inhibition of Myc and/or Notch can be accomplished through administration of inhibitors or once the activator has degraded over time.
- Activation of Atohl is accomplished by the delivery of Atohl proteins, Atohl peptides, Atohl activators, or combinations thereof, linked to s-GFP or variants thereof.
- a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which activate yc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD), or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear.
- transdifferentiation of inner ear cells comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering after a pre-determined period, inhibitors to inhibit Notch and Myc activity followed by a composition that activates Atohl and induces the transdifferentiation of the supporting cells.
- a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner
- the administration of the Myc and/or Notch inhibitors can be optional.
- the activity can be measured over time based on the half-life (ti/ 2 ) of the protein and the Atohl activator can be administered once the activity of the Myc and/or Notch has decreased to a desired level.
- a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and/or Myc activity; administering a composition comprising activators of Atohl wherein the Atohl composition induces the transdifferentiation of the supporting cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation
- a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering an activator of Atohl, wherein the Atohl activator induces the transdifferentiation of the supporting cells to hair cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell to induce proliferation
- a method of inducing proliferation and transdifferentiation of inner ear cells comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch
- Intracellular domain proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
- a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch
- Intracellular domain proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
- a method of delivering a therapeutic molecule to cells of the inner ear of a patient comprises administering to the inner ear of a patient a chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules.
- the chimeric molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
- gene editing agents include, without limitation: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof.
- the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- Oligonucleotides or polynucleotides comprise: ribonucleic acids ( NA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- the chimeric molecule also comprises a supercharged protein or variants thereof and antimicrobial or membrane destabilizing peptides, for example, aurein, or variants thereof.
- a method of inducing transdifferentiation of inner ear cells comprises contacting an inner ear cell in vitro or in vivo with a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity is decreased or inhibited by a Notch inhibitor, optionally, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
- a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity
- a method of regenerating inner ear cells comprises inducing proliferation or cell cycle reentry of inner ear cells in vitro or in vivo, the method comprising contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells.
- a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (
- a method for protecting and/or treating hearing loss in a patient in need of such treatment comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce neurite growth, proliferation or cell cycle re-entry of inner ear cells, proliferation of hair cells, proliferation of supporting cells, and/or transdifferentiation of supporting cells.
- a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch
- Figures 1A and IB show the in vivo delivery of Cre recombinase to hair cells in the mouse inner ear.
- Figure IB Ten days after (- 30)GFP-Cre delivery,intact espin (Esp)- expressing stereocilia of tdTomato-positive outer hair cells were present (arrow), similar to stereocilia in control cochlea.
- Red tdTomato
- blue DAPI
- Figures 2A-2E show the high efficiency of protein delivery mediated by aurein in the inner ear in vivo. Injection of (+36)GFP-aurein-Cre with different concentrations to Rosa- tdT t mouse cochlea resulted in tdT labeling in cochlear cell types with different efficiencies.
- Figure 2A At 5 ⁇ , tdT labeling was mainly in some IHC and SC.
- Figure 2B At 22.5 ⁇ , tdT labeling was in most IHC and OHC.
- Figure 2C At 50 ⁇ , tdT was seen in most IHC and OHC, as well as a large number of SC. IHC loss was seen under the condition.
- Figure 2D In mice injected with 50 ⁇ (+36)GFP-Cre, very few IHC and HC were labeled with tdT.
- Figure 2E In Opti-MEM injected control mice, no tdT labeling was detected in any inner ear cells. Scale bars: 10 ⁇ .
- Figure 3 shows the high efficiency of aurein mediated protein delivery in the mammalian inner ear. Comparison between different concentrations of (+36)GFP-aurein-Cre and control revealed that extremely high-efficient delivery of functional protein (Cre) with the aurein at 22.5 and 50 ⁇ , respectively.
- FIG 4 is a schematic diagram depicting hair cell regeneration. After inner ear damage that leads to hair cell loss, Myc/NICD are transiently activated in the supporting cells to induce proliferation, followed by transient Atohl activation that results in transdifferentiation from supporting cells to hair cells. Arrows point to two supporting cells that divide and give rise to new hair cells. In the repaired cochlea, the number of hair cells and supporting cells are restored.
- Figure 5 is a graph showing that after aurein-NICD infection in cultured neonatal mouse cochlea, qRT-PCR showed a general increase in expression for all Notch pathways genes including Hesl , Hes5 and Notch.
- Figures 6A-6H show HC regeneration in vivo.
- Figures 6A-6C show that Ad- Atohl infection in adult Atohl -GFP cochlea results in GFP (a readout for Atohl expression) in IHCs (arrows), cells in the IHC region (solid arrowheads) and the OHC region (open
- FIG. 6C Cross section (along the dashed line in Figure 6C) shows GFP in IHC, inner phalangeal cell (arrow) and outer pillar cell (C, arrowhead).
- Figures 6D-6F show that Dox induction and Ad-Atohl infection induced division in adult rtTa/tet-Myc/tet-NICD cochlea in vivo and supernumerary HCs (bracket) in the IHC region.
- D'-F' Cross section along the solid line ( Figure 6F) shows two ectopic HCs (eHC) adjacent to an IHC. D"-F".
- FIG. 6F Cross section along the dashed line (Figure 6F) shows numerous ectopic HCs adjacent to an IHC, some of which are EdU + (eHC). Scale bar: ⁇ .
- Figure 6G shows that Dox+ad- Atohl significantly increased the number of HCs in the IHC region.
- Figure 6H shows that in the limbus region, HCs are regenerated from dividing and non-dividing cells; whereas no HCs are seen in control limbus. Scale bars: ⁇ ⁇ .
- Figures 7A-7I show that sphere formation from adult rtTa/tet-Myc/tet-NICD cochlea treated with Dox for 7 days.
- Figures 7A-7C show spheres from adult cochleas after 2 ( Figure 7A), 4 (Figure 7B) and 7 (Figure 7C) passages.
- Figures 7D-7F show Oct4 labeled undifferentiated spheres (Figure 7D, solid sphere; Figure 7E, hollow sphere), and indication of activation of stem cell gene.
- Phal Phalloidin labels actin.
- Nestin another stem cell gene, labels sphere ( Figure 7F).
- Figures 7G-7I show that under differentiated conditions, Pax2, an early inner ear progenitor gene, is detected in the sphere.
- Myo7a a hair cell marker, stains differentiated sphere cells.
- NF neuroofilament
- pan-Cyt pan-cytokeratin.
- Embodiments of the invention are directed to compositions for the efficient intracellular delivery of therapeutic proteins to the nucleus or cytoplasm, in particular of hair cells and/or supporting cells of the inner ear.
- Conventional methods of protein delivery typically rely on cationic peptides or proteins to facilitate endocytosis, but suffer from low tolerance for serum proteins, poor endosomal escape, and limited in vivo efficacy.
- the reagents embodied herein can potently deliver proteins that are fused to polynucleotides, oligonucleotides, negatively supercharged proteins, that contain natural anionic domains, or that natively bind to anionic nucleic acids.
- the methods and compositions can be used to increase a population of hair cells and/or supporting cells diminished by environmental or genetic factors. Using the methods and compositions described herein, it may be possible to preserve or improve hearing and/or vestibular function in the inner ear.
- genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable.
- the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates.
- the genes or gene products disclosed herein which in some embodiments relate to mammalian nucleic acid and amino acid sequences, are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds.
- the genes, nucleic acid sequences, amino acid sequences, peptides, polypeptides and proteins are human.
- a "chimeric" molecule is one which comprises one or more unrelated types of components or contain two or more chemically distinct regions or domains which can be conjugated to each other, fused, linked, translated, attached via a linker, chemically synthesized, expressed from a nucleic acid sequence, etc.
- a linker for example, an antimicrobial or membrane destabilizing peptide and an unrelated peptide, a peptide and a nucleic acid sequence, a peptide and a detectable label, unrelated peptide sequences, unrelated nucleic acid sequence and the like.
- anionic molecule is one which comprises one or more "anionic" domains which confer an overall net anionic charge to the molecule. Accordingly, the chimeric molecule can be an anionic molecule.
- a “supercharged” molecule is a molecule e.g. peptide, having a positive or negative charge and when it is connected to another molecule confers an overall positive or negative charge to the entire molecule.
- a “membrane destabilizing domain” is one which disrupts a cellular membrane in vitro or in vivo, for example, aurein.
- the term encompasses proteins, peptides, polynucleotides, oligonucleotides, bacterial or viral molecules, antimicrobial peptides, antibacterial molecules, microtubules, synthetic or natural molecules.
- a chimeric molecule embodied herein, further comprises one or more membrane destabilizing domains.
- the terms “associated with,” “conjugated,” “linked,” “attached,” and “tethered,” when used with respect to two or more moieties, means that the moieties or domains are physically associated or connected with one another, either directly or via one or more additional moieties that serves as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions.
- the term “connected” will be used for the sake of brevity and is meant to include all possible methods of physically associating each domain of the chimeric molecule to each other.
- a supercharged protein is typically associated with or connected to a nucleic acid by a mechanism that involves non-covalent binding (e.g., electrostatic interactions).
- a positively charged, supercharged protein is associated with a nucleic acid through electrostatic interactions to form a complex.
- a sufficient number of weaker interactions can provide sufficient stability for moieties to remain physically associated under a variety of different conditions.
- the agent to be delivered is covalently bound to the supercharged protein.
- Notch refers to the Notch family of signaling proteins, which includes Notch 1, Notch 2, Notch 3 and Notch 4, or notch intracellular domain (NICD).
- Notch 1 refers to the Notch family of signaling proteins, which includes Notch 1, Notch 2, Notch 3 and Notch 4, or notch intracellular domain (NICD).
- Notch 1 refers to the Notch family of signaling proteins, which includes Notch 1, Notch 2, Notch 3 and Notch 4, or notch intracellular domain (NICD).
- Notch 1 refers to the Notch family of signaling proteins, which includes Notch 1, Notch 2, Notch 3 and Notch 4, or notch intracellular domain (NICD).
- NBD notch intracellular domain
- transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types.
- Notch family members play a role in a variety of developmental processes by controlling cell fate decisions.
- Notch 1 is cleaved in the trans-Golgi network, and presented on the cell surface as a heterodimer.
- Notch 1 functions as a receptor for membrane bound ligands Jagged 1 , Jagged 2 and Delta 1 to regulate cell-fate determination.
- Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus.
- Notch 1 affects the implementation of differentiation, proliferation and apoptotic programs.
- Myc refers to the Myc family of transcription factors. Myc is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The full length sequence of human Myc appears, for example, in the
- Myc functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. Myc is also known in the art as MYC, v-myc myelocytomatosis viral oncogene homolog (avian),
- transcription factor p64, bHLHe39, MRTL avian myelocytomatosis viral oncogene homolog
- v- myc avian myelocytomatosis viral oncogene homolog myc proto-oncogene protein
- class E basic helix-loop-helix protein 39 myc-related translation/localization regulatory factor
- proto-oncogene Myc and BHLHE39.
- Atohl refers to atonal homolog 1 and family thereof.
- the Atohl belongs to the basic helix-loop-helix (BHLH) family of transcription factors. It activates E-box dependent transcription along with E47.
- BHLH basic helix-loop-helix
- the full-length Atohl appears, for example, in the NCBI protein database under accession no. NC 000004.12. See, also, US Publication Nos. US 20040237127 and US 20110251120.
- green fluorescent protein refers to a protein originally isolated from the jellyfish Aequorea victoria that fluoresces green when exposed to blue light or a derivative of such a protein (e.g., a supercharged version of the protein).
- the amino acid sequence of wild type GFP is as follows: (SEQ ID NO: 1) MSKGEELFTG
- Proteins that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to SEQ ID NO: 1 are also considered to be green fluorescent proteins.
- the green fluorescent protein is supercharged.
- the green fluorescent protein is superpositively charged (e.g., +15 GFP, +25 GFP, and +36 GFP).
- the GFP may be modified to include a polyhistidine tag for ease in purification of the protein.
- the GFP may be fused with another protein or peptide (e.g., hemagglutinin 2 (HA2) peptide).
- the GFP may be further modified biologically or chemically (e.g., post-translational modifications, proteolysis, etc.).
- peptide As used herein, unless otherwise indicated, the terms “peptide”, “polypeptide” or “protein” are used interchangeably herein, and refer to a polymer of amino acids of varying sizes. These terms do not connote a specific length of a polymer of amino acids. Thus, for example, the terms oligopeptide, protein, and enzyme are included within the definition of polypeptide or peptide, whether produced using recombinant techniques, chemical or enzymatic synthesis, or be naturally occurring. This term also includes polypeptides that have been modified or derivatized, such as by glycosylation, acetylation, phosphorylation, and the like.
- nucleic acid or “nucleic acid sequence” or “cDNA” refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in a genome in which it naturally occurs, and refers to nucleic acid sequences in which one or more introns have been removed.
- nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, e.g., RNA or DNA or proteins, which naturally accompany it in the cell.
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA, for instance, DNA which is part of a hybrid gene encoding additional polypeptide sequences.
- a “polynucleotide” means a single strand or parallel and anti-parallel strands of a nucleic acid.
- a polynucleotide may be either a single-stranded or a double-stranded nucleic acid.
- variant when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, “allelic,” “splice,” “species,” or “polymorphic” variants.
- a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing.
- the corresponding polypeptide may possess additional functional domains or an absence of domains.
- Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention are variants of wild type gene products. Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
- nucleic acid sequence As used herein, the terms “nucleic acid sequence”, “polynucleotide,” and “gene” are used interchangeably throughout the specification and include complementary DNA (cDNA), linear or circular oligomers or polymers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioate, methylphosphonate, and the like.
- the nucleic acid sequences may be "chimeric” that is, composed of different regions.
- chimeric compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc.
- Each chemical region is made up of at least one monomer unit, i.e., a nucleotide.
- sequences typically comprise at least one region wherein the sequence is modified in order to exhibit one or more desired properties.
- target nucleic acid refers to a nucleic acid (often derived from a biological sample), to which the oligonucleotide is designed to specifically hybridize. It is either the presence or absence of the target nucleic acid that is to be detected, or the amount of the target nucleic acid that is to be quantified.
- the target nucleic acid has a sequence that is complementary to the nucleic acid sequence of the corresponding oligonucleotide directed to the target.
- target nucleic acid may refer to the specific subsequence of a larger nucleic acid to which the oligonucleotide is directed or to the overall sequence (e.g., gene or mRNA) whose expression level it is desired to detect. The difference in usage will be apparent from context.
- nucleobase covers naturally occurring nucleobases as well as non-naturally occurring nucleobases. It should be clear to the person skilled in the art that various nucleobases which previously have been considered “non-naturally occurring” have subsequently been found in nature. Thus, “nucleobase” includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof.
- nucleobases are adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)- alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4- triazolopyridin, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleobases described in Benner et al, U.S.
- nucleobase is intended to cover every and all of these examples as well as analogues and tautomers thereof.
- Especially interesting nucleobases are adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleobases in relation to therapeutic and diagnostic application in humans.
- nucleoside includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl forms, e.g., as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).
- nucleosides in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., described generally by Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Freier & Altmann, Nucl. Acid. Res., 1997, 25(22), 4429-4443, Toulme, J.J., Nature Biotechnology 19: 17-18 (2001); Manoharan M., Biochemica et Biophysica Acta 1489: 1 17-139(1999); Freier S. M., Nucleic Acid Research, 25:4429-4443 (1997), Uhlman, E., Drug Discovery & Development, 3: 203-213 (2000),
- bicycloarabinonucleosides see e.g. N.K Christiensen., et al, J. Am. Chem. Soc, 120: 5458-5463 (1998).
- Such analogs include synthetic nucleosides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.
- variants when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic,” “splice,” “species,” or “polymorphic” variants.
- a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing.
- the corresponding polypeptide may possess additional functional domains or an absence of domains.
- Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention are variants of wild type target gene products.
- Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
- a polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs,) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population with a propensity for a disease state, that is susceptibility versus resistance.
- SNPs single nucleotide polymorphisms
- variant of polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues.
- the variant may have "conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative” changes (e.g., replacement of glycine with tryptophan).
- Analogous minor variations may also include amino acid deletions or insertions, or both.
- Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).
- Treatment is an intervention performed with the intention of preventing the development or altering the pathology or symptoms of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures. “Treatment” may also be specified as palliative care. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
- treating or “treatment” of a state, disorder or condition includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human or other mammal that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof; or (3) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
- the benefit to an individual to be treated is either statistically significant or at least perceptible to the patient or to the physician.
- patient or “individual” or “subject” are used interchangeably herein, and refers to a mammalian subject to be treated, with human patients being preferred.
- methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
- a "therapeutically effective" amount of a compound or agent means an amount sufficient to produce a therapeutically (e.g., clinically) desirable result, for example, induce cell cycle reentry and/or proliferation of the cells of the inner ear (e.g., a hair cell or a supporting cell).
- the cells are contacted with amounts of the active agent effective to induce cell cycle reentry and/or proliferation and/or transdifferentiation of supporting cells to hair cells.
- the compositions can be administered from one or more times per day to one or more times per week; including once every other day.
- treatment of a subject with a therapeutically effective amount of the compounds of the invention can include a single treatment or a series of treatments.
- an "effective" amount of a compound or agent means an amount sufficient to produce a (e.g., clinically) desirable result.
- a "pharmaceutically acceptable" component/carrier etc. is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- determining means determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assessing may be relative or absolute. “Assessing the presence of includes determining the amount of something present, as well as determining whether it is present or absent.
- agent is meant to encompass any molecule, chemical entity, composition, drug, therapeutic agent, chemotherapeutic agent, or biological agent capable of preventing, ameliorating, or treating a disease or other medical condition.
- the term includes small molecule compounds, antisense reagents, siRNA reagents, antibodies, enzymes, peptides organic or inorganic molecules, natural or synthetic compounds and the like.
- An agent can be assayed in accordance with the methods of the invention at any stage during clinical trials, during pre-trial testing, or following FDA-approval.
- modulate it is meant that any of the mentioned activities, are, e.g., increased, enhanced, increased, agonized (acts as an agonist), promoted, decreased, reduced, suppressed blocked, or antagonized (acts as an agonist).
- Modulation can increase activity more than 1 -fold, 2-fold, 3-fold, 5-fold, 10-fold, 100-fold, etc., over baseline values. Modulation can also decrease its activity below baseline values. Modulation can also normalize an activity to a baseline value.
- Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds., Academic Press 1995); Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture.” Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998). Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, Sigma- Aldrich, and ClonTech.
- Supercharged proteins can be produced by changing non-conserved amino acids on the surface of a protein to more polar or charged amino acid residues.
- the amino acid residues to be modified may be hydrophobic, hydrophilic, charged, or a combination thereof.
- Supercharged proteins can also be produced by the attachment of charged moieties to the protein in order to supercharge the protein.
- Supercharged proteins frequently are resistant to aggregation, have an increased ability to refold, resist improper folding, have improved solubility, and are generally more stable under a wide range of conditions, including denaturing conditions such as heat or the presence of a detergent. Any protein may be modified using the inventive system to produce a supercharged protein. Natural as well as unnatural proteins (e.g., engineered proteins) may be modified.
- proteins that may be modified include receptors, membrane bound proteins, transmembrane proteins, enzymes, transcription factors, extracellular proteins, therapeutic proteins, cytokines, messenger proteins, DNA-binding proteins, RNA-binding proteins, proteins involved in signal transduction, structural proteins, cytoplasmic proteins, nuclear proteins, hydrophobic proteins, hydrophilic proteins, etc.
- a protein to be modified may be derived from any species of plant, animal, and/or microorganism.
- the protein is a mammalian protein.
- the protein is a human protein.
- the protein is derived from an organism typically used in research.
- the protein to be modified may be from a primate (e.g., ape, monkey), rodent (e.g., rabbit, hamster, gerbil), pig, dog, cat, fish (e.g., Danio rerio), nematode (e.g., C. elegans), yeast (e.g., Saccharomyces cerevisiae), or bacteria (e.g., E. coli).
- a primate e.g., ape, monkey
- rodent e.g., rabbit, hamster, gerbil
- pig e.g., dog, cat
- fish e.g., Danio rerio
- nematode e.g., C. elegans
- yeast e.g., Saccharomyces cerevisiae
- bacteria e.g., E. coli
- the protein does not have inherent biological activity or has been modified to have no biological activity. In certain embodiments, the protein is chosen based on its targeting ability. In certain embodiments, the protein is green fluorescent protein.
- compositions embodied herein, activate Myc and Notch in inner ear cells, such as, hair cells and/or supporting cells which results in the induction of hair cell and/or supporting cell proliferation.
- compositions activating Atohl induces
- transdifferentiation of supporting cells to hair cells The proliferation and the subsequent differentiation of the cell into hair and/or supporting cells can restore or improve hearing and/or vestibular function.
- Hair cells are inner ear sensory cells, including inner hair cells, outer hair cells, and vestibular hair cells.
- Supporting cells include Deiters cells, Hensen cells, Pillar cells, inner phalangeal cells, inner border cells, Claudius cells, border cells, basal cells, interdental cells, inner sulcus, spiral limbus.
- compositions for gene editing of cells of the inner ear are the hair cells and supporting cells.
- the compositions, embodied herein, modulate various pathways and associated molecules which contribute to deafness or disorders thereof, in hair cells and supporting cells.
- Hair cells are inner ear sensory cells, including inner hair cells, outer hair cells, and vestibular hair cells.
- Supporting cells include Deiters cells, Hensen cells, Pillar cells, inner phalangeal cells, inner border cells, Claudius cells, border cells, basal cells, interdental cells, inner sulcus, spiral limbus.
- Hearing loss affects a large portion of population yet no treatment is available beyond hearing aids and cochlear implant, both of which provide limited benefits.
- US alone over 30 million people suffer from hearing loss.
- the major cause of hearing loss in humans is due to irreversible loss of the inner ear sensory cells, hair cells, which are responsible for detecting sounds and sensing balance. As the result, regeneration of hair cells has become a focus aiming at developing potential therapy for hearing loss.
- Further hearing loss can be caused by defective cell types in the inner ear such as strial vascularis and supporting cells, neurites, or any cell type associated with deafness or associated disorders thereof, whose regeneration could lead to restoration of hearing.
- embodiments are directed to protein-mediated delivery systems to deliver the biological proteins directly to inner ear cell types with functional consequences.
- the proteins delivered have specific functions, and the effect is transient.
- delivery of native protein lessens any potential immune response.
- Such an approach would not only be valuable for inner ear delivery, but has far reaching effects on the delivery of proteins targeting different diseases, achieving specific effects in multiple organs and cell types.
- proteins need to enter cells with sufficient amounts, and are released from endosomes within cells and reach the targets. Improvement in the endosome release could have drastic effects on the amount of protein to reach the target with enhanced biological effect.
- Antimicrobial or membrane destabilizing peptides for example, Aurein, combination with s-GFP, can serve as an effective carrier to deliver functional proteins into mouse inner ear cell types with high efficiency.
- High-efficiency delivery of functional proteins in the inner ear has tremendous advantage over conventional systems, including (1). It allows the delivery of unlimited combinations of proteins to mammalian inner ear without limitations on the size or localization of proteins delivered; (2). The effect will be specific; (3). The effect will be transient as delivered proteins will be degraded over time, which allows the modification of proteins (e.g., to reduce the response to degradation pathway) and controls the time length of function.
- the delivery system can be used to study protein functions, inner ear regeneration for hearing recovery, hearing protection, and gene editing to correct genetic deafness by genome- editing proteins.
- a chimeric molecule comprises at least one protein or peptide fused, complexed or linked to one or more anionic molecules, wherein the one or more anionic molecules comprise one or more anionic domains or bind to an anionic nucleic acid domain.
- the chimeric molecule comprises an overall net negative charge.
- the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- RNA ribonucleic acids
- DNA deoxyribonucleic acids
- synthetic RNA or DNA sequences modified RNA or DNA sequences
- complementary DNA cDNA
- sgRNA short guide RNA
- interference RNA mRNA
- nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- the chimeric molecules are cationic, anionic or are neutrally charged.
- the one or more proteins or peptides are cationic, anionic or are neutrally charged.
- the proteins or peptides comprise: antimicrobial or membrane destabilizing peptides, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- a chimeric molecule comprises: a supercharged protein, an antimicrobial or membrane destabilizing peptide, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- a chimeric molecule comprises at least one supercharged protein linked to at least one antimicrobial or membrane destabilizing peptide, and Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- the chimeric molecule comprises a supercharged molecule connected to a membrane destabilization domain which in turn is connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- Myc protein or peptides Myc modulators
- Notch protein or peptides Notch Intracellular domain (NICD) proteins or peptides
- Atonal Homolog 1 (Atohl) Atonal Homolog 1 (Atohl)
- Atohl modulators transcription factors
- transcription modulators or combinations thereof.
- the chimeric molecule comprises one or more membrane destabilization domains connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- the chimeric molecule comprises a membrane destabilization domain connected to a supercharged molecule which in turn is connected to one or more Myc proteins or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- Myc proteins or peptides Myc modulators
- Notch protein or peptides Notch Intracellular domain (NICD) proteins or peptides
- Atonal Homolog 1 (Atohl) Atonal Homolog 1 (Atohl)
- Atohl modulators Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- the chimeric molecule comprises a membrane destabilization domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which are connected to a supercharged molecule.
- Myc protein or peptides Myc modulators
- Notch protein or peptides Notch Intracellular domain (NICD) proteins or peptides
- NBD Notch Intracellular domain
- Atonal Homolog 1 (Atohl) Atonal Homolog 1
- Atohl modulators Atohl modulators
- transcription factors transcription modulators, or combinations thereof, which are connected to a supercharged molecule.
- the letter “S” represents the supercharged domain
- the letter “M” represents the antimicrobial or membrane destabilizing domain
- the letter “X” represents the therapeutic molecules such as, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- the molecular structure of the molecule can be S-M-X, or M-X-X, or S- M-M-X, or S-S-M-M-X, etc. In those cases where there are two or more molecules that comprise a domain (e.g. a membrane destabilization domain), these domains can comprise different molecules or they can be the same molecule.
- the compositions comprise a supercharged protein linked to antimicrobial or membrane destabilizing peptides, for example, aurein, mutants or variants thereof (e.g. (GLFDIIKKIAESF; SEQ ID NO: 2).
- Membrane destabilization peptides are known in the art. See, for example, Fernandez, D. I. et al., Biochim. Biophys. Acta, 2009 Aug; 1788(8): 1630-8.
- D4A GLFAIIKKIAESF (SEQ ID NO: 6)
- a membrane destabilizing domain comprises one or more of: antimicrobial or membrane destabilizing proteins or peptides, polynucleotides, oligonucleotides, bacterial or viral (e.g. reo virus outer capsid protein or peptide, ⁇ ; papilloma virus capsid protein or peptide L2; etc.), antibacterial molecules, antimicrobial peptides, microtubules, lipids, synthetic or natural molecules, or combinations thereof.
- Antimicrobial peptides (AMPs) are a class of membrane-active peptides that penetrate microbial membranes to provide defense against bacteria, fungi, and viruses, often with high selectivity (Zasloff, M. Nature 2002, 415, 389). Table 2 shows non-limiting examples of antimicrobial peptides. Table 2. List of peptides from the Antimicrobial Peptide Database (APD)
- a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising an antimicrobial or membrane destabilizing domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a
- the method may also include the step of inhibiting Myc and/or Notch activity after proliferation of the inner ear cells, such as, strial vascularis, hair or supporting cell to induce differentiation or transdifferentiation of the cell and/or at least one of its daughter cells into a hair cell.
- the method may also further include the step of activating Atohl to induce transdifferentiation of the supporting cells to hair cells.
- the Myc activity in the hair and/or supporting cells is increased by administering an effective amount of Myc protein, Myc peptides or Myc activators linked to supercharged proteins, such as, for example, green fluorescent proteins (s-GFP) or variants thereof.
- s-GFP green fluorescent proteins
- the Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
- Inhibition of Myc and/or Notch can be accomplished through administration of inhibitors or once the activator has degraded over time.
- Activation of Atohl is accomplished by the delivery of Atohl proteins, Atohl peptides, Atohl activators, or combinations thereof, linked to s-GFP or variants thereof.
- a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising an antimicrobial or membrane destabilizing domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear.
- a composition comprising
- the supercharged protein comprises green fluorescent protein (s-GFP) linked to one or more proteins or peptides, or modified variants thereof, comprising: Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Protein Atonal Homolog 1 (Atohl), transcription factors, transcription modulators, or combinations thereof.
- s-GFP green fluorescent protein
- MBD Notch Intracellular domain
- Atohl Protein Atonal Homolog 1
- transcription modulators or combinations thereof.
- these supercharged proteins further comprise antimicrobial or membrane destabilizing peptides, for example, aurein, or variants thereof linked to the GFP or variants thereof.
- the activation of Myc and/or Notch activity induces proliferation of the inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear. Furthermore, inhibition of Myc activity, Notch activity, NICD activity or combinations thereof, in supporting cells induces transdifferentiation of the supporting cells into functional hair cells.
- a composition comprising activators of Atohl is administered to the inner ear, wherein activation of Atohl induces
- Myc activity is increased by administering an effective amount of Myc protein
- Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
- Notch protein Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
- a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising one or more proteins, peptides or variants thereof, which activate Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD), or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear.
- the method further comprises contacting the supporting cells with a composition comprising Atohl modulators or variants thereof, wherein the Atohl modulates induce transdifferentiation of the supporting cells into functional hair cells.
- the Atohl composition comprises a supercharged protein linked to one or polypeptides or variants thereof comprising: antimicrobial or membrane destabilizing peptides, aurein, Atohl proteins, Atohl peptides, activators of Atohl, variants or combinations thereof.
- the Atohl composition comprises a vector encoding for Atohl proteins, Atohl peptides, Atohl activators, variants or combinations thereof.
- the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- transdifferentiation of inner ear cells comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering a composition which activates Atohl in the supporting cells, inducing the transdifferentiation of the supporting cells to hair cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity
- the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide
- the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof
- a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering an activator of Atohl, wherein the Atohl activator induces the transdifferentiation of the supporting cells to hair cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell,
- the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
- a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide
- the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof
- transdifferentiation of inner ear cells comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial
- a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
- a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell to induce proliferation or cell cycle
- a method of delivering a therapeutic molecule to cells of an inner ear of a patient comprising: administering to the inner ear of a patient a chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules.
- the cells or the inner ear comprise hair cells, supporting cells, or
- the chimeric molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
- the gene editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof.
- the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- RNA ribonucleic acids
- DNA deoxyribonucleic acids
- synthetic RNA or DNA sequences modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- cDNA complementary DNA
- sgRNA short guide RNA
- interference RNA mRNA
- nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- the chimeric molecule further comprises a supercharged protein or variants thereof, such as, for example, a fluorescent protein, or variants thereof.
- the chimeric molecule comprises
- the chimeric molecule is encapsulated in a cationic lipid formulation.
- a method of inducing transdifferentiation of inner ear cells comprises contacting an inner ear cell in vitro or in vivo with a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity is decreased or inhibited by a Notch inhibitor, optionally, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
- a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity
- a method of regenerating inner ear cells comprises inducing proliferation or cell cycle reentry of inner ear cells in vitro or in vivo, the method comprising contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells.
- a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD)
- a method protecting and/or treating hearing loss in a patient in need of such treatment comprising: contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce neurite growth, proliferation or cell cycle re-entry of inner ear cells, proliferation of hair cells, proliferation of supporting cells, and/or transdifferentiation of supporting cells.
- a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular
- Myc and/or Notch activity may be inhibited according to methods known in the art and/or described herein to cause proliferating supporting cells to transdifferentiate into hair cells.
- Atohl activity can be increased to cause proliferating supporting cells to transdifferentiate into hair cells.
- Atohl activity can be increased according to the compositions embodied herein, or, in conjunction with or alternatively with the use of one or more conventional compounds or methods of increasing Atohl activity (including use of Atohl agonists) known in the art (see, for example, U.S. Patent No. 8, 188, 131 ; U.S. Patent Publication No. 201 10305674; U.S. Patent Publication No.
- Notch activity is decreased in a cell that originated from a supporting cell to cause the supporting cell to transdifferentiate into a hair cell.
- Atohl activity is increased in a cell that originated from a supporting cell to cause the supporting cell to transdifferentiate into a hair cell.
- Myc activity is decreased to induce differentiation of at least one of the cell and the daughter cell to produce a differentiated cochlear or utricular hair cell.
- Activation of Myc/NICD increases the response of supporting cells to Atohl to transdifferentiate to hair cells, without proliferation or cell cycle re-entry.
- Myc NICD activation both dividing and non- dividing supporting cells can transdifferentiate to hair cells in response to Atohl overexpression or Notch inhibition by gamma-secretase inhibitor.
- the method comprises increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within a hair cell and/or a supporting cell of the inner ear thereby to induce cell proliferation to produce daughter cells, and, after cell proliferation, decreasing Myc and/or Notch activity, and administering a composition embodied herein, comprising Atohl activators to induce daughter cells of hair cell origin to differentiate into hair cells or permitting daughter cells of supporting cell origin to transdifferentiate into hair cells thereby to reduce the loss of, maintain or promote hearing in the subject.
- the daughter cells of supporting cell origin can be induced to transdifferentiate into hair cells by activating Atohl activity, for example, by gene expression, by administration of an effective amount of Atohl or an Atohl agonist.
- the steps can be performed in vivo (for example, in the inner ear of a mammal, in particular in the cochlea), or ex vivo, wherein the resulting cells are cultured and/or introduced into the inner ear of the subject. Also disclosed is a method for reducing the loss of, maintaining, or promoting vestibular function in a subject.
- the method comprises increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within a hair cell and/or a supporting cell of the inner ear thereby to induce cell proliferation to produce daughter cells, and, after cell proliferation, decreasing Myc and/or Notch activity, and permitting daughter cells of hair cell origin to differentiate into hair cells or permitting daughter cells of supporting cell origin to transdifferentiate into hair cells thereby to reduce the loss of, maintain or promote vestibular function in the subject.
- the daughter cells of supporting cell origin can be induced to transdifferentiate into hair cells by activating Atohl activity, for example, by gene expression, by administration of an effective amount of Atohl or an Atohl agonist.
- the steps can be performed in vivo (for example, in the inner ear of a mammal, in particular in the utricle), or ex vivo, wherein the resulting cells are cultured and/or introduced into the inner ear of the subject.
- the methods and compositions described herein can be used for treating subjects who have, or who are at risk for developing, an auditory disorder resulting from a loss of auditory hair cells, e.g., sensorineural hair cell loss.
- Patients having an auditory disorder can be identified using standard hearing tests known in the art.
- the method can comprise (a) increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within the hair cell of the subject thereby to induce cell proliferation to produce a daughter cell, and (b) after cell proliferation, decreasing Notch activity to induce differentiation of at least one of the cell and the daughter cell to produce a differentiated cochlear or utricular hair cell. This can be accomplished by administering an agent or agents to the subject to modulate Myc and Notch activity.
- the process can occur in cells (e.g. cochlear and/or utricular cells) ex vivo, after which the resulting cells are transplanted into the inner ear of the subject.
- the methods and compositions described herein can be used to promote growth of neurites from the ganglion neurons of the inner ear.
- the regeneration of hair cells may promote the growth of new neurites from ganglion neurons and formation of new synapses with the regenerated hair cells to transmit sound and balance signals from the hair cells to the brain.
- the methods and compositions described herein can be used to promote growth of neurites from the ganglion neurons of the inner ear.
- the regeneration of hair cells may promote the growth of new neurites from ganglion neurons and formation of new synapses with the regenerated hair cells to transmit sound and balance signals from the hair cells to the brain.
- the methods and compositions described herein can be used to reestablish proper synaptic connections between hair cells and auditory neurons to treat, for example, auditory neuropathy.
- Subjects with sensorineural hair cell loss experience the degeneration of cochlea hair cells, which frequently results in the loss of spiral ganglion neurons in regions of hair cell loss. Such subjects may also experience loss of supporting cells in the organ of Corti, and degeneration of the limbus, spiral ligament, and stria vascularis in the temporal bone material.
- the present invention can be used to treat hair cell loss and any disorder that arises as a consequence of cell loss in the ear, such as hearing impairments, deafness, vestibular disorders, tinnitus (see, Kaltenbach et al. (2002) J. Neurophysiol. 88(2):699- 714s), and hyperacusis (Kujawa et al. (2009) J. Neurosci. 29(45): 14077-14085), for example, by promoting differentiation (e.g., complete or partial differentiation) of one or more cells into one or more cells capable of functioning as sensory cells of the ear, e.g., hair cells.
- differentiation e.g., complete or partial differentiation
- the subject can have sensorineural hearing loss, which results from damage or malfunction of the sensory part (the cochlea) or non-sensory part (the limbus, spiral ligament and stria vascularis) or the neural part (the auditory nerve) of the ear, or conductive hearing loss, which is caused by blockage or damage in the outer and/or middle ear.
- the subject can have mixed hearing loss caused by a problem in both the conductive pathway (in the outer or middle ear) and in the nerve pathway (the inner ear).
- An example of a mixed hearing loss is a conductive loss due to a middle-ear infection combined with a sensorineural loss due to damage associated with aging.
- the subject may be deaf or have a hearing loss for any reason, or as a result of any type of event.
- a subject may be deaf because of a genetic or congenital defect; for example, a human subject can have been deaf since birth, or can be deaf or hard-of-hearing as a result of a gradual loss of hearing due to a genetic or congenital defect.
- a human subject can be deaf or hard-of-hearing as a result of a traumatic event, such as a physical trauma to a structure of the ear, or a sudden loud noise, or a prolonged exposure to loud noises.
- a subject can experience chemical-induced ototoxicity, wherein ototoxins include therapeutic drugs including antineoplastic agents, salicylates, quinines, and aminoglycoside antibiotics, contaminants in foods or medicinals, and environmental or industrial pollutants.
- ototoxins include therapeutic drugs including antineoplastic agents, salicylates, quinines, and aminoglycoside antibiotics, contaminants in foods or medicinals, and environmental or industrial pollutants.
- a subject can have a hearing disorder that results from aging.
- the subject can have tinnitus (characterized by ringing in the ears) or hyperacusis (heightened sensitivity to sound).
- vestibular dysfunction is an inner ear dysfunction characterized by symptoms that include dizziness, imbalance, vertigo, nausea, and fuzzy vision and may be accompanied by hearing problems, fatigue and changes in cognitive functioning.
- Vestibular dysfunction can be the result of a genetic or congenital defect; an infection, such as a viral or bacterial infection; or an injury, such as a traumatic or nontraumatic injury.
- Vestibular dysfunction is most commonly tested by measuring individual symptoms of the disorder (e.g., vertigo, nausea, and fuzzy vision).
- compositions described herein can be used prophylactically, such as to prevent, reduce or delay progression of hearing loss, deafness, or other auditory disorders associated with loss of inner ear function.
- a composition containing one or more of the agents can be administered with (e.g., before, after or concurrently with) a second composition, such as an active agent that may affect hearing loss.
- Such ototoxic drugs include the antibiotics neomycin, kanamycin, amikacin, viomycin, gentamycin, tobramycin, erythromycin, vancomycin, and streptomycin; chemotherapeutics such as cisplatin; nonsteroidal anti -inflammatory drugs (NSAIDs) such as choline magnesium trisalicylate, diclofenac, diflunisal, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, salsalate, sulindac, and tolmetin; diuretics; salicylates such as aspirin; and certain malaria treatments such as, quinine and chloroquine.
- NSAIDs nonsteroidal anti -inflammatory drugs
- a human undergoing chemotherapy can be treated using the compounds and methods described herein.
- the chemotherapeutic agent cisplatin for example, is known to cause hearing loss. Therefore, a composition containing one or more agents that increase the activity of Myc and Notch can be administered with cisplatin therapy (e.g., before, after or concurrently with) to prevent or lessen the severity of the cisplatin side effect.
- a composition can be administered before, after and/or simultaneously with the second therapeutic agent.
- the two agents may be administered by different routes of
- the methods and compositions described herein can be used to increase the levels (e.g., protein levels) and/or activity (e.g., biological activity) of Myc and Notch in cells (e.g., inner ear cells).
- Exemplary methods and compositions include, but are not limited to methods and compositions for increasing Myc or Notch expression (e.g., transcription and/or translation) or levels (e.g., concentration) in cells. It is contemplated that such modulation can be achieved in hair cells and/or supporting cells in vivo and ex vivo.
- Myc, Notch, or Atohl Polypeptides It is contemplated that Myc, Notch, and Atohl proteins, including full length proteins, biologically active fragments, and homologs of Myc and Notch can be introduced into target cells using techniques known in the art.
- Exemplary Myc polypeptides include, for example, NP_002458.2, as referenced in the NCBI protein database.
- Exemplary Notch polypeptides include, for example,
- Atohl polypeptides include, for example, NP 005163.1 , as referenced in the NCBI protein database.
- nucleic acid sequences encoding Myc, Notch, and Atohl family members may be used in accordance with the methods described herein.
- Exemplary Myc family members include N-myc, referenced in the NCBI protein database as NP_005369.2.
- Exemplary Notch family members include Notch2, referenced in the NCBI protein database as NP_077719.2; Notcb.3, referenced in the NCBI protein database as NP_000426.2; and Notch4, referenced in the NCBI protein database as NP 004548.3.
- Exemplary Atohl family members include Atoh7, referenced in the NCBI protein database as NP 660161.1.
- a protein sequence of the invention may comprise a consensus protein sequence or a nucleotide sequence encoding a consensus protein sequence.
- Consensus protein sequences of Myc, Notch intracellular domain, and Atohl of the invention are set forth below.
- the Myc, Notch, or Atohl polypeptides can be used in combination with compositions to enhance uptake of the polypeptides into biological cells.
- the Atohl , Myc, or Notch polypeptides can be mutated to include amino acid sequences that enhance uptake of the polypeptides into a biological cell.
- Atohl , Myc, or Notch polypeptides can be altered or mutated to increase the stability and/or activity of the polypeptide (e.g., Myc, Notch or Atohl point mutants).
- Myc, Notch or Atohl polypeptides can be altered to increase nuclear translocation of the polypeptide.
- altered Myc, Notch or Atohl polypeptides or biologically active fragments of Myc, Notch, or Atohl retain at least 50%, 60%, 70%, 80%, 90%, or 95% of the biological activity of full length, wild type respective c-myc, Notch or Atohl protein in the species that is the same species as the subject that is or will be treated with the methods and compositions described herein.
- Myc polypeptides sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP_002458.2.
- Notch polypeptides sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP 060087.3.
- Atohl polypeptides sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP_005163.1.
- agents encoded by modified Atohl , Myc, NICD, or Notch nucleic acid sequences and Atohl , Myc, or Notch polypeptide sequences possess at least a portion of the activity (e.g., biological activity) of the molecules encoded by the corresponding, e.g., unmodified, full-length Atohl , Myc, or Notch nucleic acid sequences and Atohl , Myc, or Notch polypeptide sequences.
- molecules encoded by modified Atohl, Myc, or Notch nucleic acid sequences and modified Atohl , Myc, or Notch polypeptides retain 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the activity (e.g., biological activity) of the molecules encoded by the corresponding, e.g., unmodified, respective Atohl , Myc, or Notch nucleic acid sequences and/or full length Atohl , Myc, or Notch polypeptide sequences.
- the Myc and Notch proteins of the invention can be administered to cells as a single protein containing both Myc and Notch (or active domains thereof), preferably separated by a cleavable linker.
- cleavable linkers are known in the art (see, e.g., U.S. Patent No. 5,258,498 and U.S. Patent No. 6,083,486.)
- Myc, Notch or Atohl levels e.g., protein levels
- activity e.g., biological activity
- target cells and/or in the nucleus of target cells can be assessed using standard methods such as Western Blotting, in situ hybridization, reverse transcriptase polymerase chain reaction, immunocytochemistry, viral titer detection, and genetic reporter assays.
- Increases in Myc, Notch or Atohl levels (e.g., protein levels) and/or activity (e.g., biological activity) in target cells and/or in the nucleus of target cells can be assessed by comparing Myc, Notch or Atohl levels and/or activity in a first cell sample or a standard with Myc, Notch or Atohl levels and/or activity in a second cell sample, e.g., contacting the cell sample with an agent
- Sequence identity may be determined in various ways that are within the skill in the art, e.g., using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software, which are used to perform sequence alignments and then calculate sequence identity.
- Exemplary software programs available from the National Center for Biotechnology Information (NCBl) on the website ncbi.nlm.nih.gov include blastp, blastn, blastx, tblastn and tblastx.
- NCBl National Center for Biotechnology Information
- the search parameters for histogram, descriptions, alignments, expect i.e., the statistical significance threshold for reporting matches against database sequences
- cutoff, matrix and filter are used at the default settings.
- the default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al, (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919).
- the percent identity can be determined using the default parameters of blastp, version 2.2.26 available from the NCBL
- DNA Encoding Atohl, Myc, or Notch can be expressed in target cells using one or more expression constructs known in the art.
- expression constructs include, but are not limited to, naked DNA, viral and non-viral expression vectors.
- Exemplary Myc nucleic acid sequences that may be expressed in target cells include, for example, NM_002467.4, as referenced in the NCBl gene database.
- Exemplary Notch nucleic acid sequences that may be expressed include, for example, NM_017617.3, as referenced in the NCBl gene database.
- Exemplary Atohl nucleic acid sequences that may be expressed in target cells include, for example, NM_005172.1, as referenced in the NCBl gene database.
- Myc, Notch, and Atohl family members may be used.
- Exemplary Myc family members include N-myc, referenced in the NCBl gene database as NM_005378.4.
- Exemplary Notch family members include Notch2, referenced in the NCBl gene database as NM_024408.3; Notch3, referenced in the NCBl gene database as NM_000435.2; and Notch4, referenced in the NCBI gene database as NM 004557.3.
- Exemplary Atohl family members include Atoh7, referenced in the NCBI gene database as NM_145178.3.
- DNA encoding Myc, Notch or Atohl can be an unmodified wild type sequence.
- DNA encoding Myc, Notch or Atohl can be modified using standard techniques.
- DNA encoding Myc, Notch or Atohl can be modified or mutated, e.g., to increase the stability of the DNA or resulting polypeptide.
- DNA encoding Atohl, Myc, or Notch can be altered to increase nuclear translocation of the resulting polypeptide.
- DNA encoding Myc, Notch or Atohl can be modified using standard molecular biological techniques to include an additional DNA sequence that can encode one or more of, e.g., detectable polypeptides, signal peptides, and protease cleavage sites.
- Myc nucleic acid sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_002467.4.
- Notch nucleic acid sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_017617.3.
- Atohl nucleic acid sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_005172.1.
- Myc or Notch levels e.g., protein levels
- activity e.g., biological activity
- inhibiting Notch and activating Atohl comprises suppression of any one or more Notchl targets, such as Hes5 and Hesl , both of which act as antagonists to Atohl .
- Such suppression can be achieved by any conventional means, including, for example, anti-sense oligonucleotides against Hesl and Hes5, or by delivering proteins that suppress Hes function.
- any one or more molecules associated with the pathways of Myc, Notch, Atohl are targeted.
- Atohl levels e.g., protein levels
- activity e.g., biological activity
- compounds that target Atohl or one or more components of the Atohl pathway can be increased using compounds that target Atohl or one or more components of the Atohl pathway.
- Exemplary Myc activators include microRNAs that target FBXW-7 (Ishikawa Y et al, Oncogene 2012 Jun 4; doi: 10.1038/onc.2012.213) and activators that increase Myc expression levels or activity such as nordihydroguaiaretic acid (NDGA) (Park S et al. (2004) J. Cell. Biochem. 91(5):973-86), CD19 (Chung et al, (2012) J. Clin. Invest. 122(6):2257-2266, cohesin (Ewan et al, (2012) PLoS ONE 7(1 1): e 9160), bryostatin 1 (Hu et al. (1993) Leuk.
- NDGA nordihydroguaiaretic acid
- Exemplary Myc inhibitors include 7-nitro-N-(2-phenylphenyl)-2,l,3- benzoxadiazol-4-amine (10074-G5) (Clausen DM et al, (2010) J. Pharmacol. Exp. Ther.
- EP2487156A1 FBXW-7 expression vectors (Ishikawa Y et al, supra), and siRNAs targeting Myc transcript (Id.).
- exemplary Notch activators include microRNAs that target FBXW-7 (Ishikawa Y et al supra), AG-370, 5 (U.S. Patent No.
- Notch activators may also include chemical activators such as valproic acid (VPA, see, U.S. Patent No. 8,338,482), resveratrol and phenethyl isothiocyanate.
- VPA valproic acid
- resveratrol resveratrol
- phenethyl isothiocyanate ethyl isothiocyanate
- Notch inhibitors include gamma-secretase inhibitors such as an arylsulfonamide, a benzodiazepine, L-685,458 (U.S. Patent Publication No. 2001/0305674), MK-0752 (Purow B. (2012) Adv. Exp. Med. Biol. 727:305-19; Imbimbo BP (2008) Curr. Top. Med. Chem. 8(1):54-61), DAPT ([N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) ⁇ Id; Ishikawa Y et al.
- gamma-secretase inhibitors such as an arylsulfonamide, a benzodiazepine, L-685,458 (U.S. Patent Publication No. 2001/0305674), MK-0752 (Purow B. (2012) Adv. Exp. Med. Biol.
- Patent No. 6,541,466) ELN-46719 (2- hydroxy-valeric acid amide analog of LY411575 (where LY41 1575 is the 3,5-difluoro-mandelic acid amide) (U.S. Patent No. 6,541,466)); PF-03084014 ((S)-2-((S)-5,7-difluoro-l ,2,3 ,4- tetrahydronaphthalen-3 -ylamino)-N-( 1 -(2-methyl- 1 -(neopentylamino)propan-2-yl)- 1 H- imidazol-4-yl)pentanamide, Samon et ciL, Mol. Cancer Ther. 2012; 1 1 : 1565-1575); and
- suitable gamma secretase inhibitors include: semagacestat (also known as LY450139, (2S)-2-hydroxy-3-methyI-N-[(lS)-l-methyl-2-oxo-2- [[(lS)-2,3,4,5-tetrahydro-3-methyl-2-oxo-lH-3-benzazepin-l-yl] amino] ethylbutanamide, available from Eli Lilly; WO 02/47671 and U.S. Pat. No.
- N-[N-3,5-Difluorophenacetyl]-L-alanyl-S-phenylglycine Methyl Ester also known as DAPM, gamma- Secretase Inhibitor XVI, available from EMD Millipore
- Compound W (3,5-bis(4-Nitrophenoxy)benzoic acid, available from Tocris Bioscience); L- 685,458 ((5S)-(tert-Butoxycarbonylamino)-6-phenyl-(4R)-hydroxy-(2R)-benzylhexanoyl)-L- leucy-L-phenylalaninamide, available from Sigma-Aldrich, Shearmen et al, (2000) Biochemistry 39, 8698-8704); BMS-289948 (4-chloro-N-(2,5 -difluorophenyl)-N-(( 1 R)- ⁇ 4-fluoro
- MK-0752 (3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5- difluorophenyl)cyclohexyl)propanoic acid, available from Merck);
- MRK-003 ((3'R,6R,9R)-5'- (2,2,2-trifluoroethyl)-2-((E)-3-(4-(trifluoromethyl)piperidin- 1 -yl)prop- 1 -en- 1 -yl)-5,6,7,8,9, 10- hexahydrospiro[6,9-methanobenzo[8]annulene-l l,3'-[l,2,5]thiadiazolidine] , ⁇ -dioxide , available from Merck, Mizuma et al, (2012) Mol.
- MRK-560 N-[cis-4-[(4-Chlorophenyl)sulfonyl] ⁇ 4-(2,5-difluorophenyl)cyclohexyl]- 1 ,1,1 -trifluoro- methanesulfonamide, Best et al, (2006) J. Pharmacol. Exp. Ther. 317(2):786-90); RO-4929097 (also known as R4733, (S)-2,2-dimethyl-Nl-(6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-
- Tarenflurbil also known as (R)-Flurbiprofen, (2R)-2-(3-fluoro-4- phenylphenyl)propanoic acid
- ALX-260-127 also known as Compound 1 1, described by Wolfe et al, (1998) J. Med. Chem. 41 : 6
- Sulindac sulfide S. Side, et al, (2003) J. Biol. Chem.
- Patent Publication No. 201 10263580 N-[3-[(4-chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l, 1,1- trifluoro-N-methylmethanesulfonamide (U.S. Patent Publication No. 20110263580);N-[3-[(4- chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l, 1, 1-trifluoro-N- methylmethanesulfonamide (U.S. Patent Publication No.
- benzyloxycarbonyl-leucyl-leucyl-norleucinal available from Calbiochem
- gamma-secretase inhibitor II (MOL)(CDX) (available from Calbiochem);
- gamma secretase inhibitor III (N- Benzyloxycarbonyl-Leu-leucinal, available from Calbiochem);
- gamma secretase inhibitor IV (N- (2-Naphthoyl)-Val-phenylalaninal, available from Calbiochem);
- gamma-secretase inhibitor V also known as Z-LF-CHO, N-Benzyloxycarbonyl-Leu-phenylalaninal, available from EMD Millipore
- gamma-secretase inhibitor VI (l-(S)-endo-N-(l,3,3)-Trimethylbicyclo[2.2.1]hept-2- yl)-4-fluorophenyl Sulfonamide, available from EMD Millipore
- gamma secretase inhibitor XIII (Z-Tyr-Ile-Leu-CHO, available from Calbiochem); gamma secretase inhibitor XIV, (Z-Cys(t-Bu)-Ile-Leu-CHO, available from Calbiochem); gamma secretase inhibitor XVII, (also known as WPE-III-31C), (MOL)(CDX) (available from Calbiochem);gamma secretase inhibitor XIX, (also known as benzodiazepine, (2S,3R)-3-(3,4 Difluorophenyl)-2-(4- fluorophenyl)-4-hydroxy-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- butyramide, Churcher et al, (2003) J.
- gamma secretase inhibitor XX (also known as dibenzazepine, (S,S)-2-[2-(3,5-Difluorophenyl)acetylamino]-N-(5-methyl-6- oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propionamide, (MOL)(CDX) (Weihofen et al, Science 296: 2215-2218, 2002, available from Calbiochem); gamma secretase inhibitor XXI, ((S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(l-methyl-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-propionamide, available from Calbiochem);5-
- propionamide hydrochloride U.S. Patent No. 8188069
- S -2-fluoro-3-methyl-butyric acid
- U.S. Patent No. 8188069 (S)-2-hydroxy-3-methyl-N-[(S)-l-((S)-l-methyl-2-oxo-5-phenyl-2,3- dihydro-lH-azepin-3-ylcarbamoyl)-ethyl]-butyramide (U.S. Patent No.
- Notch inhibitors include nonsteroidal anti-inflammatory drugs (NSAIDs) such as flurbiprofen (Purow B, supra), MPC-7869 (Imbimbo BP, supra), ibuprofen (Id.), sulindac sulphide, indomethacin, alpha-secretase inhibitors (ASIs) (Purow B, supra), the Na + /H + antiporter Monensin (Id.); small molecules that block Notch binding to interacting proteins such as Jagged, Numb, Numb-like, CBF1 transcription factor, and mastermind-like (MAML) (Id.
- NSAIDs nonsteroidal anti-inflammatory drugs
- Atohl activators include, for example, ⁇ -Catenin or ⁇ - catenin pathway agonists, e.g., Wnt ligands, DSH/DVL1 , 2, 3, LRP65N, WNT3A, WNT5A, and
- WNT3 A 5A. Additional Wnt/ ⁇ -catenin pathway activators and inhibitors are reviewed in the art (Moon et al, Nature Reviews Genetics, 5:689-699, 2004).
- suitable Wnt/ -catenin pathway agonists can include antibodies and antigen binding fragments thereof, and peptides that bind specifically to frizzled (Fzd) family of receptors.
- CK1 casein kinase 1
- GSK3 glycogen synthase kinase 3 ⁇
- GSK3 ⁇ inhibitors include, but are not limited to, lithium chloride (LiCl), Purvalanol A, olomoucine, alsterpaullone, kenpaullone, benzyl-2-methyl-l,2,4-thiadiazolidine-3,5-dione (TDZD-8), 2-thio(3-iodobenzyl)-5-(l-pyridyl)-[l,3,4]-oxadiazole (GSK3 inhibitor II), 2,4- dibenzyl-5-oxothiadiazolidine-3-thione (OTDZT), (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO), ⁇ -4-Dibromoacetophenone (i.e., Tau Protein Kinase I (TPK I) Inhibitor), 2-Chloro-l-(4,5- dibromo-thiophen-2-yl)-ethanone, N-(4-Methoxybenzyl
- GKEAPPAPPQSpP-NH2 (L803-mts).
- Other GSK3p inhibitors are disclosed in U.S. Patent Nos. 6,417, 185; 6,489,344; and 6,608,063.
- suitable kinase inhibitors can include RNAi and siRNA designed to decrease GSK3p and/or CKI protein levels.
- useful kinase inhibitors include FGF pathway inhibitors.
- FGF pathway inhibitors include, for example, SU5402.
- Atohl activators include gamma secretase inhibitors (e.g., gamma secretase inhibitors).
- arylsulfonamides dibenzazepines, benzodiazepines, N-[N-(3,5-difluorophenacetyl)-L-alanyl]- (S)-phenylglycine t-butyl ester (DAPT; EMD Biosciences, San Diego, CA, USA), L-685,458, or MK0752ho, in addition to those listed above under Notch inhibitors), gentamycin, and the combination of transcription factors Eyal and Sixl (and optionally Sox2), as described in Ahmed et al (2012) Dev. Cell. 22(2):377-390.
- DAPT N-[N-(3,5-difluorophenacetyl)-L-alanyl]- (S)-phenylglycine t-butyl ester
- L-685,458 or MK0752ho in addition to those listed above under Notch inhibitors
- gentamycin and the combination of transcription factors Eyal and Sixl
- Atohl activators are described in U.S. Patent No. 8,188, 131, including a compound represented by Formula ⁇ .
- each of Rug, R1 19, Ri20, and RI 2 I is, independently selected from H, halo, OH, CN, N0 2 , C]-C 3 alkyl, C1-C3 haloalkyl, alkoxy, and Ci-C 8 haloalkoxy;
- R122 is hydrogen or— Z— R a ; wherein:
- Z is O or a bond
- R a is:
- Ci-C 6 alkyl or Ci-C 6 haloalkyl each of which is optionally substituted with from 1 -3 R b ;
- Ci-C 6 alkyl or Ci-C 6 haloalkyl each of which is optionally substituted with from 1-3 R b ;
- R at each occurrence is, independently:
- C 3 -C 7 cycloalkyl optionally substituted with from 1-3 substituents independently selected from C,-C 6 alkyl, NH 2 ; NH(Ci-C 3 alkyl); N(C r C 3 alkyl) 2 ; hydroxy; C C 6 alkoxy or Ci-C 6 haloalkoxy;
- R c at each occurrence is, independently:
- R d at each occurrence is, independently:
- -C 6 haloalkyl or a pharmaceutically acceptable salt thereof.
- Atohl activators described in U.S. Patent No. 8,188, 131 include 4-(4-chlorophenyl)- 1 -(5H-pyrimido [5,4-b] indol-4-yl)- 1 H-pyrazol-3 -amine; 6-chloro- 1 -(2- chlorobenzyloxy)-2-phenyl- lH-benzo[d]imidazole; 6-chloro- 1 -(2-chlorobenzyloxy)-2-(4- methoxyphenyl)-lH-benzo[d] imidazole; 6-chloro-2-(4-methoxyphenyl)-l-(4-methylbenzyloxy)- lH-benzo[d] imidazole; 6-chloro- 1 -(3,5-dimethylbenzyloxy)-2-(4-methoxyphenyl)- 1 H-benzo [d] imidazole; 6-chloro- 1 -(4-(4
- Agents for Modulating Myc, Notch andAtohl The method of delivery of modulators of Myc, Notch or Atohl activity will depend, in part, upon whether the hair cells or supporting cells are being contacted with the agents of interest in vivo or ex vivo.
- the agents are delivered into the inner ear of a mammal.
- cells are contacted with the agents ex vivo.
- the resulting hair cells can then be transplanted into the inner ear of a recipient using techniques known and used in the art.
- Myc activity is increased by administering Myc protein or a Myc activator in the inner ear of a recipient to give, for example, a final concentration of greater than about 30 ⁇ , for example, in the range of about 30 ⁇ to about 1000 ⁇ .
- the Myc protein or Myc activator can be administered in an amount sufficient to give a final concentration of greater than about 30 ⁇ .
- the Myc protein or Myc activator may be administered in an amount sufficient to give a final concentration in the range from about 30 ⁇ to about 1000 ⁇ , 50 ⁇ to about 1000 ⁇ , 80 ⁇ to about 1000 ⁇ , about 100 ⁇ to about 1000 ⁇ , about 150 ⁇ to about 1000 ⁇ , from about 200 ⁇ to about 800 ⁇ , or from about 200 ⁇ to about 600 ⁇ .
- Myc protein or a Myc activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Myc protein or Myc activator can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Myc protein or Myc activator is administered locally to the inner ear.
- from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Myc protein or Myc activator can be administered locally to the inner ear of a mammal.
- Notch activity is increased by administering a Notch protein, a NICD protein or a Notch activator to an inner ear of a recipient to give a final concentration of greater than about 30 ⁇ , for example, in the range of about 30 ⁇ to about 1000 ⁇ .
- a Notch protein, NICD protein or Notch activator can be administered in an amount sufficient to give a final concentration of greater than about 30 ⁇ .
- the Notch protein, NICD protein or Notch activator may be administered in an amount sufficient to give a final concentration in the range from about 30 ⁇ to about 1000 ⁇ , 50 ⁇ to about 1000 ⁇ , 80 ⁇ to about 1000 ⁇ , about 100 ⁇ to about 1000 ⁇ , about 150 ⁇ to about 1000 ⁇ , from about 200 ⁇ to about 800 ⁇ , or from about 200 ⁇ to about 600 ⁇ .
- Notch protein, NICD protein or Notch activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Notch protein, NICD protein or Notch activator can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Notch protein, NICD protein or Notch activator is administered locally to the inner ear of a mammal.
- from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Notch protein, NICD protein or Notch activator can be administered locally to the inner ear of a mammal.
- Notch activity is inhibited by administering a Notch inhibitor.
- a Notch inhibitor can be administered to give a final concentration of greater than about 30 ⁇ , for example, in the range of about 30 ⁇ to about 1000 ⁇ .
- a Notch inhibitor can be administered in an amount sufficient to give a final concentration of greater than about 30 ⁇ .
- the Notch inhibitor may be administered in an amount sufficient to give a final concentration in the range from about 30 ⁇ to about 1000 ⁇ , 50 ⁇ to about 1000 ⁇ , 80 ⁇ to about 1000 ⁇ , about 100 ⁇ to about 1000 ⁇ , about 150 ⁇ to about 1000 ⁇ , from about 200 ⁇ to about 800 ⁇ , or from about 200 ⁇ to about 600 ⁇ .
- the Notch inhibitor is administered in an amount sufficient to give a final concentration of about 400 ⁇ .
- a Notch inhibitor is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Notch inhibitor can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Notch inhibitor is administered locally to the inner ear of a mammal.
- from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Notch inhibitor can be administered locally to the inner ear of a mammal. In certain embodiments, about 0.7 mg Notch inhibitor is administered locally to the inner ear of a mammal.
- Atohl activity is increased by administering Atohl protein or an Atohl activator in the inner ear of a recipient to give, for example, a final concentration of greater than about 30 ⁇ , for example, in the range of about 30 ⁇ to about
- the Atohlprotein or Atohl activator can be administered in an amount sufficient to give a final concentration of greater than about 30 ⁇ .
- the Atohlprotein or Atohl activator may be administered in an amount sufficient to give a final concentration in the range from about 30 ⁇ to about 1000 ⁇ , 50 ⁇ to about 1000 ⁇ , 80 ⁇ to about 1000 ⁇ , about 100 ⁇ to about 1000 ⁇ , about 150 ⁇ to about 1000 ⁇ , from about 200 ⁇ to about 800 ⁇ , or from about 200 ⁇ to about 600 ⁇ .
- Atohl protein or a Atohl activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0. 1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Atohl protein or Atohl activator can be administered locally to the inner ear of a mammal.
- 0.5 mg of Atohl protein or Atohl activator is administered locally to the inner ear.
- from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0. 15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Atohl protein or Atohl activator can be administered locally to the inner ear of a mammal.
- the activity of Myc, Notch or Atohl can be increased in a target cell using expression constructs known in the art, e.g., naked DNA constructs, DNA vector based constructs, and/or viral vector and/or viral based constructs to express nucleic acids encoding a desired Myc, Notch or Atohl protein.
- expression constructs known in the art e.g., naked DNA constructs, DNA vector based constructs, and/or viral vector and/or viral based constructs to express nucleic acids encoding a desired Myc, Notch or Atohl protein.
- a single DNA construct expressing Myc and Notch or NICD as two separate genes can be delivered into the inner ear of a subject.
- a single DNA construct expressing Myc and Notch or NICD and Atohl as three separate genes can be delivered into the inner ear of a subject.
- Exemplary expression constructs can be formulated as a pharmaceutical composition, e.g., for administration to a subject.
- DNA constructs and the therapeutic use of such constructs are well known to those of skill in the art (see, e.g. Chiarella et al. (2008) Recent Patents Anti-Infect. Drug Disc. 3: 93- 101 ; Gray et al. (2008) Expert Opin. Biol. Ther. 8:91 1- 922; Melman et al. (2008) Hum. Gene Ther. 17: 1165- 1 176).
- Naked DNA constructs typically include one or more therapeutic nucleic acids (e.g., DNA encoding Myc and/or Notch) and a promoter sequence.
- a naked DNA construct can be a DNA vector, commonly referred to as pDNA.
- DNA vectors are known in the art and typically are circular double stranded DNA molecules. DNA vectors usually range in size from three to five kilo-base pairs (e.g., including inserted therapeutic nucleic acids). Like naked DNA, DNA vectors can be used to deliver and express one or more therapeutic proteins in target cells. DNA vectors do not integrate into chromosomal DNA. Generally, DNA vectors include at least one promoter sequence that allows for replication in a target cell.
- Uptake of a DNA vector may be facilitated by combining the DNA vector with, for example, a cationic lipid, and forming a DNA complex.
- viral vectors are double stranded circular DNA molecules that are derived from a virus.
- Viral vectors typically are larger in size than naked DNA and DNA vector constructs and have a greater capacity for the introduction of foreign (i.e., not virally encoded) genes.
- viral vectors can be used to deliver and express one or more therapeutic nucleic acids in target cells.
- certain viral vectors Unlike naked DNA and DNA vectors, certain viral vectors stably incorporate themselves into chromosomal DNA.
- viral vectors include at least one promoter sequence that allows for replication of one or more vector encoded nucleic acids, e.g., a therapeutic nucleic acid, in a host cell.
- Viral vectors may optionally include one or more non-therapeutic components described herein.
- uptake of a viral vector into a target cell does not require additional components, e.g., cationic lipids. Rather, viral vectors transfect or infect cells directly upon contact with a target cell.
- the approaches described herein include the use of retroviral vectors, adenovirus- derived vectors, and/or adeno-associated viral vectors as recombinant gene delivery systems for the transfer of exogenous genes in vivo, particularly into humans. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals.
- Viruses that are used as transduction agents of DNA vectors and viral vectors such as adenoviruses, retroviruses, and lentiviruses may be used in practicing the present invention.
- Illustrative retroviruses include, but are not limited to: Moloney murine leukemia virus (M- MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus
- lentivirus refers to a group (or genus) of complex retroviruses.
- Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna- maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
- HIV human immunodeficiency virus
- VMV visna- maedi virus
- CAEV caprine arthritis-encephalitis virus
- EIAV equine infectious anemia virus
- FV feline immunodeficiency virus
- BIV bovine immune deficiency virus
- SIV simian immunodeficiency virus
- an adenovirus can be used in accordance with the methods described herein.
- the genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle.
- Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art.
- Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells.
- virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.
- introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situ where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA).
- the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors.
- Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. It is also one of the few viruses that may integrate its DNA into non- dividing cells, and exhibits a high frequency of stable integration.
- one or more viral vectors that expresses a therapeutic transgene or transgenes encoding a polypeptide or polypeptides of the invention is administered by direct injection to a cell, tissue, or organ of a subject, in vivo.
- a cell, cell type, cell lineage or tissue specific expression control sequence may be desirable to use to achieve cell type specific, lineage specific, or tissue specific expression of a desired polynucleotide sequence, for example, to express a particular nucleic acid encoding a polypeptide in only a subset of cell types, cell lineages, or tissues, or during specific stages of development.
- Illustrative examples of cell, cell type, cell lineage or tissue specific expression control sequences include, but are not limited to: an Atohl enhancer for all hair cells; a Pou4f3 promoter for all hair cell; a Myo7a promoter for all hair cells; a Hes5 promoter for vestibular supporting cells and cochlear inner phalangeal cells, Deiters cells and Pillar cells; and GFAP promoter for vestibular supporting cells and cochlear inner phalangeal cells, Deiters cells and Pillar cells.
- Certain embodiments of the invention provide conditional expression of a polynucleotide of interest.
- expression is controlled by subjecting a cell, tissue, organism, etc., to a treatment or condition that causes the polynucleotide to be expressed or that causes an increase or decrease in expression of the polynucleotide encoded by the polynucleotide of interest.
- inducible promoters/systems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter (inducible by treatment with various heavy metals), MX- 1 promoter (inducible by interferon), the "GeneSwitch” mifepristone-regulatable system (Sirin et al, 2003, Gene, 323:67), the cumate inducible gene switch (WO 2002/088346), tetracycline-dependent regulatory systems, etc.
- steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter (inducible by treatment with various heavy metals), MX- 1 promoter (inducible by interferon), the "GeneSwitch”
- vectors comprise a selection gene, also termed a selectable marker.
- selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, hygromycin, methotrexate, Zeocin, Blastocidin, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. Any number of selection systems may be used to recover transformed cell lines.
- herpes simplex virus thymidine kinase (Wigler et al, (1977) Cell, 1 1 :223-232) and adenine phosphoribosyltransferase (Lowy et al, (1990) Cell, 22:817-823) genes which can be employed in tk- or aprt- cells, respectively.
- DNA delivery may occur by use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, optionally mixing with cell penetrating polypeptides, and the like, for the introduction of the compositions of the present invention into suitable host cells.
- the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, a nanoparticle or the like.
- the formulation and use of such delivery vehicles can be carried out using known and conventional techniques. Duration of Delivery
- the duration of Myc, Notch and Atohl activation can be varied to achieve a desired result. For example, it may be beneficial to expose a target cell to a Myc protein or Myc activator and a Notch protein, NICD protein, or a Notch activator for one to six days, one week, two weeks, three weeks, one month, three months, six months, nine months, one year, two years or more.
- Myc is increased by constitutive activation (e.g., using an adenovirus to overexpress Myc)
- the duration of increased Myc activity can be controlled by administering a Myc inhibitor following administration of a myc protein or a myc activator.
- Inhibiting Myc activity after a period of increased Myc activity can be used to control proliferation, promote cell survival, and avoid tumorigenesis.
- the duration of increased Notch activity can be controlled by administering a Notch inhibitor, as discussed above, following administration of a Notch protein, NICD protein, or a Notch activator.
- the route of administration will vary depending on the disease being treated. Hair cell loss, sensorineural hearing loss, and vestibular disorders can be treated using direct therapy using systemic administration and/or local administration. In certain embodiments, the route of administration can be determined by a subject's health care provider or clinician, for example following an evaluation of the subject.
- the invention provides (i) a composition for use in proliferating or regenerating a cochlear or a utricular hair cell, (ii) a composition for use in proliferating or regenerating a cochlear or a utricular supporting cell, (iii) a composition for use in reducing the loss of, maintaining, or promoting hearing in a subject, and (iv) a composition for use in reducing the loss of, maintaining, or promoting vestibular function in a subject.
- the invention provides a first composition comprising an agent, for example, each of the agents discussed hereinabove, for example, an agent that increases Myc activity and/or an agent that increases Notch activity within a hair or supporting cell, either alone or in combination with a
- the invention provides a second composition comprising an agent, for each of the agents discussed hereinabove, for example, an agent that reduces or inhibits Myc activity and/or an agent that reduces or inhibits Notch activity within a hair or supporting cell, either alone or in combination with in a pharmaceutically acceptable carrier for use in each of the foregoing approaches.
- a third composition comprising an agent, for example, an agent for increasing Atohl activity, to induce trans differentiation of a proliferated supporting cell into a hair cell.
- the Myc protein or activator and/or the Notch protein, NICD protein, or Notch activator, and/or Atohl protein or activator can be formulated so as to permit release of one or more proteins and/or activators over a prolonged period of time.
- a release system can include a matrix of a biodegradable material or a material, which releases the incorporated active agents.
- the active agents can be homogeneously or heterogeneously distributed within a release system.
- release systems may be useful in the practice of the invention, however, the choice of the appropriate system will depend upon the rate of release required by a particular drug regime. Both non-degradable and degradable release systems can be used.
- Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar (for example, trehalose). Release systems may be natural or synthetic.
- the agents can be administered to a subject, e.g., a subject identified as being in need of treatment for hair cell loss, using a systemic route of
- Systemic routes of administration can include, but are not limited to, parenteral routes of administration, e.g., intravenous injection, intramuscular injection, and intraperitoneal injection; enteral routes of administration, e.g., administration by the oral route, lozenges, compressed tablets, pills, tablets, capsules, drops (e.g., ear drops), syrups, suspensions and emulsions; rectal administration, e.g., a rectal suppository or enema; a vaginal suppository; a urethral suppository; transdermal routes of administration; and inhalation (e.g., nasal sprays).
- the agents can be administered to a subject, e.g., a subject identified as being in need of treatment for hair cell loss, using a local route of administration.
- Such local routes of administration include administering one or more
- the agents may be injected into the ear (e.g., auricular administration), such as into the luminae of the cochlea (e.g., the Scala media, Sc vestibulae, and Sc tympani).
- the agents can be administered by intratympanic injection (e.g., into the middle ear), and/or injections into the outer, middle, and/or inner ear.
- intratympanic injection e.g., into the middle ear
- injections into the outer, middle, and/or inner ear e.g., for the administration of steroids and antibiotics into human ears.
- Injection can be, for example, through the round window of the ear or through the cochlea capsule.
- the agents can be delivered via nanoparticles, for example, protein-coated nanoparticles. Nanoparticles can be targeted to cells of interest based on cell-type specific receptor affinity for ligands coating the nanoparticles.
- the dosage of the agent can be modulated by regulating the number of nanoparticles administered per dose.
- the agent may be administered to the inner ear using a catheter or pump.
- a catheter or pump can, for example, direct the agent into the cochlea luminae or the round window of the ear.
- Exemplary drug delivery systems suitable for administering one or more compounds into an ear, e.g., a human ear are described in U.S. Patent Publication No. 2006/0030837 and U.S. Patent No. 7,206,639.
- a catheter or pump can be positioned, e.g., in the ear (e.g., the outer, middle, and/or inner ear) of a subject during a surgical procedure.
- the agents can be delivered in combination with a mechanical device such as a cochlea implant or a hearing aid, which is worn in the outer ear.
- the modes of administration described above may be combined in any order and can be simultaneous or interspersed.
- the agents may be administered to a subject simultaneously or sequentially. It will be appreciated that when administered simultaneously, the agents may be in the same pharmaceutically acceptable carrier (e.g., solubilized in the same viscoelastic carrier that is introduced into the inner ear) or the two agents may be dissolved or dispersed in separate pharmaceutical carriers, which are administered at the same time. Alternatively, the agents may be provided in separate dosage forms and administered sequentially.
- the hair cells and supporting cells can be harvested and cultured using techniques known and used in the art.
- the agents protein expression vectors, activators and inhibitors (for example, as discussed above)
- the agents can then be contacted with the cultured hair cells or supporting cells to induce the cells to reenter the cell cycle, and proliferate. Thereafter, once the cells have proliferated, the Myc and Notch activities can be inhibited using appropriate inhibitors, for example, those discussed above.
- the resulting hair cells can then be maintained in culture for any number of uses, including, for example, to study the biological, biophysical, physiological and pharmacological characteristics of hair cells and/or supporting cells.
- the resulting hair cells can then be implanted in to the inner ear of a recipient using standard surgical procedures.
- suitable cells can be derived from a mammal, such as a human, mouse, rat, pig, sheep, goat, or non-human primate.
- the cells can be harvested from the inner ear of a subject, and cells can be obtained from the cochlea organ of Corti, the modiolus (center) of the cochlea, the spiral ganglion of the cochlea, the vestibular sensory epithelia of the saccular macula, the utricular macula, or the cristae of the semicircular canals.
- methods include obtaining tissue from the inner ear of the animal, where the tissue includes at least a portion of the utricular maculae.
- Tissue isolated from a subject can be suspended in a neutral buffer, such as phosphate buffered saline (PBS), and subsequently exposed to a tissue-digesting enzyme (e.g., trypsin, leupeptin, chymotrypsin, and the like) or a combination of enzymes, or a mechanical (e.g., physical) force, such as trituration, to break the tissue into smaller pieces.
- a tissue-digesting enzyme e.g., trypsin, leupeptin, chymotrypsin, and the like
- a mechanical force such as trituration
- the tissue can be incubated in about 0.05% enzyme (e.g., about 0.001 %, 0.01 %, 0.03%, 0.07%, or 1.0% of enzyme) for about 5, 10, 15, 20, or 30 minutes, and following incubation, the cells can be mechanically disrupted.
- the disrupted tissue can be passed through a device, such as a filter or bore pipette, that separates a stem cell or progenitor cell from a differentiated cell or cellular debris.
- the separation of the cells can include the passage of cells through a series of filters having progressively smaller pore size.
- the filter pore size can range from about 80 ⁇ or less, about 70 ⁇ or less, about 60 ⁇ or less, about 50 ⁇ or less, about 40 ⁇ or less, about 30 ⁇ or less, about 35 ⁇ or less, or about 20 ⁇ or less.
- Partially and/or fully differentiated cells can be maintained in culture for a variety of uses, including, for example, to study the biological, biophysical, physiological and pharmacological characteristics of hair cells and/or supporting cells.
- Cell cultures can be established using inner ear cells from subjects with hearing loss and/or loss in vestibular function to develop potential treatments (e.g., to screen for drugs effective in treating the hearing loss and/or loss in vestibular function).
- the methods of the present invention can be used in combination with induced pluripotent stem (iPS) cell technology to establish cell lines (e.g., hair cell lines and/or supporting cell lines).
- iPS induced pluripotent stem
- fibroblasts from a subject with hearing loss can be induced to form iPS cells using known techniques (see, for example, Oshima et al. (2010) Cell, 141(4):704-716).
- the methods provided herein can be used in combination with iPS cell technology to produce sufficient numbers of cells to establish cell lines (e.g., hair cell lines and/or supporting cell lines).
- cell lines e.g., hair cell lines and/or supporting cell lines.
- Partially and/or fully differentiated cells e.g., generated by the methods described above, can be transplanted or implanted, such as in the form of a cell suspension, into the ear by injection, such as into the luminae of the cochlea.
- Injection can be, for example, through the round window of the ear or through the bony capsule surrounding the cochlea.
- the cells can be injected through the round window into the auditory nerve trunk in the internal auditory meatus or into the scala tympani.
- the cells described herein can be used in a cochlea implant, for example, as described in U.S. Patent Publication No. 2007/0093878.
- cells can be modified prior to differentiation.
- the cells can be engineered to overexpress one or more anti-apoptotic genes.
- the Fak tyrosine kinase or Akt genes are candidate anti-apoptotic genes that can be used for this purpose; overexpression of FAK or Akt can prevent cell death in spiral ganglion cells and encourage engraftment when transplanted into another tissue, such as an explanted organ of Corti (see, for example, Mangi et al, (2003) Nat. Med. 9: 1195-201).
- Neural progenitor cells overexpressing ⁇ ⁇ ⁇ 3 integrin may have an enhanced ability to extend neurites into a tissue explant, as the integrin has been shown to mediate neurite extension from spiral ganglion neurons on laminin substrates (Aletsee et al., (2001) Audiol. Neu. Ootol. 6:57-65).
- ephrinB2 and ephrinB3 expression can be altered, such as by silencing with RNAi or overexpression with an exogenously expressed cDNA, to modify EphA4 signaling events.
- Spiral ganglion neurons have been shown to be guided by signals from EphA4 that are mediated by cell surface expression of ephrin-B2 and -B3 (Brors et al., (2003) J. Comp. Neurol. 462:90-100). Inactivation of this guidance signal may enhance the number of neurons that reach their target in an adult inner ear. Exogenous factors such as the neurotrophins BDNF and NT3, and LIF can be added to tissue transplants to enhance the extension of neurites and their growth towards a target tissue in vivo and in ex vivo tissue cultures. Neurite extension of sensory neurons can be enhanced by the addition of neurotrophins (BDNF, NT3) and LIF (Gillespie et al. (2010) Neuro. Report 12:275-279). Measurement ofMyc, Notch or Atohl Activity in Target Cells
- the methods and compositions described herein can be used to induce cells, e.g., adult mammalian inner ear cells, to reenter the cell cycle and proliferate.
- the number of hair cells can be increased about 2-, 3-, 4-, 6-, 8-, or 10-fold, or more, as compared to the number of hair cells before treatment.
- the hair cell can be induced to reenter the cell cycle in vivo or ex vivo. It is contemplated that using these approaches it may be possible to improve the hearing of a recipient.
- using the methods and compositions described herein it may be possible to improve the hearing of a recipient by at least about 5, 10, 15, 20, 40, 60, 80, or 90% relative to the hearing prior to the treatment. Tests of auditory or vestibular function also can be performed to measure hearing improvement.
- Cells that have been contacted with (i) a Myc protein or Myc activator and/or (ii) a Notch protein, NICD protein or Notch activator, can be assayed for markers indicative of cell cycle reentry and proliferation.
- a cell can be assayed for incorporation of EdU (5-ethynyl-2'-deoxyuridine) followed sequentially by BrdU (5-bromo-2'-deoxyuridine) by using, for example, an anti-EdU antibody and an anti-BrdU antibody. Labelling by EdU and/or BrdU is indicative of cell proliferation.
- double labeling of EdU and BrdU can be used to demonstrate that a cell has undergone division at least two times.
- a cell can be assayed for the presence of phosphorylated histone H3 (Ph3) or aurora B, which are indicative of a cell that has reentered the cell cycle and is undergoing metaphase and cytokinesis.
- Cell markers can also be used to determine whether a target cell, e.g., a hair cell or a supporting cell, has entered the cell cycle.
- Exemplary markers indicative of hair cells include Myo7a, Myo6, Prestin, Lhx3, Dner, espin, parvalbumin, and calretinin.
- Exemplary markers indicative of supporting cells include Sox2, SlOOal, Proxl, Rps6, and Jagl . Double labeling of a cell cycle and/or proliferation marker and a cell-type molecule can be used to determine which cells have reentered the cell cycle and are proliferating.
- neuronal markers e.g., acetylated tubulin, neurofilament and CtBP2
- neurofilament and CtBP2 can be used to detect neuronal structure, to determine whether proliferating hair cells are in contact with neurons.
- the presence of neuronal markers adjacent to or in contact with hair cells suggests that newly-generated hair cells have formed synapses with neurons (e.g., ganglion neurons) and that the hair cells are differentiated.
- the subject for example, a human subject, can be tested for an improvement in hearing or in other symptoms related to inner ear disorders.
- Methods for measuring hearing are well-known and include pure tone audiometry, air conduction, auditory brainstem response (ABR) and bone conduction tests.
- a composition comprises a cationic lipid encapsulating one or more chimeric molecules.
- These chimeric molecules comprise one or more proteins or peptides fused, complexed or linked to one or more anionic molecules.
- the anionic molecules can vary as long as they comprise one or more anionic domains or bind to an anionic nucleic acid domain. It is preferred that the anionic molecules confer an overall net negative charge to the chimeric molecule.
- proteins that are engineered to be highly negatively charged or that are naturally highly anionic may be able to take advantage of the same electrostatics-driven complexation and encapsulation used by cationic liposomal reagents for nucleic acid delivery.
- the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), a short interfering RNA (siRNA), a micro, interfering RNA (miRNA), a small, temporal RNA (stRNA), a short, hairpin RNA (shRNA), mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- RNA ribonucleic acids
- DNA deoxyribonucleic acids
- synthetic RNA or DNA sequences modified RNA or DNA sequences
- modified RNA or DNA sequences complementary DNA
- cDNA complementary DNA
- sgRNA short guide RNA
- siRNA short interfering RNA
- miRNA micro, interfering RNA
- shRNA small, temporal RNA
- shRNA short, hairpin RNA
- the one or more proteins or peptides of the chimeric or anionic molecule can possess any charge as long as the overall net charge of the chimeric molecule is anionic.
- proteins or peptides are cationic, anionic or are neutrally charged.
- proteins or peptides of the chimeric molecule which can be complexed or linked to the polyanionic molecule or domain comprise: enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, gene editing agents, synthetic molecules or combinations thereof.
- the protein or peptide is a therapeutic agent for delivery to a specific target.
- the target can be any desired intracellular target.
- the target is a nucleic acid sequence or gene.
- the protein or peptide is a gene or genome editing agent.
- the gene editing agents comprise: transcriptional activators, transcriptional repressors, transcription factors, enhancer modulating molecules, recombinases, nucleases, nucleic acid binding-proteins, nucleic acid binding-polynucleotides or oligonucleotides, DNA- binding proteins or DNA -binding nucleic acids, or combinations thereof.
- the target is a protein or peptide.
- the chimeric or anionic molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
- the chimeric molecule optionally comprises one or more detectable labels, anions, radiolabels, tags, targeting agents, negatively charged proteins or peptides, or combinations thereof. These molecules can be selected based on the user's desired goal, e.g. for diagnostic or research purposes, or to increase the anionic charge, targeting signals and the like.
- a liposomal formulation for complexing protein and nucleic acid e.g. transcription factors with their target binding region as oligonucleotides
- the chimeric molecule can be tailored for regeneration (e.g. hair cell and auditory neuron regeneration), repair (e.g. re- establishment of connections between hair cells and neurons for hearing recovery) and prevention (e.g. by protein function of isll that prevents hair cell death during aging and noise exposure, thus preserving hearing).
- a chimeric molecule comprises at least one protein or peptide fused, complexed or linked to one or more anionic molecules.
- the one or more anionic molecules comprise one or more anionic domains or bind to an anionic nucleic acid domain.
- the chimeric molecule comprises an overall net negative charge.
- the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), a short interfering RNA (siRNA), a micro, interfering RNA (miRNA), a small, temporal RNA (stRNA), a short, hairpin RNA (shRNA), mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
- the chimeric molecule also comprises one or more proteins or peptides which are cationic, anionic or are neutrally charged.
- proteins include without limitation: enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, genome or gene editing agents, synthetic molecules or combinations thereof.
- the gene or genome editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof.
- the chimeric molecule optionally comprises one or more detectable labels, radiolabels, tags, anions, targeting agents or combinations thereof.
- a cationic liposome encapsulates an anionic molecule comprising a protein or peptide complexed, fused or linked to a negatively charged molecule.
- the negatively charged molecule comprises oligonucleotides
- polynucleotides proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
- the polynucleotide or oligonucleotide is a guide RNA.
- the protein or peptide is a negatively charged fluorescent protein.
- the one or more proteins or peptides are cationic, anionic or are neutrally charged.
- the negatively charged protein is fused or linked to one or more protems or peptides.
- the protein or peptide comprises: enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, gene editing agents, synthetic molecules or combinations thereof.
- the gene editing agents comprise: transcriptional activators, transcriptional repressors, transcription factors, enhancer modulating molecules, recombinases, nucleases, nucleic acid binding-proteins, nucleic acid binding-polynucleotides or oligonucleotides, DNA-binding proteins or DNA-binding nucleic acids, or combinations thereof.
- the liposome comprises one or more cationic lipids, modified lipids or combinations thereof.
- a liposome encapsulating one or more molecules embodied herein comprises a liposome, a nanoliposome, a niosome, a microsphere, a
- nanosphere a nanoparticle, a micelle, or an archaeosome.
- Hybrid proteins comprising a polypeptide or fragment thereof may be linked to other types of polypeptides, for example, a negatively supercharged green fluorescent protein in addition to a reporter polypeptide, or in lieu of a reporter polypeptide.
- additional polypeptides may be any amino acid sequence useful for the purification, identification, overall charge of the protein or peptide, and/or therapeutic or prophylactic application of the peptide.
- the additional polypeptide can be a signal peptide, or targeting peptide, etc.
- the other additions, substitutions or deletions may increase the stability (including but not limited to, resistance to proteolytic degradation) of the polypeptide or increase affinity of the polypeptide for its appropriate receptor, ligand and/or binding proteins. In some cases, the other additions, substitutions or deletions may increase the solubility of the polypeptide.
- sites are selected for substitution with a naturally encoded or non-natural amino acid in addition to another site for incorporation of a non-natural amino acid for the purpose of increasing the polypeptide solubility following expression in recombinant host cells.
- the polypeptides comprise another addition, substitution, or deletion that modulates affinity for the associated ligand, binding proteins, and/or receptor, modulates (including but not limited to, increases or decreases) receptor dimerization, stabilizes receptor dimers, modulates circulating half-life, modulates release or bio-availability, facilitates purification, or improves or alters a particular route of administration.
- non-natural amino acid polypeptide can comprise chemical or enzyme cleavage sequences, protease cleavage sequences, reactive groups, antibody-binding domains (including but not limited to, FLAG or poly-His) or other affinity based sequences (including but not limited to, FLAG, poly-His, GST, etc.) or linked molecules (including but not limited to, biotin) that improve detection (including but not limited to, GFP), purification, transport through tissues or cell membranes, prodrug release or activation, size reduction, or other traits of the polypeptide.
- chemical or enzyme cleavage sequences including but not limited to, FLAG or poly-His
- affinity based sequences including but not limited to, FLAG, poly-His, GST, etc.
- linked molecules including but not limited to, biotin
- the methods and compositions described herein include incorporation of one or more non-natural amino acids into a polypeptide.
- One or more non-natural amino acids may be incorporated at one or more particular positions which does not disrupt activity of the polypeptide. This can be achieved by making "conservative" substitutions, including but not limited to, substituting hydrophobic amino acids with non-natural or natural hydrophobic amino acids, bulky amino acids with non-natural or natural bulky amino acids, hydrophilic amino acids with non-natural or natural hydrophilic amino acids) and/or inserting the non-natural amino acid in a location that is not required for activity.
- a variety of biochemical and structural approaches can be employed to select the desired sites for substitution with a non-natural amino acid within the polypeptide.
- Any position of the polypeptide chain is suitable for selection to incorporate a non-natural amino acid, and selection may be based on rational design or by random selection for any or no particular desired purpose. Selection of desired sites may be based on producing a non-natural amino acid polypeptide (which may be further modified or remain unmodified) having any desired property or activity, including but not limited to agonists, super-agonists, partial agonists, inverse agonists, antagonists, receptor binding modulators, receptor activity modulators, modulators of binding to binder partners, binding partner activity modulators, binding partner conformation modulators, dimer or multimer formation, no change to activity or property compared to the native molecule, or manipulating any physical or chemical property of the polypeptide such as solubility, aggregation, or stability.
- locations in the polypeptide required for biological activity of a polypeptide can be identified using methods including, but not limited to, point mutation analysis, alanine scanning or homolog scanning methods. Residues other than those identified as critical to biological activity by methods including, but not limited to, alanine or homolog scanning mutagenesis may be good candidates for substitution with a non-natural amino acid depending on the desired activity sought for the polypeptide. Alternatively, the sites identified as critical to biological activity may also be good candidates for substitution with a non-natural amino acid, again depending on the desired activity sought for the polypeptide. Another alternative would be to make serial substitutions in each position on the polypeptide chain with a non-natural amino acid and observe the effect on the activities of the polypeptide. Any means, technique, or method for selecting a position for substitution with a non-natural amino acid into any polypeptide is suitable for use in the methods, techniques and compositions described herein.
- Modified Oligonucleotides examples include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
- modified oligonucleotides comprise those with phosphorothioate backbones and those with heteroatom backbones, CH 2 ⁇ NH ⁇ 0 ⁇ CH 2 , CH,-N(CH 3 )-0-CH 2 [known as a methyl ene(methylimino) or MMI backbone], CH 2 -O-N (CH 3 )-CH 2 , CH 2 -N (CH 3 )-N (CH 3 )-CH 2 and O-N (CH 3 ) ⁇ CH 2 — CH 2 backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH).
- the oligonucleotides having morphohno backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506), peptide nucleic acid (PNA) backbone wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleobases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al. Science 1991, 254, 1497).
- Oligonucleotides may also comprise one or more substituted sugar moieties. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.
- Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
- base any nucleobase
- nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U).
- Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimi dines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2- (imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil,
- oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide.
- moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al. Ann. N Y. Acad. Sci. 1992, 660, 306;
- a phospholipid e.g., di-hexadecyl-rac-glycerol or triethylammonium l ,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.
- the present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.
- Labeled Molecules In another preferred embodiment, the chimeric molecules can be labeled. Uses include therapeutic and imaging for diagnostic and prognostic purposes.
- the label may be a radioactive atom, an enzyme, or a chromophore moiety.
- the label may be radioactive.
- Some examples of useful radioactive labels include 32 P, 125 I, 131 I, and 3 H. Use of radioactive labels have been described in U.K. 2,034,323, U.S. Pat. No. 4,358,535, and U.S. Pat. No. 4,302,204.
- non-radioactive labels include enzymes, chromophores, atoms and molecules detectable by electron microscopy, and metal ions detectable by their magnetic properties.
- Some useful enzymatic labels include enzymes that cause a detectable change in a substrate.
- Some useful enzymes and their substrates include, for example, horseradish peroxidase (pyrogallol and o-phenylenediamine), ⁇ -galactosidase (fluorescein ⁇ -D- galactopyranoside), and alkaline phosphatase (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium).
- horseradish peroxidase pyrogallol and o-phenylenediamine
- ⁇ -galactosidase fluorescein ⁇ -D- galactopyranoside
- alkaline phosphatase 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
- Useful chromophores include, for example, fluorescent, chemiluminescent, and bioluminescent molecules, as well as dyes.
- Some specific chromophores useful in the present invention include, for example, fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone, luminol.
- the labels may be conjugated to the chimeric molecule by methods that are well known in the art.
- the labels may be directly attached through a functional group on the probe.
- the probe either contains or can be caused to contain such a functional group.
- suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide, isocyanate, isothiocyanate.
- labels such as enzymes and chromophores may be conjugated to the antibodies or nucleotides by means of coupling agents, such as dialdehydes, carbodiimides, dimaleimides, and the like.
- the chimeric fusion molecules of the invention can be used for imaging.
- imaging uses the complexes are labeled so that they can be detected outside the body.
- Typical labels are radioisotopes, usually ones with short half-lives.
- the usual imaging radioisotopes such as 123 I, 124 I, 125 I, 131 1, 99m TC, 186 Re, 188 Re, 64 Cu, 67 Cu, 2,2 Bi, 2 l3 Bi, 67 Ga, 90 Y, 1 1 'in, 18 F, 3 H, 14 C, 35 S or 32 P can be used.
- Nuclear magnetic resonance (NMR) imaging enhancers such as gadolinium- 153, can also be used to label the complex for detection by NMR. Methods and reagents for performing the labeling, either in the polynucleotide or in the protein moiety, are considered known in the art.
- Reporter genes useful in the present invention include acetohydroxy acid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof.
- AHAS acetohydroxy acid synthase
- AP alkaline phosphatase
- LacZ beta galactosidase
- GUS beta glucoronidase
- CAT chloramphenicol acetyltransferase
- GFP green fluorescent protein
- RFP red fluorescent protein
- YFP yellow fluorescent protein
- CFP cyan fluorescent protein
- Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline.
- Methods to determine modulation of a reporter gene include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), antibiotic resistance determination.
- kits for targeting nucleic acid sequences of cells and molecules associated with modulation of the target molecule can be used to target any desired nucleic sequence and as such, have many applications.
- a kit comprises: (a) a cationic lipid, and a chimeric molecule or an encapsulated chimeric molecule, or a protein and a separate polyanionic molecule, or any combinations thereof, and (b) instructions to administer to cells or an individual a therapeutically effective amount of the composition.
- the kit may comprise
- the kit can further comprise instructions for suitable operational parameters in the form of a label or a separate insert.
- the kit may have standard instructions informing a physician or laboratory technician to prepare a dose of chimeric molecule.
- the kit may further comprise a standard or control information so that a patient sample can be compared with the control information standard to determine if the test amount of chimeric molecule is a therapeutic amount consistent with for example, treating deafness in a patient.
- a standard or control information so that a patient sample can be compared with the control information standard to determine if the test amount of chimeric molecule is a therapeutic amount consistent with for example, treating deafness in a patient.
- Example 1 Efficient Delivery of Proteins In vitro and In vivo.
- One of the goals is to develop a protein-based hair cell regeneration paradigm by delivering functional Myc/NICD proteins to adult guinea pig inner ear to induce supporting cell proliferation, and to transdifferentiate them to hair cells.
- the approach is to restore hearing in deafened guinea pig models exposed to noise and treated by ototoxic drugs.
- the protein based- therapy is to be applied to adult human inner ear ex vivo for induction of proliferation and hair cell regeneration.
- a protein-based therapy was chosen as it delivers biological molecules with specific and transient function. With this approach, the dose, duration and relative ratio of proteins to be delivered can be optimized in vitro and in vivo.
- the protein-based therapy is delivered using a modified supercharged GFP protein that is linked to aurein (s-GFP-aurein or alternatively referred to, herein, as aurein- +36GFP), a peptide with antibacterial function secreted by frog.
- s-GFP-aurein or alternatively referred to, herein, as aurein- +36GFP
- Cre recombinase is taken up by inner ear supporting cells in vivo after being directly injected into the inner ears of neonatal and adult mice. Cre recombinase delivered was translocated into nuclei, leading to the cleavage of the floxP sites and expression of a reporter gene tdTomato.
- s-GFP-aurein is fused with Myc and NICD and delivery to the supporting cells of adult guinea pig inner ears is tested.
- Production of fusion proteins including s-GFP-aurein, s-GFP-aurein-NICD and s-GFP -aurein- Atohl The respective proteins are purified at micro molar ( ⁇ ) concentrations and tested for inner ear delivery. s-GFP-aurein- Atohl is used for the study.
- Myc NICD activation and take up s-GFP-aurein, the adult mouse inner ear is used for a proof- of-principle experiment testing the ability of s-GFP-aurein carrying the transcription factors Myc and NICD to induce the proliferation of supporting cells.
- Combinations of s-GFP-aurein-Myc/s-GFP-aurein-NICD are injected into adult guinea pig inner ears.
- Induction of proliferation is evaluated by doses, the ratios between the two proteins, the duration of effects and single vs. multiple injections.
- the conditions under which limited proliferation is induced in the inner ear sensory epithelial region that is suitable for transdifferentiation into hair cells are to be identified. Further attention will be paid to any sign of tumor formation.
- In the current study by continuous expression of Myc/NICD through viral infection or by induced Myc NICD trans gene expression for over 30 days tumors were not observed.
- Guinea pigs serve as an excellent model to optimize the surgical procedure for protein delivery that should be applicable to humans.
- the cochlea is a snail-shaped structure that senses sounds ranging from high frequency at the base to low frequency at the apex. It is critical to regenerate hair cells along the length of the cochlea so hearing can be recovered in most frequencies. Ways to reach different cochlear regions will be evaluated, including single injection of fluorophore-labeled s- GFP-aurein (which itself does not have fluorescence due to modifications to GFP) to the middle turn, multiple injections to different turns, and injections to different chambers of the cochlea (scala tympani vs. scala media). The goal is to identify a simple procedure that optimizes therapeutic effects while avoiding damage to the inner ear.
- Example 2 Hair cell regeneration in adult guinea pig in vivo
- Hair cell regeneration by Atohl overexpression Delivery of s-GFP-aurein- Atohl into supporting cells is evaluated for hair cell induction. This is performed three to five days after Myc/NICD induced proliferation, as Myc/NICD activity is required for proliferation and their downregulation is important to Atohl induced hair cell transdifferentiation. Due to the relatively short half-life of the delivered proteins, downregulation of Myc/NICD is thus achieved by slightly delayed Atohl delivery. Following the protein-delivery of Atohl, hair cell production at different time points is examined. The shortest period within which differentiated and functional hair cells are regenerated is to be identified.
- Hair cell regeneration by blocking Notch pathway by DAPT and LY411575 The advantage of using Notch inhibitors is that they are well characterized and there are multiple forms, some of which have been approved for clinical use, including Eli Lilly's Alzheimer drug (gamma-secretase inhibitor LY411575).
- Local delivery of DAPT and LY411575 is tested by placing PEG400 or gelform containing different concentrations of DAPT and LY411575 in the round window niche (just outside the membrane of the inner ear that separates middle and inner ear). Two to four weeks later, hair cell regeneration will be evaluated. The shortest period within which differentiated hair cells can be regenerated is determined.
- Example 3 Hair cell regeneration to restore hearing
- Hearing loss in guinea pigs can be induced by noise exposure or ototoxic drug treatment (e.g. gentamicin).
- ototoxic drug treatment e.g. gentamicin
- the functional test following hair cell regeneration is hearing restoration.
- auditory brainstem response (ABR) hearing recovery can be precisely measured.
- Hearing restoration in noise-induced deaf guinea pig model Guinea pigs are subjected to noise to create profound (complete) hearing loss across different frequencies that are associated with major hair cell loss. Supporting cell proliferation is induced by protein delivery and hair cell regeneration by Atohl protein and by application of Notch inhibitors in one ear; whereas the contralateral uninjected ear serves as a control. ABR is performed 1-4 months following injection, to study hearing recovery. In control ear, no ABR or significantly elevated ABR thresholds are detected at any frequencies. In the injected inner ear, ABR will ascertain hearing recovery (by dB) across different frequencies.
- ABR For instance detection by ABR at 50 dB at 16 kHz is a demonstration of hearing in the middle frequency with a threshold at 50 dB (i.e. the animal can hear the sound at 50 dB or above at this frequency). This study will demonstrate precisely how much hearing has recovered and at what frequencies. ABR identifies whether or not regenerated hair cells are functional and the effect on hearing recovery. It will provide information regarding the procedure that produces the best outcome. For instance by correlating the surgical and delivery procedure with ABR, it can be determined how effective the approach is on hearing restoration at different frequencies, which has a direct relevance in human study.
- Ototoxic drugs (aminoglycoside antibiotics neomycin and gentamicin, and anti-cancer drug Cisplatin) preferentially kill hair cells to cause hearing loss.
- Guinea pigs will be treated with gentamicin to create permanent deafness.
- Protein delivery of Myc NICD followed by Atohl and Notch inhibitors will be similarly studied.
- ABR will be performed to analyze hearing recovery in the injected inner ears vs. uninfected control inner ears. Detection of ABR will be a demonstration of hearing recovery following delivery of key molecules.
- Hearing recovery between the above two models is compared to determine which recovery is more prominent. This information would be useful in determining the type of patients to enroll in clinical study.
- Example 4 Induction of proliferation and hair cell regeneration in adult human cochlea ex vivo.
- Protein delivery of Myc/NICD is performed for proliferation and Atohl and Notch inhibitor for hair cell regeneration using cultured human inner ear.
- This study will evaluate the similarity and difference in protein-based therapy in guinea pig and human inner ears, providing important information that is relevant to clinical study. Due to extreme conservation between mammalian inner ear, it is expected to see a highly similar outcome in human inner ear explant study as in the guinea pig.
- Example 5 Protein Delivery Into the Inner Ear
- the goal of this study was to use protein-mediated delivery system to deliver the biological proteins directly inner ear cell types with functional consequences. With this method, the proteins delivered have specific functions, and the effect is transient. Further, delivery of native protein lessens any potential immune response.
- cell surface is cationic (positively charged)
- GFP green fluorescent protein
- supercharged protein both positively and negatively, named supercharged protein
- s-GFP-Cre s-GFP carrying Cre recombinase
- aurein an antimicrobial peptide, in combination with s- GFP, can serve as an effective carrier to deliver functional proteins into mouse inner ear cell types with high efficiency.
- (+36)-GFP-aurein-Cre was injected with different concentrations into P3 PvOsa-tdT mouse inner ear by cochleostomy in vivo. The tissues were harvested 5 days later for immunolabeling to identify tdT + inner ear cell types. Overall it was found that cochlear hair cells were primarily labeled with tdT, with additional tdT labeling in supporting cells. At low concentrations of 5 ⁇ , few IHC and some supporting cells (SC) were tdT + .
- the protein complex can be directly injected into mammalian inner ear that leads to uptake by a wide range of inner ear cell types.
- the protein delivered was properly localized in the nuclei and had the specific biological function in cleaving floxP sites on the DNA sequence, to activate tdTomato in the inner ear cells with high efficiency.
- the delivery system can be used to study protein functions, inner ear regeneration for hearing recovery, hearing protection, etc.
- Example 6 Delivery of functional NICD by aurein in the inner ear.
- aurein linked with NICD was prepared for inner ear delivery in vitro.
- Cultured mouse cochlea were treated with aurein-NICD without lipofectamine2000.
- Five days after the treatment tissues were harvested for qRT-PCR, to determine the level Notch and its two downstream targets Hesl and Hes5.
- qRT-PCR showed overall that there was an increase in the level for all three genes, judging by qRT-PCR. 40%, 70% and 15% of upregulation were observed for Hesl , hes5 and Notch respectively. The level increase in Notch is smaller, which may be a reflection of degradation of Notch.
- Example 7 Supporting cells reprogrammed by Myc/NICD combination can
- Myc/NICD co-activation leads to renewed proliferation of many cell types including supporting cells, hair cells, stria vascularis and fibrocytes. Proliferating supporting cells react to Atohl over expression robustly and transdifferentiate to hair cells. Further upon Myc/NICD c-activation, even without cell cycle re-entry, the supporting cells can still be reprogrammed by Myc NICD and transdifferentiate to hair cells by Atohl over expression ( Figures6A-6H). Thus the Myc and NICD dosage is likely to play an important role, in which high activity induces proliferation and subsequent transdifferentiation, and low activity induces transdifferentiation.
- Inner ear stem cells have been isolated only from neonatal and early postnatal mouse (Oshima, K. et al. Differential distribution of stem cells in the auditory and vestibular organs of the inner ear. J. Assoc. Res. Otolaryngol. 8, 18-31 (2007)). In adult no inner ear stem cells have been isolated, an indication that the stem cells lose their potential to proliferate and regenerate. It was shown by using rtTa tet-Myc/tet-NICD mice, in which Myc/NICD is induced by doxycycline, adult inner ear stem cells can be isolated as spheres.
- the spheres can differentiate to inner ear neurons, supporting cells and hair cells as neonatal mice ( Figures 7A-7I).
- Myc/NICD activation can be used to re-activate dormant adult inner ear stem cells, for regeneration of inner ear cell types for hearing recovery.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
Description
EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES
TO CELLS OF THE INNER EAR
FIELD OF THE INVENTION The present invention relates to protein therapeutics including compositions, methods of treatment and delivery of the therapeutic molecules for inducing inner ear cells to reenter the cell cycle and to proliferate.
BACKGROUND
One of the most common types of hearing loss is sensorineural deafness that is caused by the loss of hair cells or hair cell function. Hair cells are sensory cells in the cochlea responsible for transduction of sound into an electrical signal. The human inner ear contains only about 15,000 hair cells per cochlea at birth, and, although these cells can be lost as a result of various genetic or environmental factors (e.g., noise exposure, ototoxic drug toxicity, viral infection, aging, and genetic defects), the lost or damaged cells cannot be replaced. Hair cells also are found in the utricle of the vestibule, an organ which regulates balance. Therefore, hair cell regeneration is an important approach to restoring hearing and vestibular function.
Studies of regeneration of hair cells in mature mammalian inner ear to date have focused on transdifferentiation of existing supporting cells. Supporting cells underlie, at least partially surround, and physically support sensory hair cells within the inner ear. Examples of supporting cells include inner rod (pillar cells), outer rod (pillar cells), inner phalangeal cells, outer phalangeal cells (of Deiters), cells of Held, cells of Hensen, cells of Claudius, cells of Boettcher, interdental cells and auditory teeth (of Huschke). Transdifferentiation of supporting cells to hair cells by overexpression or activation of Atonal Homolog 1 (Atohl) in supporting cells or by exposure of supporting cells to Atohl agonists is one such approach to generating new hair cells. One limitation to this approach, however, is that transdifferentiation of supporting cells to hair cells diminishes the existing population of supporting cells, which can impair inner ear function. In addition, overexpression of Atohl in aged inner ear or flat epithelium, which lacks supporting cells, is not sufficient to induce hair cells. Furthermore, it is not clear if all types of supporting cells can be transdifferentiated into hair cells upon Atohl overexpression.
Other studies of hair cell regeneration have examined cell cycle reentry for hair cells in embryonic or neonatal mice by, for example, blocking Rb 1 and p27kip 1. However similar manipulations in the adult inner ear have not induced cell cycle reentry. In addition, the hair cells in embryonic and neonatal mice that reenter the cell cycle, in general, subsequently die.
Over 150 types of genetic deafness are due to mutations in genes that affect both hair cells and supporting cells. For example, mutations in Myosin Vila (Myo7a) cause hair cell stereocilia abnormalities that lead to permanent deafness. Mutations in GJB2 (connexin 26) cause damage to supporting cells that lead to the most common form of genetic deafness.
Approaches (e.g., gene therapy and anti-sense oligonucleotide therapy) have been developed as potential treatments for hereditary deafness. However, most of these defects occur during embryonic development. By birth, affected hair cells and supporting cells already have died or are severely degenerated, making intervention difficult. Therefore, to treat genetic deafness, there is an ongoing need to regenerate hair cells and/or supporting cells in utero and after birth, which can be combined with other approaches to correct the genetic defects underlying the disease.
In addition, inner ear non-sensory cells (e.g., fibrocytes in the ligament) play essential roles in hearing. Inner ear non-sensory cells can be damaged by factors such as noise and aging, which contribute to hearing loss. These cell types, like many of those in the inner ear, lack the capacity to regenerate spontaneously after damage. Because spontaneous regeneration does not occur in the mammalian inner ear, recovery from hearing loss requires intervention to replace any inner ear cell types that are lost or degenerated. Therefore, there is an ongoing need to regenerate hair and/or supporting cells within the mammalian ear, in particular in the inner ear, to replace those lost, for example, by genetic or environmental factors. The regenerated hair and supporting cells may be used to slow the loss of hearing and/or vestibular function and/or partially or fully to restore loss of hearing and/or vestibular function.
SUMMARY
Embodiments of the invention are directed, inter alia, to therapeutic compositions and delivery of these compositions to the inner ear of patients. These compositions activate Myc and Notch in inner ear cells, the hair cells and/or supporting cells which results in the induction of hair cell and/or supporting cell proliferation. Inhibition of Myc and/or Notch in the supporting cells induces transdifferentiation of supporting cells to hair cells. In addition, activating Atohl
induces transdifferentiation of supporting cells to hair cells. The proliferation and the subsequent differentiation of the cell into hair and/or supporting cells can restore or improve hearing and/or vestibular function.
Activation and subsequent inactivation of Myc and Notchl can lead to
regeneration of cells within the strial vascularis that includes marginal cells, intermediate cells, basal cells and fibrocytes. Degeneration of strial vascularis causes hearing loss. Regeneration of any of the cell types could lead to hearing recovery. Accordingly, embodiments of the invention include all cells and cell types associated with hearing and hearing loss, including neural cells, such as for example, neurites. In an embodiment, a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear. The method may also include the step of inhibiting Myc and/or Notch expression or activity after proliferation of the hair or supporting cell to induce differentiation or transdifferentiation of the cell and/or at least one of its daughter cells into a hair cell. The method may also further include the step of activating Atohl to induce transdifferentiation of the supporting cells to hair cells. The Myc activity in the hair and/or supporting cells is increased by administering an effective amount of Myc protein, Myc peptides or Myc activators linked to supercharged proteins, such as, for example, green fluorescent proteins (s-GFP) or variants thereof. The Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof. Inhibition of Myc and/or Notch can be accomplished through administration of inhibitors or once the activator has degraded over time. Activation of Atohl is accomplished by the delivery of Atohl proteins, Atohl peptides, Atohl activators, or combinations thereof, linked to s-GFP or variants thereof. In another embodiment, a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of patient in need of such
treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which activate yc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD), or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear. In another embodiment, a method of inducing proliferation and
transdifferentiation of inner ear cells, in vivo or in vitro, comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering after a pre-determined period, inhibitors to inhibit Notch and Myc activity followed by a composition that activates Atohl and induces the transdifferentiation of the supporting cells. The administration of the Myc and/or Notch inhibitors can be optional. The activity can be measured over time based on the half-life (ti/2 ) of the protein and the Atohl activator can be administered once the activity of the Myc and/or Notch has decreased to a desired level.
In another embodiment, a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and/or Myc activity; administering a composition comprising activators of Atohl wherein the Atohl composition induces the transdifferentiation of the supporting cells.
In another embodiment, a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations
thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering an activator of Atohl, wherein the Atohl activator induces the transdifferentiation of the supporting cells to hair cells. In yet another embodiment, a method of inducing proliferation and transdifferentiation of inner ear cells, in vivo or in vitro, comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch
Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
In yet another embodiment, a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch
Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
In another embodiment, a method of delivering a therapeutic molecule to cells of the inner ear of a patient, comprises administering to the inner ear of a patient a chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules. The chimeric molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
Examples of gene editing agents include, without limitation: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or
combinations thereof. The anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. Oligonucleotides or polynucleotides comprise: ribonucleic acids ( NA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof. The chimeric molecule also comprises a supercharged protein or variants thereof and antimicrobial or membrane destabilizing peptides, for example, aurein, or variants thereof.
In an embodiment, a method of inducing transdifferentiation of inner ear cells comprises contacting an inner ear cell in vitro or in vivo with a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity is decreased or inhibited by a Notch inhibitor, optionally, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
In another embodiment, a method of regenerating inner ear cells comprises inducing proliferation or cell cycle reentry of inner ear cells in vitro or in vivo, the method comprising contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells. In another embodiment, a method for protecting and/or treating hearing loss in a patient in need of such treatment, comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof
within a cell, to induce neurite growth, proliferation or cell cycle re-entry of inner ear cells, proliferation of hair cells, proliferation of supporting cells, and/or transdifferentiation of supporting cells.
Other aspects are described infra. BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1A and IB show the in vivo delivery of Cre recombinase to hair cells in the mouse inner ear. Figure 1 A: The scala media (cochlear duct) of P0 floxP-tdTomato mice (n = 4) were injected with 0.3 μΐ, of 23 μΜ (-30)GFP-Cre in 50% RNAiMAX or with RNAiMAX alone (control). After 5 days, tdTomato expression indicative of Cre-mediated recombination was visualized using immunohistology. Red = tdTomato; green = Myo7a; white = Sox2; blue = DAPI. Yellow brackets indicate the outer hair cell (OHC) region. Figure IB: Ten days after (- 30)GFP-Cre delivery,intact espin (Esp)- expressing stereocilia of tdTomato-positive outer hair cells were present (arrow), similar to stereocilia in control cochlea. Red = tdTomato; green = Esp, white = Sox2; blue = DAPI, Scale bars: 10 μπι. Figures 2A-2E show the high efficiency of protein delivery mediated by aurein in the inner ear in vivo. Injection of (+36)GFP-aurein-Cre with different concentrations to Rosa- tdT t mouse cochlea resulted in tdT labeling in cochlear cell types with different efficiencies. Figure 2A: At 5μΜ, tdT labeling was mainly in some IHC and SC. Figure 2B: At 22.5 μΜ, tdT labeling was in most IHC and OHC. Figure 2C: At 50μΜ, tdT was seen in most IHC and OHC, as well as a large number of SC. IHC loss was seen under the condition. Figure 2D: In mice injected with 50μΜ (+36)GFP-Cre, very few IHC and HC were labeled with tdT. Figure 2E: In Opti-MEM injected control mice, no tdT labeling was detected in any inner ear cells. Scale bars: 10 μπι.
Figure 3 shows the high efficiency of aurein mediated protein delivery in the mammalian inner ear. Comparison between different concentrations of (+36)GFP-aurein-Cre and control reveled that extremely high-efficient delivery of functional protein (Cre) with the aurein at 22.5 and 50 μΜ, respectively.
Figure 4 is a schematic diagram depicting hair cell regeneration. After inner ear damage that leads to hair cell loss, Myc/NICD are transiently activated in the supporting cells to
induce proliferation, followed by transient Atohl activation that results in transdifferentiation from supporting cells to hair cells. Arrows point to two supporting cells that divide and give rise to new hair cells. In the repaired cochlea, the number of hair cells and supporting cells are restored. Figure 5 is a graph showing that after aurein-NICD infection in cultured neonatal mouse cochlea, qRT-PCR showed a general increase in expression for all Notch pathways genes including Hesl , Hes5 and Notch.
Figures 6A-6H show HC regeneration in vivo. Figures 6A-6C show that Ad- Atohl infection in adult Atohl -GFP cochlea results in GFP (a readout for Atohl expression) in IHCs (arrows), cells in the IHC region (solid arrowheads) and the OHC region (open
arrowheads). None of the infected SCs became new HCs. A'-C. Cross section (along the dashed line in Figure 6C) shows GFP in IHC, inner phalangeal cell (arrow) and outer pillar cell (C, arrowhead). Figures 6D-6F show that Dox induction and Ad-Atohl infection induced division in adult rtTa/tet-Myc/tet-NICD cochlea in vivo and supernumerary HCs (bracket) in the IHC region. D'-F'. Cross section along the solid line (Figure 6F) shows two ectopic HCs (eHC) adjacent to an IHC. D"-F". Cross section along the dashed line (Figure 6F) shows numerous ectopic HCs adjacent to an IHC, some of which are EdU+(eHC). Scale bar: ΙΟμηι. Figure 6G shows that Dox+ad- Atohl significantly increased the number of HCs in the IHC region. Figure 6H shows that in the limbus region, HCs are regenerated from dividing and non-dividing cells; whereas no HCs are seen in control limbus. Scale bars: Ι Ομπτ.
Figures 7A-7I show that sphere formation from adult rtTa/tet-Myc/tet-NICD cochlea treated with Dox for 7 days. Figures 7A-7C show spheres from adult cochleas after 2 (Figure 7A), 4 (Figure 7B) and 7 (Figure 7C) passages. Figures 7D-7F show Oct4 labeled undifferentiated spheres (Figure 7D, solid sphere; Figure 7E, hollow sphere), and indication of activation of stem cell gene. Phal: Phalloidin labels actin. Nestin, another stem cell gene, labels sphere (Figure 7F). Figures 7G-7I show that under differentiated conditions, Pax2, an early inner ear progenitor gene, is detected in the sphere. Myo7a, a hair cell marker, stains differentiated sphere cells. NF (neurofilament) stains many cells under the condition, an indication that some cells start to become neurons (Figure 71). pan-Cyt: pan-cytokeratin.
DETAILED DESCRIPTION
Embodiments of the invention are directed to compositions for the efficient intracellular delivery of therapeutic proteins to the nucleus or cytoplasm, in particular of hair cells and/or supporting cells of the inner ear. Conventional methods of protein delivery typically rely on cationic peptides or proteins to facilitate endocytosis, but suffer from low tolerance for serum proteins, poor endosomal escape, and limited in vivo efficacy. The reagents embodied herein can potently deliver proteins that are fused to polynucleotides, oligonucleotides, negatively supercharged proteins, that contain natural anionic domains, or that natively bind to anionic nucleic acids. The methods and compositions can be used to increase a population of hair cells and/or supporting cells diminished by environmental or genetic factors. Using the methods and compositions described herein, it may be possible to preserve or improve hearing and/or vestibular function in the inner ear.
All genes, gene names, and gene products disclosed herein are intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable. Thus, the terms include, but are not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates. Thus, for example, for the genes or gene products disclosed herein, which in some embodiments relate to mammalian nucleic acid and amino acid sequences, are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds. In preferred embodiments, the genes, nucleic acid sequences, amino acid sequences, peptides, polypeptides and proteins are human.
It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One having ordinary skill in the relevant art, however, will readily recognize that the invention can be practiced without one or more of the specific details or with other methods. The present invention is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Furthermore, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
Definitions
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "including", "includes", "having", "has", "with", or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term
"comprising." As used herein, the terms "comprising," "comprise" or "comprised," and variations thereof, in reference to defined or described elements of an item, composition, apparatus, method, process, system, etc. are meant to be inclusive or open ended, permitting additional elements, thereby indicating that the defined or described item, composition, apparatus, method, process, system, etc. includes those specified elements—or, as appropriate, equivalents thereof— and that other elements can be included and still fall within the
scope/definition of the defined item, composition, apparatus, method, process, system, etc.
The term "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value or range. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude within 5-fold, and also within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise
stated the term "about" meaning within an acceptable error range for the particular value should be assumed.
"Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
As used herein, a "chimeric" molecule is one which comprises one or more unrelated types of components or contain two or more chemically distinct regions or domains which can be conjugated to each other, fused, linked, translated, attached via a linker, chemically synthesized, expressed from a nucleic acid sequence, etc. For example, an antimicrobial or membrane destabilizing peptide and an unrelated peptide, a peptide and a nucleic acid sequence, a peptide and a detectable label, unrelated peptide sequences, unrelated nucleic acid sequence and the like.
The term "anionic" molecule is one which comprises one or more "anionic" domains which confer an overall net anionic charge to the molecule. Accordingly, the chimeric molecule can be an anionic molecule.
A "supercharged" molecule is a molecule e.g. peptide, having a positive or negative charge and when it is connected to another molecule confers an overall positive or negative charge to the entire molecule.
As used herein, a "membrane destabilizing domain" is one which disrupts a cellular membrane in vitro or in vivo, for example, aurein. The term encompasses proteins, peptides, polynucleotides, oligonucleotides, bacterial or viral molecules, antimicrobial peptides, antibacterial molecules, microtubules, synthetic or natural molecules. A chimeric molecule embodied herein, further comprises one or more membrane destabilizing domains.
As used herein, the terms "associated with," "conjugated," "linked," "attached," and "tethered," when used with respect to two or more moieties, means that the moieties or domains are physically associated or connected with one another, either directly or via one or more additional moieties that serves as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. The term "connected" will be used for the sake
of brevity and is meant to include all possible methods of physically associating each domain of the chimeric molecule to each other. For example, a supercharged protein is typically associated with or connected to a nucleic acid by a mechanism that involves non-covalent binding (e.g., electrostatic interactions). In certain embodiments, a positively charged, supercharged protein is associated with a nucleic acid through electrostatic interactions to form a complex. In some embodiments, a sufficient number of weaker interactions can provide sufficient stability for moieties to remain physically associated under a variety of different conditions. In certain embodiments, the agent to be delivered is covalently bound to the supercharged protein.
As used herein, the term, "Notch" refers to the Notch family of signaling proteins, which includes Notch 1, Notch 2, Notch 3 and Notch 4, or notch intracellular domain (NICD). The full length sequence of human Notchl appears, for example, in the NCBI protein database under accession no. NP 060087.3 (see ncbi.nlm.nih.gov). Members of this Type 1
transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. Notch family members play a role in a variety of developmental processes by controlling cell fate decisions. Notch 1 is cleaved in the trans-Golgi network, and presented on the cell surface as a heterodimer. Notch 1 functions as a receptor for membrane bound ligands Jagged 1 , Jagged 2 and Delta 1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. Notch 1 affects the implementation of differentiation, proliferation and apoptotic programs.
As used herein, "Myc" refers to the Myc family of transcription factors. Myc is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The full length sequence of human Myc appears, for example, in the
NCBI protein database under accession no. NP 002458.2 (see ncbi.nlm.nih.gov). Myc functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. Myc is also known in the art as MYC, v-myc myelocytomatosis viral oncogene homolog (avian),
transcription factor p64, bHLHe39, MRTL, avian myelocytomatosis viral oncogene homolog, v-
myc avian myelocytomatosis viral oncogene homolog, myc proto-oncogene protein, class E basic helix-loop-helix protein 39, myc-related translation/localization regulatory factor, and proto-oncogene Myc, and BHLHE39.
As used herein "Atohl" refers to atonal homolog 1 and family thereof. The Atohl belongs to the basic helix-loop-helix (BHLH) family of transcription factors. It activates E-box dependent transcription along with E47. The full-length Atohl appears, for example, in the NCBI protein database under accession no. NC 000004.12. See, also, US Publication Nos. US 20040237127 and US 20110251120.
As used herein, the term "green fluorescent protein" (GFP) refers to a protein originally isolated from the jellyfish Aequorea victoria that fluoresces green when exposed to blue light or a derivative of such a protein (e.g., a supercharged version of the protein). The amino acid sequence of wild type GFP is as follows: (SEQ ID NO: 1) MSKGEELFTG
VVPILVELDG DVNGHKFSVS GEGEGDATYG LTLKFICTT GKLPVPWPTL VTTFSYGVQC FSRYPDHMKQ HDFFKSAMPE GYVQERTIFF DDGNYKTRA EV FEGDTLV NRIELKGIDF KEDGNILGHK LEYNYNSHNV YIMADKQKNG IKVNFKIRHN IEDGSVQLAD HYQQNTPIGD GPVLLPDNHY LSTQSALSKD PNEKRDHMVL LEFVTAAGIT HGMDELY .
Proteins that are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% homologous to SEQ ID NO: 1 , are also considered to be green fluorescent proteins. In certain embodiments, the green fluorescent protein is supercharged. In certain embodiments, the green fluorescent protein is superpositively charged (e.g., +15 GFP, +25 GFP, and +36 GFP). In certain embodiments, the GFP may be modified to include a polyhistidine tag for ease in purification of the protein. In certain embodiments, the GFP may be fused with another protein or peptide (e.g., hemagglutinin 2 (HA2) peptide). In certain embodiments, the GFP may be further modified biologically or chemically (e.g., post-translational modifications, proteolysis, etc.).
As used herein, unless otherwise indicated, the terms "peptide", "polypeptide" or "protein" are used interchangeably herein, and refer to a polymer of amino acids of varying sizes. These terms do not connote a specific length of a polymer of amino acids. Thus, for example, the terms oligopeptide, protein, and enzyme are included within the definition of
polypeptide or peptide, whether produced using recombinant techniques, chemical or enzymatic synthesis, or be naturally occurring. This term also includes polypeptides that have been modified or derivatized, such as by glycosylation, acetylation, phosphorylation, and the like.
As used herein, a "nucleic acid" or "nucleic acid sequence" or "cDNA" refers to a nucleic acid segment or fragment which has been separated from sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in a genome in which it naturally occurs, and refers to nucleic acid sequences in which one or more introns have been removed. The term also applies to nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, e.g., RNA or DNA or proteins, which naturally accompany it in the cell. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA, for instance, DNA which is part of a hybrid gene encoding additional polypeptide sequences.
A "polynucleotide" means a single strand or parallel and anti-parallel strands of a nucleic acid. Thus, a polynucleotide may be either a single-stranded or a double-stranded nucleic acid. The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention are variants of wild type gene products. Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that
give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
As used herein, the terms "nucleic acid sequence", "polynucleotide," and "gene" are used interchangeably throughout the specification and include complementary DNA (cDNA), linear or circular oligomers or polymers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioate, methylphosphonate, and the like. The nucleic acid sequences may be "chimeric" that is, composed of different regions. In the context of this invention "chimeric" compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc. Each chemical region is made up of at least one monomer unit, i.e., a nucleotide. These sequences typically comprise at least one region wherein the sequence is modified in order to exhibit one or more desired properties.
The term "target nucleic acid" refers to a nucleic acid (often derived from a biological sample), to which the oligonucleotide is designed to specifically hybridize. It is either the presence or absence of the target nucleic acid that is to be detected, or the amount of the target nucleic acid that is to be quantified. The target nucleic acid has a sequence that is complementary to the nucleic acid sequence of the corresponding oligonucleotide directed to the target. The term target nucleic acid may refer to the specific subsequence of a larger nucleic acid to which the oligonucleotide is directed or to the overall sequence (e.g., gene or mRNA) whose expression level it is desired to detect. The difference in usage will be apparent from context.
In the present context, the terms "nucleobase" covers naturally occurring nucleobases as well as non-naturally occurring nucleobases. It should be clear to the person skilled in the art that various nucleobases which previously have been considered "non-naturally occurring" have subsequently been found in nature. Thus, "nucleobase" includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof. Illustrative examples of nucleobases are adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazaxanthine, 7-deazaguanine,
N4,N4-ethanocytosin, N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)- alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4- triazolopyridin, isocytosine, isoguanin, inosine and the "non-naturally occurring" nucleobases described in Benner et al, U.S. Pat No. 5,432,272. The term "nucleobase" is intended to cover every and all of these examples as well as analogues and tautomers thereof. Especially interesting nucleobases are adenine, guanine, thymine, cytosine, and uracil, which are considered as the naturally occurring nucleobases in relation to therapeutic and diagnostic application in humans.
As used herein, "nucleoside" includes the natural nucleosides, including 2'-deoxy and 2'-hydroxyl forms, e.g., as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).
"Analogs" in reference to nucleosides includes synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., described generally by Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Freier & Altmann, Nucl. Acid. Res., 1997, 25(22), 4429-4443, Toulme, J.J., Nature Biotechnology 19: 17-18 (2001); Manoharan M., Biochemica et Biophysica Acta 1489: 1 17-139(1999); Freier S. M., Nucleic Acid Research, 25:4429-4443 (1997), Uhlman, E., Drug Discovery & Development, 3: 203-213 (2000),
Herdewin P., Antisense & Nucleic Acid Drug Dev., 10:297-310 (2000) ); 2'-0, S'-C-linked
[3.2.0] bicycloarabinonucleosides (see e.g. N.K Christiensen., et al, J. Am. Chem. Soc, 120: 5458-5463 (1998). Such analogs include synthetic nucleosides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.
The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic," "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention are variants of wild type target gene products. Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs
or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs,) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population with a propensity for a disease state, that is susceptibility versus resistance.
As used herein, "variant" of polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).
"Treatment" is an intervention performed with the intention of preventing the development or altering the pathology or symptoms of a disorder. Accordingly, "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. "Treatment" may also be specified as palliative care. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. Accordingly, "treating" or "treatment" of a state, disorder or condition includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human or other mammal that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of
the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof; or (3) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms. The benefit to an individual to be treated is either statistically significant or at least perceptible to the patient or to the physician.
The terms "patient" or "individual" or "subject" are used interchangeably herein, and refers to a mammalian subject to be treated, with human patients being preferred. In some cases, the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.
As defined herein, a "therapeutically effective" amount of a compound or agent (i.e., an effective dosage) means an amount sufficient to produce a therapeutically (e.g., clinically) desirable result, for example, induce cell cycle reentry and/or proliferation of the cells of the inner ear (e.g., a hair cell or a supporting cell). The cells are contacted with amounts of the active agent effective to induce cell cycle reentry and/or proliferation and/or transdifferentiation of supporting cells to hair cells. The compositions can be administered from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of the compounds of the invention can include a single treatment or a series of treatments.
As defined herein, an "effective" amount of a compound or agent (i.e., an effective dosage) means an amount sufficient to produce a (e.g., clinically) desirable result.
As used herein, a "pharmaceutically acceptable" component/carrier etc. is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
The terms "determining", "measuring", "evaluating", "detecting", "assessing" and "assaying" are used interchangeably herein to refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or
qualitative determinations. Assessing may be relative or absolute. "Assessing the presence of includes determining the amount of something present, as well as determining whether it is present or absent.
As used herein, the term "agent" is meant to encompass any molecule, chemical entity, composition, drug, therapeutic agent, chemotherapeutic agent, or biological agent capable of preventing, ameliorating, or treating a disease or other medical condition. The term includes small molecule compounds, antisense reagents, siRNA reagents, antibodies, enzymes, peptides organic or inorganic molecules, natural or synthetic compounds and the like. An agent can be assayed in accordance with the methods of the invention at any stage during clinical trials, during pre-trial testing, or following FDA-approval.
By the term "modulate," it is meant that any of the mentioned activities, are, e.g., increased, enhanced, increased, agonized (acts as an agonist), promoted, decreased, reduced, suppressed blocked, or antagonized (acts as an agonist). Modulation can increase activity more than 1 -fold, 2-fold, 3-fold, 5-fold, 10-fold, 100-fold, etc., over baseline values. Modulation can also decrease its activity below baseline values. Modulation can also normalize an activity to a baseline value.
General Techniques
For further elaboration of general techniques useful in the practice of this invention, the practitioner can refer to standard textbooks and reviews in cell biology, tissue culture, embryology, and physiology.
With respect to tissue culture and embryonic stem cells, the reader may wish to refer to Teratocarcinomas and embryonic stem cells: A practical approach (E. J. Robertson, ed., IRL Press Ltd. 1987); Guide to Techniques in Mouse Development (P. M. Wasserman et al. eds., Academic Press 1993); Embryonic Stem Cell Differentiation in vitro (M. V. Wiles, Meth.
Enzymol. 225:900, 1993); Properties and uses of Embryonic Stem Cells: Prospects for
Application to Human Biology and Gene Therapy (P. D. Rathjen et al., Reprod. Fertil. Dev. 10:31 , 1998).
General methods in molecular and cellular biochemistry can be found in such standard textbooks as Molecular Cloning: A Laboratory Manual, 3rd Ed. (Sambrook et al, Harbor Laboratory Press 2001); Short Protocols in Molecular Biology, 4th Ed. (Ausubel et al. eds., John Wiley & Sons 1999); Protein Methods (Bollag et al, John Wiley & Sons 1996);
Nonviral Vectors for Gene Therapy (Wagner et al. eds., Academic Press 1999); Viral Vectors (Kaplift & Loewy eds., Academic Press 1995); Immunology Methods Manual (I. Lefkovits ed., Academic Press 1997); and Cell and Tissue Culture." Laboratory Procedures in Biotechnology (Doyle & Griffiths, John Wiley & Sons 1998). Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, Sigma- Aldrich, and ClonTech.
The following description of the preferred embodiments is merely exemplary in nature and is in no way intended to limit the invention, its application or uses. Embodiments of the invention may be practiced without the theoretical aspects presented. Moreover, the theoretical aspects are presented with the understanding that Applicants do not seek to be bound by the theory presented.
Supercharged Proteins
Supercharged proteins can be produced by changing non-conserved amino acids on the surface of a protein to more polar or charged amino acid residues. The amino acid residues to be modified may be hydrophobic, hydrophilic, charged, or a combination thereof. Supercharged proteins can also be produced by the attachment of charged moieties to the protein in order to supercharge the protein. Supercharged proteins frequently are resistant to aggregation, have an increased ability to refold, resist improper folding, have improved solubility, and are generally more stable under a wide range of conditions, including denaturing conditions such as heat or the presence of a detergent. Any protein may be modified using the inventive system to produce a supercharged protein. Natural as well as unnatural proteins (e.g., engineered proteins) may be modified. Example of proteins that may be modified include receptors, membrane bound proteins, transmembrane proteins, enzymes, transcription factors, extracellular proteins, therapeutic proteins, cytokines, messenger proteins, DNA-binding proteins, RNA-binding proteins, proteins involved in signal transduction, structural proteins, cytoplasmic proteins,
nuclear proteins, hydrophobic proteins, hydrophilic proteins, etc. A protein to be modified may be derived from any species of plant, animal, and/or microorganism. In certain embodiments, the protein is a mammalian protein. In certain embodiments, the protein is a human protein. In certain embodiments, the protein is derived from an organism typically used in research. For example, the protein to be modified may be from a primate (e.g., ape, monkey), rodent (e.g., rabbit, hamster, gerbil), pig, dog, cat, fish (e.g., Danio rerio), nematode (e.g., C. elegans), yeast (e.g., Saccharomyces cerevisiae), or bacteria (e.g., E. coli). In certain embodiments, the protein is non-immunogenic. In certain embodiments, the protein is non-antigenic. In certain
embodiments, the protein does not have inherent biological activity or has been modified to have no biological activity. In certain embodiments, the protein is chosen based on its targeting ability. In certain embodiments, the protein is green fluorescent protein.
Compositions and Treatments
Disclosed herein are methods of inducing proliferation or cell cycle reentry of inner ear cells, such as, for example, strial vascularis, hair cells and supporting cells. Methods of transdifferentiation of supporting cells, neurite growth, are also described. In general, the methods comprise increasing Myc, Notch or both Myc activity and Notch activity within the cell sufficient to induce proliferation or cell cycle reentry of the hair cells and/or supporting cells. Inhibition of Myc and/or Notch and/or the activation of Atohl induce the transdifferentiation of supporting cells to hair cells. The compositions, embodied herein, activate Myc and Notch in inner ear cells, such as, hair cells and/or supporting cells which results in the induction of hair cell and/or supporting cell proliferation. In addition, compositions activating Atohl induces
transdifferentiation of supporting cells to hair cells. The proliferation and the subsequent differentiation of the cell into hair and/or supporting cells can restore or improve hearing and/or vestibular function.
Activation and subsequent inactivation of Myc and Notchl can lead to
regeneration of cells within the strial vascularis that includes marginal cells, intermediate cells, basal cells and fibrocytes. Degeneration of strial vascularis causes hearing loss. Regeneration of any of the cell types could lead to hearing recovery, including neurite growth or other neural cells associated with hearing and hearing loss due to any cause. Hair cells are inner ear sensory
cells, including inner hair cells, outer hair cells, and vestibular hair cells. Supporting cells include Deiters cells, Hensen cells, Pillar cells, inner phalangeal cells, inner border cells, Claudius cells, border cells, basal cells, interdental cells, inner sulcus, spiral limbus.
Disclosed herein are compositions for gene editing of cells of the inner ear. In particular, the targeted cells are the hair cells and supporting cells. The compositions, embodied herein, modulate various pathways and associated molecules which contribute to deafness or disorders thereof, in hair cells and supporting cells. Hair cells are inner ear sensory cells, including inner hair cells, outer hair cells, and vestibular hair cells. Supporting cells include Deiters cells, Hensen cells, Pillar cells, inner phalangeal cells, inner border cells, Claudius cells, border cells, basal cells, interdental cells, inner sulcus, spiral limbus.
Hearing loss affects a large portion of population yet no treatment is available beyond hearing aids and cochlear implant, both of which provide limited benefits. In the US alone, over 30 million people suffer from hearing loss. The major cause of hearing loss in humans is due to irreversible loss of the inner ear sensory cells, hair cells, which are responsible for detecting sounds and sensing balance. As the result, regeneration of hair cells has become a focus aiming at developing potential therapy for hearing loss. Further hearing loss can be caused by defective cell types in the inner ear such as strial vascularis and supporting cells, neurites, or any cell type associated with deafness or associated disorders thereof, whose regeneration could lead to restoration of hearing.
Accordingly, embodiments are directed to protein-mediated delivery systems to deliver the biological proteins directly to inner ear cell types with functional consequences. With these methods, the proteins delivered have specific functions, and the effect is transient. Further, delivery of native protein lessens any potential immune response. Such an approach would not only be valuable for inner ear delivery, but has far reaching effects on the delivery of proteins targeting different diseases, achieving specific effects in multiple organs and cell types.
For efficient protein delivery, proteins need to enter cells with sufficient amounts, and are released from endosomes within cells and reach the targets. Improvement in the endosome release could have drastic effects on the amount of protein to reach the target with enhanced biological effect. Antimicrobial or membrane destabilizing peptides, for example,
Aurein, combination with s-GFP, can serve as an effective carrier to deliver functional proteins into mouse inner ear cell types with high efficiency.
High-efficiency delivery of functional proteins in the inner ear has tremendous advantage over conventional systems, including (1). It allows the delivery of unlimited combinations of proteins to mammalian inner ear without limitations on the size or localization of proteins delivered; (2). The effect will be specific; (3). The effect will be transient as delivered proteins will be degraded over time, which allows the modification of proteins (e.g., to reduce the response to degradation pathway) and controls the time length of function. The delivery system can be used to study protein functions, inner ear regeneration for hearing recovery, hearing protection, and gene editing to correct genetic deafness by genome- editing proteins.
In one embodiment, a chimeric molecule comprises at least one protein or peptide fused, complexed or linked to one or more anionic molecules, wherein the one or more anionic molecules comprise one or more anionic domains or bind to an anionic nucleic acid domain. In some embodiments, the chimeric molecule comprises an overall net negative charge. The anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. In some embodiments, the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
In another embodiment, the chimeric molecules are cationic, anionic or are neutrally charged. In another embodiment, the one or more proteins or peptides are cationic, anionic or are neutrally charged. The proteins or peptides comprise: antimicrobial or membrane destabilizing peptides, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In an embodiment, a chimeric molecule comprises: a supercharged protein, an antimicrobial or membrane destabilizing peptide, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal
Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, a chimeric molecule comprises at least one supercharged protein linked to at least one antimicrobial or membrane destabilizing peptide, and Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, the chimeric molecule comprises a supercharged molecule connected to a membrane destabilization domain which in turn is connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, the chimeric molecule comprises one or more membrane destabilization domains connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, the chimeric molecule comprises a membrane destabilization domain connected to a supercharged molecule which in turn is connected to one or more Myc proteins or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, the chimeric molecule comprises a membrane destabilization domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which are connected to a supercharged molecule.
One of ordinary skill in the art would understand that there are a multitude of configurations which can be obtained. Accordingly, if the letter "S" represents the supercharged
domain, the letter "M" represents the antimicrobial or membrane destabilizing domain, and the letter "X" represents the therapeutic molecules such as, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof. The molecular structure of the molecule can be S-M-X, or M-X-X, or S- M-M-X, or S-S-M-M-X, etc. In those cases where there are two or more molecules that comprise a domain (e.g. a membrane destabilization domain), these domains can comprise different molecules or they can be the same molecule.
For efficient protein delivery, proteins need to enter cells with sufficient amount, and are released from endosomes within cells and reach the targets. Improvement in the endosome release would have drastic effects on the amount of protein to reach the target with enhanced biological effect. Aurein, an antimicrobial peptide in combination with s-GFP, can serve as an effective earner to deliver functional proteins into mouse inner ear cell types with high efficiency. Accordingly, in embodiments, the compositions comprise a supercharged protein linked to antimicrobial or membrane destabilizing peptides, for example, aurein, mutants or variants thereof (e.g. (GLFDIIKKIAESF; SEQ ID NO: 2). Membrane destabilization peptides are known in the art. See, for example, Fernandez, D. I. et al., Biochim. Biophys. Acta, 2009 Aug; 1788(8): 1630-8.
Examples of aurein mutants are shown in Table 1.
Label Sequence
Aurein 1.2 GLFDIIKKIAESF (SEQ ID NO: 2)
G1A ALFDIIKKIAESF (SEQ ID NO: 3)
L2A GAFDIIKKIAESF (SEQ ID NO: 4)
F3A GLADIIKKIAESF (SEQ ID NO: 5)
D4A GLFAIIKKIAESF (SEQ ID NO: 6)
I5A GLFDAIKKIAESF (SEQ ID NO: 7)
I6A GLFDIAKKIAESF (SEQ ID NO: 8)
K7A GLFDIIAKIAESF (SEQ ID NO: 9)
K8A GLFDIIKAIAESF (SEQ ID NO: 10)
I9A GLFDIIKKAAESF (SEQ ID NO: 1 1)
E1 1A GLFDIIKKIAASF (SEQ ID NO: 12)
S12A GLFDIIKKIAEAF (SEQ ID NO: 13)
F13A GLFDIIKKIAESA (SEQ ID NO: 14)
K7H GLFDIIHKIAESF (SEQ ID NO: 15)
K8H GLFDIIKHIAESF (SEQ ID NO: 16)
E1 1 H GLFDIIKKIAHSF (SEQ ID NO: 17)
K7R GLFDIIRKIAESF (SEQ ID NO: 18)
K8R GLFDIIKRIAESF (SEQ ID NO: 19)
E1 1R GLFDIIKKIARSF (SEQ ID NO: 20)
E1 1D GLFDIIKKIADSF (SEO ID NO: 21)
In an embodiment, a membrane destabilizing domain comprises one or more of: antimicrobial or membrane destabilizing proteins or peptides, polynucleotides, oligonucleotides, bacterial or viral (e.g. reo virus outer capsid protein or peptide, μΐ ; papilloma virus capsid protein or peptide L2; etc.), antibacterial molecules, antimicrobial peptides, microtubules, lipids, synthetic or natural molecules, or combinations thereof. Antimicrobial peptides (AMPs) are a class of membrane-active peptides that penetrate microbial membranes to provide defense against bacteria, fungi, and viruses, often with high selectivity (Zasloff, M. Nature 2002, 415, 389). Table 2 shows non-limiting examples of antimicrobial peptides. Table 2. List of peptides from the Antimicrobial Peptide Database (APD)
APD number Sequence
AP00408 FLFPLITSFLS VL (SEQ ID NO: 22)
AP00405-1 1 FISAIASMLGKFL (SEQ ID NO: 23)
AP00327 GWFDVVKHIASAV (SEQ ID NO: 24)
AP01434 FFGSVLKLIPKIL (SEQ ID NO: 25)
AP00013 GLFDIIKKIAESF (SEQ ID NO: 26)
AP00025 HGVSGHGQHGVHG (SEQ ID NO: 27)
AP00094 FLPLIGRVLSGIL (SEQ ID NO: 28)
AP00012 GLFDIIKKIAES I (SEQ ID NO: 29)
AP00014 GLLD I VKKVVGAFGS L (SEQ ID NO: 30)
AP00015 GLFDIV KVVGALGSL (SEQ ID NO: 31 )
AP00016 GLFDIVKKVVGAIGSL (SEQ ID NO: 32)
AP00017 GLFDIVKKVVGTLAGL (SEQ ID NO: 33)
AP00018 GLFDIVKKVVGAFGSL (SEQ ID NO: 34)
AP00019 GLFDIAK VIGVIGSL (SEQ ID NO: 35)
AP00020 GLFDIVKKIAGHIAGSI (SEQ ID NO: 36)
AP00021 GLFDIVKKIAGHIASSI (SEQ ID NO: 37)
AP00022 GLFDIVKKIAGHIVSSI (SEQ ID NO: 38)
AP00101 FVQWFSKFLGRIL (SEQ ID NO: 39)
AP00351 GLFDVIKKVASVIGGL (SEQ ID NO: 40)
AP00352 GLFDIIKKVASVVGGL (SEQ ID NO: 41)
AP00353 GLFDIIKKVASVIGGL (SEQ ID NO: 42)
AP00567 VWPLGLVICKALKIC (SEQ ID NO: 43)
AP00597 NFLGTLVNLAKKIL (SEQ ID NO: 44)
AP00818 FLPLIGKILGTIL (SEQ ID NO: 45)
AP00866 FLPIIAKVLSGLL (SEQ ID NO: 46)
AP00870 FLPIVGKLLSGLL (SEQ ID NO: 47)
AP00875 FLSSIGKILGNLL (SEQ ID NO: 48)
AP00898 FLSGIVGMLGKLF (SEQ ID NO: 49)
AP0121 1 TPFKLSLHL (SEQ ID NO: 50)
AP01249 GILDAIKAIAKAAG (SEQ ID NO: 51)
AP00013-G LFDIIKKIAESF (SEQ ID NO: 52)
AP00013-2x LFDIIKKIAESGFLFDIIKKIAESF (SEQ ID NO: 53)
AP00722-75 GLLNGLALRLGKRALKKIIKRLCR (SEQ ID NO: 54)
His 13 GHHHHHHHHHHHHH (SEQ ID NO: 55)
AP00512 FKCRRWQWRM (SEQ ID NO: 56)
AP00553 KTCENLADTY iSEO ID NO: 57)
In an embodiment, the chimeric molecules embodied herein are encapsulated in a liposome. In one embodiment, the liposome is a cationic liposome.
In an embodiment, a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising an antimicrobial or membrane destabilizing domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear. The method may also include the step of inhibiting Myc and/or Notch activity after proliferation of the inner ear cells, such as, strial vascularis, hair or supporting cell to induce differentiation or transdifferentiation of the cell and/or at least one of its daughter cells into a hair cell. The method may also further include the step of activating Atohl to induce transdifferentiation of the supporting cells to hair cells. The Myc activity in the hair and/or supporting cells is increased by administering an effective amount of Myc protein, Myc peptides or Myc activators linked to supercharged proteins, such as, for example, green fluorescent proteins (s-GFP) or variants thereof. The Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof. Inhibition of Myc and/or Notch can be accomplished through administration of inhibitors or once the activator has degraded over time. Activation of Atohl is accomplished by the delivery of Atohl proteins, Atohl peptides, Atohl activators, or combinations thereof, linked to s-GFP or variants thereof. In an embodiment, a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising an antimicrobial or membrane destabilizing domain connected to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, which modulate activity of Myc, Notch,
Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear. In embodiments, the chimeric molecule further comprises a supercharged protein, such as, for example, a fluorescent protein or variants thereof. In one embodiment, the supercharged protein is green fluorescent protein (s-GFP), or variants thereof. In one
embodiment, the supercharged protein comprises green fluorescent protein (s-GFP) linked to one or more proteins or peptides, or modified variants thereof, comprising: Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Protein Atonal Homolog 1 (Atohl), transcription factors, transcription modulators, or combinations thereof. In some embodiments these supercharged proteins further comprise antimicrobial or membrane destabilizing peptides, for example, aurein, or variants thereof linked to the GFP or variants thereof. When the chimeric molecule comprising Myc and/or Notch activators are administered to a patient, or, contact a cell, the activation of Myc and/or Notch activity induces proliferation of the inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear. Furthermore, inhibition of Myc activity, Notch activity, NICD activity or combinations thereof, in supporting cells induces transdifferentiation of the supporting cells into functional hair cells. Once the Myc activity and/or Notch activity is inhibited or reaches a predetermined level of activity due to the normal degradation of the protein, the activity of which can be measured by any one or more conventional assays, a composition comprising activators of Atohl is administered to the inner ear, wherein activation of Atohl induces
transdifferentiation of the supporting cells into functional hair cells. Myc activity is increased by administering an effective amount of Myc protein,
Myc peptides or Myc activators linked to GFP or variants thereof. Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
In another embodiment, a method of regenerating inner ear cells in vitro or in vivo comprises contacting a cell in vitro or administering to an inner ear of patient in need of such treatment, a composition comprising an effective amount of a chimeric molecule comprising one or more proteins, peptides or variants thereof, which activate Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD), or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear. The method further comprises contacting the supporting cells with a composition comprising Atohl modulators or variants thereof, wherein the Atohl modulates induce transdifferentiation of the supporting cells into functional hair cells. In embodiments, the Atohl composition comprises a supercharged protein linked to one or polypeptides or variants thereof comprising: antimicrobial or membrane destabilizing peptides, aurein, Atohl proteins, Atohl peptides, activators of Atohl, variants or combinations thereof. In other embodiments, the Atohl composition comprises a vector encoding for Atohl proteins, Atohl peptides, Atohl activators, variants or combinations thereof. In another embodiment, the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof. In another embodiment, a method of inducing proliferation and
transdifferentiation of inner ear cells, in vivo or in vitro, comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering a composition which activates Atohl in the supporting cells, inducing the transdifferentiation of the supporting cells to hair cells. In another embodiment, the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain
(NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering an activator of Atohl, wherein the Atohl activator induces the transdifferentiation of the supporting cells to hair cells. In another embodiment, the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
In another embodiment, a method of inducing proliferation and
transdifferentiation of inner ear cells, in vivo or in vitro, comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells. In another embodiment, a method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprises contacting a hair cell and/or a supporting cell with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the
inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
In another embodiment, a method of delivering a therapeutic molecule to cells of an inner ear of a patient, comprising: administering to the inner ear of a patient a chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules. The cells or the inner ear comprise hair cells, supporting cells, or
combinations thereof. The chimeric molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof. In some embodiments, the gene editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof. The anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. The oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof. The chimeric molecule further comprises a supercharged protein or variants thereof, such as, for example, a fluorescent protein, or variants thereof. In some embodiments the chimeric molecule comprises
antimicrobial or membrane destabilizing peptides, for example, aurein, or variants thereof. In some embodiments, the chimeric molecule is encapsulated in a cationic lipid formulation.
In an embodiment, a method of inducing transdifferentiation of inner ear cells comprises contacting an inner ear cell in vitro or in vivo with a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity is decreased or inhibited by a Notch inhibitor, optionally, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
In another embodiment, a method of regenerating inner ear cells comprises inducing proliferation or cell cycle reentry of inner ear cells in vitro or in vivo, the method comprising contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells.
In another embodiment, a method protecting and/or treating hearing loss in a patient in need of such treatment, comprising: contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce neurite growth, proliferation or cell cycle re-entry of inner ear cells, proliferation of hair cells, proliferation of supporting cells, and/or transdifferentiation of supporting cells.
As discussed above, after Myc activity, Notch activity, or both Myc and Notch activities, as appropriate, is or are increased, Myc and/or Notch activity may be inhibited according to methods known in the art and/or described herein to cause proliferating supporting cells to transdifferentiate into hair cells. Alternatively, or in addition, after Myc activity, Notch activity, or both Myc and Notch activity is or are increased, as appropriate, Atohl activity can be increased to cause proliferating supporting cells to transdifferentiate into hair cells. Atohl activity can be increased according to the compositions embodied herein, or, in conjunction with or alternatively with the use of one or more conventional compounds or methods of increasing Atohl activity (including use of Atohl agonists) known in the art (see, for example, U.S. Patent No. 8, 188, 131 ; U.S. Patent Publication No. 201 10305674; U.S. Patent Publication No.
20090232780; Kwan et al. (2009) Int'l Symposium on Olfaction and Taste: Ann. N. Y. Acad. Sci. 170:28-33; Daudet et al. (2009) Dev. Bio. 326:86- 100; Takebayashi et al. (2007) Dev. Bio. 307: 165- 178; and Ahmed et al. (2012) Dev. Cell 22(2):377-390.)
The process described herein can occur in vivo or ex vivo. In one embodiment, Notch activity is decreased in a cell that originated from a supporting cell to cause the supporting cell to transdifferentiate into a hair cell. In another embodiment, Atohl activity is increased in a cell that originated from a supporting cell to cause the supporting cell to transdifferentiate into a hair cell. In certain embodiments, after Myc and Notch induce proliferation within a hair cell or supporting cell, Myc activity is decreased to induce differentiation of at least one of the cell and the daughter cell to produce a differentiated cochlear or utricular hair cell. Activation of Myc/NICD increases the response of supporting cells to Atohl to transdifferentiate to hair cells, without proliferation or cell cycle re-entry. After Myc NICD activation, both dividing and non- dividing supporting cells can transdifferentiate to hair cells in response to Atohl overexpression or Notch inhibition by gamma-secretase inhibitor.
Also disclosed is a method for reducing the loss of, maintaining, or promoting hearing in a subject. The method comprises increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within a hair cell and/or a supporting cell of the inner ear thereby to induce cell proliferation to produce daughter cells, and, after cell proliferation, decreasing Myc and/or Notch activity, and administering a composition embodied herein, comprising Atohl activators to induce daughter cells of hair cell origin to differentiate into hair cells or permitting daughter cells of supporting cell origin to transdifferentiate into hair cells thereby to reduce the loss of, maintain or promote hearing in the subject. The daughter cells of supporting cell origin can be induced to transdifferentiate into hair cells by activating Atohl activity, for example, by gene expression, by administration of an effective amount of Atohl or an Atohl agonist. The steps can be performed in vivo (for example, in the inner ear of a mammal, in particular in the cochlea), or ex vivo, wherein the resulting cells are cultured and/or introduced into the inner ear of the subject. Also disclosed is a method for reducing the loss of, maintaining, or promoting vestibular function in a subject. The method comprises increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within a hair cell and/or a supporting cell of the inner ear thereby to induce cell proliferation to produce daughter cells, and, after cell proliferation, decreasing Myc and/or Notch activity, and permitting daughter cells of hair cell origin to differentiate into hair cells or permitting daughter cells of supporting cell origin to transdifferentiate into hair cells thereby to reduce the loss of, maintain or promote vestibular
function in the subject. The daughter cells of supporting cell origin can be induced to transdifferentiate into hair cells by activating Atohl activity, for example, by gene expression, by administration of an effective amount of Atohl or an Atohl agonist. The steps can be performed in vivo (for example, in the inner ear of a mammal, in particular in the utricle), or ex vivo, wherein the resulting cells are cultured and/or introduced into the inner ear of the subject.
The methods and compositions described herein can be used for treating subjects who have, or who are at risk for developing, an auditory disorder resulting from a loss of auditory hair cells, e.g., sensorineural hair cell loss. Patients having an auditory disorder can be identified using standard hearing tests known in the art. The method can comprise (a) increasing Myc activity, Notch activity, or both Myc activity and Notch activity, as appropriate, within the hair cell of the subject thereby to induce cell proliferation to produce a daughter cell, and (b) after cell proliferation, decreasing Notch activity to induce differentiation of at least one of the cell and the daughter cell to produce a differentiated cochlear or utricular hair cell. This can be accomplished by administering an agent or agents to the subject to modulate Myc and Notch activity. Alternatively, the process can occur in cells (e.g. cochlear and/or utricular cells) ex vivo, after which the resulting cells are transplanted into the inner ear of the subject. In certain embodiments, the methods and compositions described herein can be used to promote growth of neurites from the ganglion neurons of the inner ear. For example, the regeneration of hair cells may promote the growth of new neurites from ganglion neurons and formation of new synapses with the regenerated hair cells to transmit sound and balance signals from the hair cells to the brain.
In certain embodiments, the methods and compositions described herein can be used to promote growth of neurites from the ganglion neurons of the inner ear. For example, the regeneration of hair cells may promote the growth of new neurites from ganglion neurons and formation of new synapses with the regenerated hair cells to transmit sound and balance signals from the hair cells to the brain. In some embodiments, the methods and compositions described herein can be used to reestablish proper synaptic connections between hair cells and auditory neurons to treat, for example, auditory neuropathy.
Subjects with sensorineural hair cell loss experience the degeneration of cochlea hair cells, which frequently results in the loss of spiral ganglion neurons in regions of hair cell
loss. Such subjects may also experience loss of supporting cells in the organ of Corti, and degeneration of the limbus, spiral ligament, and stria vascularis in the temporal bone material.
In certain embodiments, the present invention can be used to treat hair cell loss and any disorder that arises as a consequence of cell loss in the ear, such as hearing impairments, deafness, vestibular disorders, tinnitus (see, Kaltenbach et al. (2002) J. Neurophysiol. 88(2):699- 714s), and hyperacusis (Kujawa et al. (2009) J. Neurosci. 29(45): 14077-14085), for example, by promoting differentiation (e.g., complete or partial differentiation) of one or more cells into one or more cells capable of functioning as sensory cells of the ear, e.g., hair cells.
In certain embodiments, the subject can have sensorineural hearing loss, which results from damage or malfunction of the sensory part (the cochlea) or non-sensory part (the limbus, spiral ligament and stria vascularis) or the neural part (the auditory nerve) of the ear, or conductive hearing loss, which is caused by blockage or damage in the outer and/or middle ear. Alternatively or in addition, the subject can have mixed hearing loss caused by a problem in both the conductive pathway (in the outer or middle ear) and in the nerve pathway (the inner ear). An example of a mixed hearing loss is a conductive loss due to a middle-ear infection combined with a sensorineural loss due to damage associated with aging.
In certain embodiments, the subject may be deaf or have a hearing loss for any reason, or as a result of any type of event. For example, a subject may be deaf because of a genetic or congenital defect; for example, a human subject can have been deaf since birth, or can be deaf or hard-of-hearing as a result of a gradual loss of hearing due to a genetic or congenital defect. In another example, a human subject can be deaf or hard-of-hearing as a result of a traumatic event, such as a physical trauma to a structure of the ear, or a sudden loud noise, or a prolonged exposure to loud noises. For example, prolonged exposures to concerts, airport runways, and construction areas can cause inner ear damage and subsequent hearing loss. In certain embodiments, a subject can experience chemical-induced ototoxicity, wherein ototoxins include therapeutic drugs including antineoplastic agents, salicylates, quinines, and aminoglycoside antibiotics, contaminants in foods or medicinals, and environmental or industrial pollutants.
In certain embodiments, a subject can have a hearing disorder that results from aging. Alternatively or in addition, the subject can have tinnitus (characterized by ringing in the ears) or hyperacusis (heightened sensitivity to sound).
In addition, the methods and compositions described herein can be used to treat a subject having a vestibular dysfunction, including bilateral and unilateral vestibular dysfunction. Vestibular dysfunction is an inner ear dysfunction characterized by symptoms that include dizziness, imbalance, vertigo, nausea, and fuzzy vision and may be accompanied by hearing problems, fatigue and changes in cognitive functioning. Vestibular dysfunction can be the result of a genetic or congenital defect; an infection, such as a viral or bacterial infection; or an injury, such as a traumatic or nontraumatic injury. Vestibular dysfunction is most commonly tested by measuring individual symptoms of the disorder (e.g., vertigo, nausea, and fuzzy vision).
Alternatively or in addition, the methods and compositions described herein can be used prophylactically, such as to prevent, reduce or delay progression of hearing loss, deafness, or other auditory disorders associated with loss of inner ear function. For example, a composition containing one or more of the agents can be administered with (e.g., before, after or concurrently with) a second composition, such as an active agent that may affect hearing loss. Such ototoxic drugs include the antibiotics neomycin, kanamycin, amikacin, viomycin, gentamycin, tobramycin, erythromycin, vancomycin, and streptomycin; chemotherapeutics such as cisplatin; nonsteroidal anti -inflammatory drugs (NSAIDs) such as choline magnesium trisalicylate, diclofenac, diflunisal, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, salsalate, sulindac, and tolmetin; diuretics; salicylates such as aspirin; and certain malaria treatments such as, quinine and chloroquine. For example, a human undergoing chemotherapy can be treated using the compounds and methods described herein. The chemotherapeutic agent cisplatin, for example, is known to cause hearing loss. Therefore, a composition containing one or more agents that increase the activity of Myc and Notch can be administered with cisplatin therapy (e.g., before, after or concurrently with) to prevent or lessen the severity of the cisplatin side effect. Such a composition can be administered before, after and/or simultaneously with the second therapeutic agent. The two agents may be administered by different routes of
administration.
In certain embodiments, the methods and compositions described herein can be used to increase the levels (e.g., protein levels) and/or activity (e.g., biological activity) of Myc and Notch in cells (e.g., inner ear cells). Exemplary methods and compositions include, but are not limited to methods and compositions for increasing Myc or Notch expression (e.g., transcription and/or translation) or levels (e.g., concentration) in cells. It is contemplated that such modulation can be achieved in hair cells and/or supporting cells in vivo and ex vivo.
Methods and Compositions for Increasing Myc and Notch andAtohl Activity:
(i) Myc, Notch, or Atohl Polypeptides: It is contemplated that Myc, Notch, and Atohl proteins, including full length proteins, biologically active fragments, and homologs of Myc and Notch can be introduced into target cells using techniques known in the art.
Exemplary Myc polypeptides include, for example, NP_002458.2, as referenced in the NCBI protein database. Exemplary Notch polypeptides include, for example,
NP 060087.3, as referenced in the NCBI protein database.
Exemplary Atohl polypeptides include, for example, NP 005163.1 , as referenced in the NCBI protein database.
In certain embodiments, nucleic acid sequences encoding Myc, Notch, and Atohl family members may be used in accordance with the methods described herein. Exemplary Myc family members include N-myc, referenced in the NCBI protein database as NP_005369.2. Exemplary Notch family members include Notch2, referenced in the NCBI protein database as NP_077719.2; Notcb.3, referenced in the NCBI protein database as NP_000426.2; and Notch4, referenced in the NCBI protein database as NP 004548.3. Exemplary Atohl family members include Atoh7, referenced in the NCBI protein database as NP 660161.1.
In certain embodiments, a protein sequence of the invention may comprise a consensus protein sequence or a nucleotide sequence encoding a consensus protein sequence. Consensus protein sequences of Myc, Notch intracellular domain, and Atohl of the invention are set forth below. The Myc, Notch, or Atohl polypeptides can be used in combination with compositions to enhance uptake of the polypeptides into biological cells. In certain
embodiments, the Atohl , Myc, or Notch polypeptides can be mutated to include amino acid sequences that enhance uptake of the polypeptides into a biological cell. In certain embodiments,
Atohl , Myc, or Notch polypeptides can be altered or mutated to increase the stability and/or activity of the polypeptide (e.g., Myc, Notch or Atohl point mutants). In certain embodiments, Myc, Notch or Atohl polypeptides can be altered to increase nuclear translocation of the polypeptide. In certain embodiments, altered Myc, Notch or Atohl polypeptides or biologically active fragments of Myc, Notch, or Atohl retain at least 50%, 60%, 70%, 80%, 90%, or 95% of the biological activity of full length, wild type respective c-myc, Notch or Atohl protein in the species that is the same species as the subject that is or will be treated with the methods and compositions described herein.
In certain embodiments, Myc polypeptides sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP_002458.2. In certain embodiments, Notch polypeptides sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP 060087.3. In certain embodiments, Atohl polypeptides sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NP_005163.1. In certain embodiments, agents encoded by modified Atohl , Myc, NICD, or Notch nucleic acid sequences and Atohl , Myc, or Notch polypeptide sequences possess at least a portion of the activity (e.g., biological activity) of the molecules encoded by the corresponding, e.g., unmodified, full-length Atohl , Myc, or Notch nucleic acid sequences and Atohl , Myc, or Notch polypeptide sequences. For example, molecules encoded by modified Atohl, Myc, or Notch nucleic acid sequences and modified Atohl , Myc, or Notch polypeptides retain 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% of the activity (e.g., biological activity) of the molecules encoded by the corresponding, e.g., unmodified, respective Atohl , Myc, or Notch nucleic acid sequences and/or full length Atohl , Myc, or Notch polypeptide sequences.
In certain embodiments, the Myc and Notch proteins of the invention can be administered to cells as a single protein containing both Myc and Notch (or active domains thereof), preferably separated by a cleavable linker. Examples of cleavable linkers are known in the art (see, e.g., U.S. Patent No. 5,258,498 and U.S. Patent No. 6,083,486.)
Myc, Notch or Atohl levels (e.g., protein levels) and/or activity (e.g., biological activity) in target cells and/or in the nucleus of target cells can be assessed using standard methods such as Western Blotting, in situ hybridization, reverse transcriptase polymerase chain reaction, immunocytochemistry, viral titer detection, and genetic reporter assays. Increases in
Myc, Notch or Atohl levels (e.g., protein levels) and/or activity (e.g., biological activity) in target cells and/or in the nucleus of target cells can be assessed by comparing Myc, Notch or Atohl levels and/or activity in a first cell sample or a standard with Myc, Notch or Atohl levels and/or activity in a second cell sample, e.g., contacting the cell sample with an agent
contemplated to increase Myc, Notch or Atohl levels and/or activity.
Sequence identity may be determined in various ways that are within the skill in the art, e.g., using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software, which are used to perform sequence alignments and then calculate sequence identity. Exemplary software programs available from the National Center for Biotechnology Information (NCBl) on the website ncbi.nlm.nih.gov include blastp, blastn, blastx, tblastn and tblastx. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are used at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al, (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919). In one approach, the percent identity can be determined using the default parameters of blastp, version 2.2.26 available from the NCBL
(ii) DNA Encoding Atohl, Myc, or Notch: Atohl , Myc, or Notch can be expressed in target cells using one or more expression constructs known in the art. Such expression constructs include, but are not limited to, naked DNA, viral and non-viral expression vectors. Exemplary Myc nucleic acid sequences that may be expressed in target cells include, for example, NM_002467.4, as referenced in the NCBl gene database. Exemplary Notch nucleic acid sequences that may be expressed include, for example, NM_017617.3, as referenced in the NCBl gene database. Exemplary Atohl nucleic acid sequences that may be expressed in target cells include, for example, NM_005172.1, as referenced in the NCBl gene database.
In certain embodiments, Myc, Notch, and Atohl family members may be used. Exemplary Myc family members include N-myc, referenced in the NCBl gene database as NM_005378.4. Exemplary Notch family members include Notch2, referenced in the NCBl gene database as NM_024408.3; Notch3, referenced in the NCBl gene database as NM_000435.2; and
Notch4, referenced in the NCBI gene database as NM 004557.3. Exemplary Atohl family members include Atoh7, referenced in the NCBI gene database as NM_145178.3.
In certain embodiments, DNA encoding Myc, Notch or Atohl can be an unmodified wild type sequence. Alternatively, DNA encoding Myc, Notch or Atohl can be modified using standard techniques. For example, DNA encoding Myc, Notch or Atohl can be modified or mutated, e.g., to increase the stability of the DNA or resulting polypeptide.
Polypeptides resulting from such altered DNAs should retain the biological activity of wild type Myc, Notch or Atohl . In certain embodiments, DNA encoding Atohl, Myc, or Notch can be altered to increase nuclear translocation of the resulting polypeptide. In certain embodiments, DNA encoding Myc, Notch or Atohl can be modified using standard molecular biological techniques to include an additional DNA sequence that can encode one or more of, e.g., detectable polypeptides, signal peptides, and protease cleavage sites.
In certain embodiments, Myc nucleic acid sequences can be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_002467.4. In certain embodiments, Notch nucleic acid sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_017617.3. In certain embodiments, Atohl nucleic acid sequences are 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to NM_005172.1.
(in) Myc, Notch or Atohl Pathway Modulators: In certain embodiments, Myc or Notch levels (e.g., protein levels) and/or activity (e.g., biological activity) can be increased or decreased using compounds or compositions that target Myc or Notch, or one or more components of the Myc or Notch pathway. Accordingly, in some embodiments, inhibiting Notch and activating Atohl comprises suppression of any one or more Notchl targets, such as Hes5 and Hesl , both of which act as antagonists to Atohl . Such suppression can be achieved by any conventional means, including, for example, anti-sense oligonucleotides against Hesl and Hes5, or by delivering proteins that suppress Hes function. In some embodiments, any one or more molecules associated with the pathways of Myc, Notch, Atohl are targeted. Similarly, Atohl levels (e.g., protein levels) and/or activity (e.g., biological activity) can be increased using compounds that target Atohl or one or more components of the Atohl pathway.
Exemplary Myc activators include microRNAs that target FBXW-7 (Ishikawa Y et al, Oncogene 2012 Jun 4; doi: 10.1038/onc.2012.213) and activators that increase Myc
expression levels or activity such as nordihydroguaiaretic acid (NDGA) (Park S et al. (2004) J. Cell. Biochem. 91(5):973-86), CD19 (Chung et al, (2012) J. Clin. Invest. 122(6):2257-2266, cohesin (Ewan et al, (2012) PLoS ONE 7(1 1): e 9160), bryostatin 1 (Hu et al. (1993) Leuk. Lymphoma 10(1-2): 135-42), 2'-3-dimethyl-4-aminoazobenzene (ortho-aminoazotoluene, OAT) (Smetanina et al. (201 1) Toxicol. Appl. Pharmacol. 255(l):76-85), 2-amino-l-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) (Lauber et al. (2004) Carcinogenesis 25(12):2509-l 7), β- estradiol (U.S. Patent No. 7,544,51 1 B2), RU38486 (U.S. Patent No. 7,544,51 1 B2), dexamethasone (U.S. Patent No. 7,544,51 1 B2), thyroid hormones (U.S. Patent No. 7,544,51 1 B2), retinoids (U.S. Patent No. 7,544,51 1 B2), and ecdysone (U.S. Patent No. 7,544,51 1 B2). Exemplary Myc inhibitors include 7-nitro-N-(2-phenylphenyl)-2,l,3- benzoxadiazol-4-amine (10074-G5) (Clausen DM et al, (2010) J. Pharmacol. Exp. Ther.
335(3):715-27), thioxothiazolidinone [Z- ]-5-[4-ethylbenzylidene]-2-thioxo-l,3-thiazolidin-4-one (10058-F4) (Clausen et al (2010) J. Pharmacol. Exp. Ther. 335(3):715-27; Lin CP et al (200Ί) Anticancer Drugs, 18(2): 161-70; Huang et al (2006) Exp. Hematol. 34(1 1): 1480-9), 4- phenylbutyrate (phenylbutyrate) (Engelhard et al (1998) J. Neurooncol. 37(2):97-l 08),
Compound 0012 (Hurley et al (2010) J. Vase. Res. 47(1): 80-90), curcumin (Aggarwal et al (2005) Clin. Cancer Res. 1 l(20):7490-8), magnesium hydroxide (Mori et al (1997) J. Cell. Biochem. Suppl. 27:35-41), BP-1 -102 (Zhang et al (2012) Proc. Natl. Acad. Sci. U.S.A.
109(24):9623-8), WPl 193 (Sai et al (2012) J. Neurooncol. 107(3):487-501), BP- 1-107 (Page et al (2012) J. Med. Chem. 55(3): 1047-55), BP-1 -108 (Page et al (2012) J. Med. Chem. 55(3): 1047-55), SF-1-087 (Page et al (2012) J. Med. Chem. 55(3): 1047-55), SF-1-088 (Page ei a/ (2012) J. Med. Chem. 55(3): 1047-55), STX-01 19 (Ashizawa et al (201 1) Int. J. Oncol. 38(5): 1245-52), substituted thiazol-4-one compounds (U.S. Patent No. 7,872,027), (Z,E)-5-(4- ethylbenzylidene)-2-thioxothiazolidin-4-one (10058-F4) (U.S. Patent No. 7,026,343), S2T1- 60TD (U.S. Publication No. 20120107317A1), Quarfloxin (CX-3543) (U.S. Publication No. 20120107317A1), benzoylanthranilic acid (U.S. Publication No. 20120107317A1), cationic porphyrin TMPyP4 (U.S. Publication No. 20120107317A1), tyrphostin and tryphostin-like compounds (European Patent No. EP2487156A1), AG490 (European Patent No.
EP2487156A1), FBXW-7 expression vectors (Ishikawa Y et al, supra), and siRNAs targeting Myc transcript (Id.).
Exemplary Notch activators include microRNAs that target FBXW-7 (Ishikawa Y et al supra), AG-370, 5 (U.S. Patent No. 8,1 14,422), AG-1296 (6,7-dimethoxy-3- phenylquinoxaline) {Id.), nigericin Na {Id.), cytochalasin D {Id.), FCCP (carbonylcyanide-4- (trifluoromethoxy)-phenylhydrazone) {Id.), SP60012 {Id.), and vectors that produce protein of or isolated protein of Jagged-1, Jagged-2, Jagged-3, Serrate, any member of the Jagged/Serrate protein family, Delta, Delta-like-1, Delta-like-3, Delta-like-4, Delta-like homolog- 1 (DLK1), any member of the Delta protein family, and any portion of any of these proteins (PCT
Publication WO20040901 10A3). Exemplary Notch activators may also include chemical activators such as valproic acid (VPA, see, U.S. Patent No. 8,338,482), resveratrol and phenethyl isothiocyanate.
Exemplary Notch inhibitors include gamma-secretase inhibitors such as an arylsulfonamide, a benzodiazepine, L-685,458 (U.S. Patent Publication No. 2001/0305674), MK-0752 (Purow B. (2012) Adv. Exp. Med. Biol. 727:305-19; Imbimbo BP (2008) Curr. Top. Med. Chem. 8(1):54-61), DAPT ([N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) {Id; Ishikawa Y et al. supra; PCT Publication WO201 1 149762A3), LY-374973 (N-[N- (3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) (PCT Publication WO201 1 149762A3), N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-l,l-dimethylethyl ester {Id.); Lilly GSI L685,458 (Purow B, supra), compound E ((2S)-2- {[(3,5-Difluorophenyl)acetyl] amino} -N-[(3 S)-l -methyl-2-oxo-5-phenyl-2,3-dihydro- 1H- l ,4-benzodiazepin-3- yljpropanamide) (Purow B, supra), DBZ (dibenzazepine) (Purow B, supra), isocoumarin (Purow B, supra), JLK6 (7-amino-4-chloro-3-methoxyisocoumarin) (Purow B (2012) Adv. Exp. Med. Biol. 727:305-19), Compound 18 ([1 l-endo]-N-(5,6,7,8,9,10-hexahydro- 6,9-methano benzo[9][8]annulen-l l-yl)-thiophene-2 -sulfonamide) (Purow B, supra), E2012 (Imbimbo BP, supra; PCT Publication WO2009005688A3), MRK560 (Imbimbo BP, supra), LY-41 1575 (Imbimbo BP, supra), LY-450139 (Imbimbo BP, supra; PCT Publication WO2009005688A3), γ-secretase inhibitor XII (PCT Publication WO201 1 149762A3; PCT Publication
WO2009005688A3), 2, 2-dimethyl-N-((S)-6-oxo-6, 7-dihydro-5H-dibenzo(b, d)azepin-7-yl)-N'- (2, 2, 3, 3, 3-pentafluoro-propyl)-malonamide (U.S. Patent Publication No. 20090181944A1), GSI-LX (EP 1949916B1), GSI-X (EP 1 49916B1), tocopherol derivatives (PCT Publication WO2009040423A1), [(2S)-2- {[(3,5- Difluorophenyl)acetyl]amino}-N- [(3S)l-methyl-2-oxo-5- phenyl-2,3-dihydro-l H-l ,4-benzodiazepin-3-yl] propanamide] (PCT Publication
WO2009005688A3), N- [N-(3,5-difluorophenacetyl)-L-alanyl]-Sphenylglycine-t-butylester (Id.), [ I, r-BiphenyI]-4-acetic acid (Id.), 2-fluoro-alpha-methyl (Id.), NGX-555 (Id.), LY-41 1575 (Id.), Cellzome (Id.), 2-Thiophenesulfonamide (Id.), 5-chloro-N-[(lS)-3,3,3-trifluoro-l- (hydroxymethyl)-2- (trifluoromethyl)propyl] (Id.), NIC5-15 (Id.), BMS (Id.), CHF-5074 (Id.), BMS-299897 (Imbimbo BP, supra), RO4929097; L-685458 ((5S)-(t-Butoxycarbonylamino)-6- phenyl-(4R)hydroxy-(2R)benzylhexanoyl)-L-leu-L-phe-amide); BMS-708163 (Avagacestat); BMS-299897 (2-[(lR)-l-[[(4-Chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl-5- fluorobenzenebutanoic acid); MK-0752; YO-01027; MDL28170 (Sigma); LY41 1575 (N- 2((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-Nl-((7S)-5-methyl-6-oxo-6,7-dihydro-5H- dibenzo[b,d]azepin-7-yl)-l-alaninamide, see U.S. Patent No. 6,541,466); ELN-46719 (2- hydroxy-valeric acid amide analog of LY411575 (where LY41 1575 is the 3,5-difluoro-mandelic acid amide) (U.S. Patent No. 6,541,466)); PF-03084014 ((S)-2-((S)-5,7-difluoro-l ,2,3 ,4- tetrahydronaphthalen-3 -ylamino)-N-( 1 -(2-methyl- 1 -(neopentylamino)propan-2-yl)- 1 H- imidazol-4-yl)pentanamide, Samon et ciL, Mol. Cancer Ther. 2012; 1 1 : 1565-1575); and
Compound E ( (2S)-2- {[(3,5-Diflurophenyl)acetyl]amino}-N-[(3S)-l-methyl-2-oxo-5-phenyl- 2,3-dihydro-lH-l,4-benzodiazepin-3-yl]propanamide; see WO 98/28268 and Samon et al, Mol. Cancer Ther. 2012;11 : 1565-1575; available from Alexis Biochemicals)), or pharmaceutically acceptable salts thereof. In some embodiments, suitable gamma secretase inhibitors include: semagacestat (also known as LY450139, (2S)-2-hydroxy-3-methyI-N-[(lS)-l-methyl-2-oxo-2- [[(lS)-2,3,4,5-tetrahydro-3-methyl-2-oxo-lH-3-benzazepin-l-yl] amino] ethylbutanamide, available from Eli Lilly; WO 02/47671 and U.S. Pat. No. 7,468,365); LY41 1575 (N-2((2S)-2- (3,5-difluorophenyl)-2-hydroxyethanoyl)-Nl-((7S)-5-methyl-6-oxo-6,7-dihydro-5H- dibenzo[b,d]azepin-7-yl)-L-alaninamide, available from Eli Lilly, Fauq et al, (2007) Bioorg. Med. Chem. Lett. 17: 6392-5); begacestat (also known as GSI-953, U.S. Pat. No. 7,300,951); arylsulfonamides (AS, Fuwa et al, (2006) Bioorg. Med. Chem. Lett. l6(16):4184-4189); N-[N- (3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester (DAPT, Shih et al, (2007) Cancer Res. 67: 1879-1882); N-[N-3,5-Difluorophenacetyl]-L-alanyl-S-phenylglycine Methyl Ester (also known as DAPM, gamma- Secretase Inhibitor XVI, available from EMD Millipore); Compound W (3,5-bis(4-Nitrophenoxy)benzoic acid, available from Tocris Bioscience); L- 685,458 ((5S)-(tert-Butoxycarbonylamino)-6-phenyl-(4R)-hydroxy-(2R)-benzylhexanoyl)-L- leucy-L-phenylalaninamide, available from Sigma-Aldrich, Shearmen et al, (2000) Biochemistry
39, 8698-8704); BMS-289948 (4-chloro-N-(2,5 -difluorophenyl)-N-(( 1 R)- {4-fluoro-2- [3 -( 1 H-imidazol- 1 -yl)propyl]phenyl}ethyl)benzenesulfonamide hydrochloride, available from Bristol Myers Squibb); BMS-299897 (4-[2-((lR)-l-{[(4-chlorophenyl)sulfonyl]-2,5- difluoroanilino}ethyl)-5-fluorophenyl]butanoic acid, available from Bristol Myers Squibb, see Zheng et al, (2009) Xenobiotica 39(7):544-55); avagacestat (also known as BMS-708163, (R)-2- (4-chloro-N-(2-fluoro-4-(l,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5- trifluoropentanamide, available from Bristol Myers Squibb, Albright et al, (2013) J Pharmacol. Exp. Ther. 344(3):686-695); MK-0752 (3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5- difluorophenyl)cyclohexyl)propanoic acid, available from Merck); MRK-003 ((3'R,6R,9R)-5'- (2,2,2-trifluoroethyl)-2-((E)-3-(4-(trifluoromethyl)piperidin- 1 -yl)prop- 1 -en- 1 -yl)-5,6,7,8,9, 10- hexahydrospiro[6,9-methanobenzo[8]annulene-l l,3'-[l,2,5]thiadiazolidine] ,Γ-dioxide , available from Merck, Mizuma et al, (2012) Mol. Cancer Ther. 11(9): 1999-2009); MRK-560 (N-[cis-4-[(4-Chlorophenyl)sulfonyl]~ 4-(2,5-difluorophenyl)cyclohexyl]- 1 ,1,1 -trifluoro- methanesulfonamide, Best et al, (2006) J. Pharmacol. Exp. Ther. 317(2):786-90); RO-4929097 (also known as R4733, (S)-2,2-dimethyl-Nl-(6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-
N3-(2,2,3,3,3-pentafluoropropyl)malonamide, available from Hoffman-La Roche Inc., Tolcher et al, (2012) J. Clin. Oncol. 30(19):2348-2353); JLK6 (also known as 7-Amino-4-chloro-3- methoxyisocoumarin, available from Santa Cruz Biotechnology, Inc., Petit et al, (2001) Nat. Cell. Biol. 3: 507-51 1); Tarenflurbil (also known as (R)-Flurbiprofen, (2R)-2-(3-fluoro-4- phenylphenyl)propanoic acid); ALX-260-127 (also known as Compound 1 1, described by Wolfe et al, (1998) J. Med. Chem. 41 : 6); Sulindac sulfide (S. Side, et al, (2003) J. Biol. Chem.
278(20): 18664-70); l,l,l-trifluoro-N-(4-[5-fluoro-2-(trifluoromethy l)pheny 1] -4- { [4
(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)methanesulfonamide (U.S. Patent Publication No. 20110275719);N-[trans-3-[(4-chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l,l,l- trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580);N-[cis-3-[(4- chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l,l,l-trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); N-[cis-3-[(4-chlorophenyl)sulfonyl]-3-(2-cyano-5- fluorophenyl)cyclobutyl]-l,l,l-trifluoromethanesulfonamide (U.S. Patent Publication No.
201 10263580); N-[cis-3 - [(4-chlorophenyl)sulfonyl] -3 -(2,5 -dichlorophenyl)cyclobutyl] -1,1,1- trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580);N-(cis-3-(2,5- difluorophenyl)-3 - { [4-(trifluoromethyl)phenyl] sulfonyl} cyclobutyl)- 1,1,1-
trifluoromethanesulfonamide (U.S. Patent Publication No. 20110263580);N- {cis-3-(5-chloro-2-f luorophenyl)-3 -[(4-chlorophenyl)sulfonyl]cyclobutyl} - 1,1 ,1 -trifluoromethanesulfonamide (U.S. Patent Publication No. 20110263580);N-{cis-3-(2,5-difluorophenyl)-3-[(4- fluorophenyl)sulfonyl]cyclobutyl}- 1 ,1 ,1 -trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); N-{cis-3-(2,5-difluorophenyl)-3-[(3,4-difluorophenyl)sulfonyl]cyclobutyl}- 1 ,1,1 -trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580);N-[cis-3-[(4- cyanophenyl)sulfonyl]-3 -(2,5-difluorophenyl)cyclobutyl]- 1,1,1 -trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); 4-{[cis-3-[(4-chlorophenyl)sulfonyl]-3-(2,5- difluorophenyl)cyclobutyl][trifluoromethyl) sulfonyl]amino}butanoic acid (U.S. Patent
Publication No. 20110263580); N-[cis-3-[(4-chlorophenyl)sulfonyl]-3-(2,5- difluorophenyl)cyclobutyl]- 1, 1,1 -trifluoro-N-[2-(tetrahydro-2-pyran-2- yloxy)ethyl]methanesulfonamide (U.S. Patent Publication No. 201 10263580);Methyl {[cis-3- [(4-chlorophenyl)sulfonyl]-3-(2,5- difluorophenyl)cyclobutyl][(trifluoromethyl)sulfonyl]amino}acetate (U.S. Patent Publication No. 201 10263580); N-[3-[(4-chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l, 1,1- trifluoro-N-methylmethanesulfonamide (U.S. Patent Publication No. 20110263580);N-[3-[(4- chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-l, 1, 1-trifluoro-N- methylmethanesulfonamide (U.S. Patent Publication No. 201 10263580);Methyl 4- {[cis-3-[(4- chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl] [(trifluoro- methyl)sulfonyl] amino jbutanoate (U.S. Patent Publication No. 201 10263580);N-[cis-3-[(4- chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclobutyl]-N-[(trifluoromethyl)sulfonyl]glycine (U.S. Patent Publication No. 201 10263580); N-[cis-3-[(4-chlorophenyl)sulfonyl]-3-(2,5- difluorophenyl)- 1 -m ethyl cyclobutyl]- 1, 1 ,1 -trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); N-(cis-3-(2,5-difluorophenyl)-l-methyl-3- {[4- (trifluoromethyl)phenyl]sulfonyl}cyclobutyl)-l, 1, 1-trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); N-[cis-3-[(4-chlorophenyl)sulfonyl]-3-(2,5- difluorophenyl)cyclobutyl]- 1 , 1 ,1 -trifluoro-N-[ (trifluoromethyl)sulfonyl]methanesulfonamide (U.S. Patent Publication No. 201 10263580); Sodium[cis-3 -[( 4-chlorophenyl)sulfonyl]-3-(2,5- di fluorophenyl) cyclobutyl] [(trifluoromethyl)sulfonyl]azanide (U.S. Patent Publication No. 201 10263580); Potassium[ cis-3-[ (4-chlorophenyl)sulfonyl]-3-(2,5-difluorophenyl)cyclo butyl] [(trifluoromefhyl )sulfonyl]azanide (U.S. Patent Publication No. 201 10263580); N-[cis-3-[(4-
trifluoromethoxyphenyl)sulfonyl ]-3 -(2,5 -difluorophenyl)cyclobutyl] -1, 1, 1- trifluoromethanesulfonamide (U.S. Patent Publication No. 201 10263580); 1 , 1 , 1 -trifluoro-N- (4-[5-fluoro-2-(trifluoromethyl)phenyl]-4- {[4-
(trifluoromethyl)phenyl]sulfonyl}cyclohexyl)methanesulfonamide (U.S. Patent Publication No. 201 10263580); gamma-Secretase Inhibitor I (also known as Z-Leu-Leu-Nle-CHO,
benzyloxycarbonyl-leucyl-leucyl-norleucinal, available from Calbiochem); gamma-secretase inhibitor II: (MOL)(CDX) (available from Calbiochem);gamma secretase inhibitor III, (N- Benzyloxycarbonyl-Leu-leucinal, available from Calbiochem);gamma secretase inhibitor IV, (N- (2-Naphthoyl)-Val-phenylalaninal, available from Calbiochem);gamma-secretase inhibitor V (also known as Z-LF-CHO, N-Benzyloxycarbonyl-Leu-phenylalaninal, available from EMD Millipore); gamma-secretase inhibitor VI (l-(S)-endo-N-(l,3,3)-Trimethylbicyclo[2.2.1]hept-2- yl)-4-fluorophenyl Sulfonamide, available from EMD Millipore); gamma secretase inhibitor VII, (also known as Compound A, MOC-LL-CHO, Menthyloxycarbonyl-LL-CHO, available from Calbiochem);gamma secretase inhibitor X, ({ lS-Benzyl-4R-[l-(lS-carbamoyl-2- phenethylcarbamoyl)-lS-3-methylbutylcarbamoyl]-2R-hydroxy-5-phenylpentyl}carbamic acid tert-butyl ester, available from Calbiochem);gamma secretase inhibitor XI, (7-Amino-4-chloro-3- methoxyisocoumarin, available from Calbiochem);gamma secretase inhibitor XII, (also known as Z-Ile-Leu-CHO, Shih and Wang, (2007) Cancer Res. 67: 1879- 1882); gamma secretase inhibitor XIII, (Z-Tyr-Ile-Leu-CHO, available from Calbiochem); gamma secretase inhibitor XIV, (Z-Cys(t-Bu)-Ile-Leu-CHO, available from Calbiochem); gamma secretase inhibitor XVII, (also known as WPE-III-31C), (MOL)(CDX) (available from Calbiochem);gamma secretase inhibitor XIX, (also known as benzodiazepine, (2S,3R)-3-(3,4 Difluorophenyl)-2-(4- fluorophenyl)-4-hydroxy-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- butyramide, Churcher et al, (2003) J. Med. Chem. 46(12):2275-8); gamma secretase inhibitor XX, (also known as dibenzazepine, (S,S)-2-[2-(3,5-Difluorophenyl)acetylamino]-N-(5-methyl-6- oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propionamide, (MOL)(CDX) (Weihofen et al, Science 296: 2215-2218, 2002, available from Calbiochem); gamma secretase inhibitor XXI, ((S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(l-methyl-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-propionamide, available from Calbiochem);5-methyl-2-propan-2- ylcyclohexyl)N-[4-methyl-l-[(4-methyl-l-oxopentan-2-yl)amino]-l-oxopentan-2-yljcarbamate (available from HDH Pharma Inc.);N-trans-3,5-Dimethoxycinnamoyl-Ile-leucinal (available
from Calbiochem); N-tert-Butyloxycarbonyl-Gly-Val-Valinal; isovaleryl-V V-Sta-A- Sta-OCH3 (available from Calbiochem);diethyl-(5-phenyl-3H-azepin-2-yl)-amine (U.S. Patent No.
8188069);diethyl-(5-isopropyl-3H-azepin-2-yl)-amine (Patent No. 8188069);diethyl-(4-phenyl- 3H-azepin-2-yl)-amine (U.S. Patent No. 8188069); diethyl-(6-phenyl-3H-azepin-2-yl)-amine (U.S. Patent No. 8188069); 5-phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); - Isopropyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); 4-phenyl-l,3-dihydro-azepin-2- one (U.S. Patent No. 8188069); 6-phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069);2- butoxy-5-phenyl-3H-azepine (U.S. Patent No. 8188069); l-methyl-5-phenyl-l,3-dihydro-azepin- 2-one (U.S. Patent No. 8188069); 5-isopropyl-l-methyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); l-methyl-4-phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); 1-methyl- 6-phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069);l-methyl-5-phenyl-lH-azepine- 2,3 -dione-3 -oxime (U.S. Patent No. 8188069);5-isopropyl-l-methyl-lH-azepine-2,3-dione-3- oxime (U.S. Patent No. 8188069); l-methyl-6-phenyl-lH-azepine-2,3-dione-3-oxime (U.S. Patent No. 8188069); l-methyl-4-phenyl-lH-azepine-2,3-dione-3-oxime (U.S. Patent No. 8188069); 3- amino-l-methyl-5-phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); 3-amino-5- isopropyl-l-methyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); 3-amino-l-methyl-4- phenyl-l,3-dihydro-azepin-2-one (U.S. Patent No. 8188069); 3-amino-l-methyl-6-phenyl-l,3- dihydro-azepin-2-one (U.S. Patent No. 8188069);(S)-[l-(l-methyl-2-oxo-5-phenyl-2,3-dihydro- lH-azepin-3-ylcarbamoyl)-ethyl]-carbamic acid tertbutyl ester (U.S. Patent No. 8188069); [(S)-l - (5-isopropyl-l-methyl-2-oxo-2,3-dihydro-lH-azepin-3-ylcarbamoyl)-ethyl]carbamic acid tertbutyl ester (U.S. Patent No. 8188069); [(S)-l-(l-methyl-2-oxo-4-phenyl-2,3-dihydro-lH-azepin-3- ylcarbamoyl)-etbyl]carbamic acid tert-butyl ester (U.S. Patent No. 8188069); [(S)-l-(l -methyl-2- oxo-6-phenyl-2,3-dihydro-lH-azepin-3-ylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (U.S. Patent No. 8188069); (S)-2-amino-N-(l -methyl-2-oxo-5 -phenyl-2,3 -dihydro- 1 H-azepin-3 - yl)-propionamide (U.S. Patent No. 8188069); (S)-2-amino-N-(5-isopropyl-l-methyl-2-oxo-2,3- dihydro-lH-azepin-3-yl)propionarnide (U.S. Patent No. 8188069);(S)-2-Amino-N-(I-methyl-2- oxo-6-phenyl-2,3-dihydro-lH-azepin-3-yl)propionamide hydrochloride (U.S. Patent No.
8188069); (S)-2-Amino-N-(I-methyl-2-oxo-4-phenyl-2,3-dihydro-l H -azepin-3-yl)
propionamide hydrochloride (U.S. Patent No. 8188069); (S)-2-fluoro-3-methyl-butyric acid (U.S. Patent No. 8188069); (S)-2-hydroxy-3-methyl-N-[(S)-l-((S)-l-methyl-2-oxo-5-phenyl-2,3- dihydro-lH-azepin-3-ylcarbamoyl)-ethyl]-butyramide (U.S. Patent No. 8188069); (S)-2-fluoro-3-
methyl-N-[(S)-l-(l-methyl-2-oxo-5-phenyl-2,3-dihydro-lH-azepin-3-ylcarbamoyl)-ethyl] - butyramide (U.S. Patent No. 8188069); (S)-2-hydroxy-N-[(S)-l-(5-isopropyl-l-methyl-2-oxo-2, 3-dihydro-lH-azepin-3-ylcarbamoyl)ethyl]-3-methyl-butyramide (U.S. Patent No. 8188069); (S)-
2- hydroxy-3-methyl-N-[(S)-l-(l-methyl-2-oxo-4-phenyl-2,3-dihydro-lH-azepin-3 -ylcarbamoyl)- ethyl] -butyramide (U.S. Patent No. 8188069); (S)-2-hydroxy-3-methyl-N-[(S)-l-(l-mefhyl-2- oxo-6-phenyl-2,3-dihydro-lH-azepin-3-ylcarbamoyl)-ethyl]-butyramide (U.S. Patent No.
8188069); and(S)-2-fluoro-3-methyl-N-[(S)-l-(l-methyl-2-oxo-6-phenyl-2,3-dihydro-lH-azepin-
3- ylcarbamoyl)-ethyl] -butyramide (U.S. Patent No. 8188069), and pharmaceutically acceptable salts thereof. Additional exemplary Notch inhibitors include nonsteroidal anti-inflammatory drugs (NSAIDs) such as flurbiprofen (Purow B, supra), MPC-7869 (Imbimbo BP, supra), ibuprofen (Id.), sulindac sulphide, indomethacin, alpha-secretase inhibitors (ASIs) (Purow B, supra), the Na+/H+ antiporter Monensin (Id.); small molecules that block Notch binding to interacting proteins such as Jagged, Numb, Numb-like, CBF1 transcription factor, and mastermind-like (MAML) (Id. ; Ishikawa Y et al, supra.); antibodies that bind Notch proteins or Notch ligands such as Delta-Like-4 (Purow B, supra); stapled peptides that bind Notch such as SAHM1 (Id.); dominant-negative forms of genes such as MAML (Id; Ishikawa Y et al., supra), Numb/Numb-Like (Purow B, supra), and FBXW-7 (Id. ); expression vectors that increase levels of Notch regulators such as FBXW-7 (Id. ; Ishikawa Y et al., supra); siRNAs that target Notch transcripts (Purow B, supra); microRNAs such as miR-326, miR-34a, microRNA-206, and miR- 124 (Id.); and Notch antibodies (U.S. Patent No. 8,226,943, U.S. Publication No.
20090258026A2, PCT Publication WO2012080926A2).
Exemplary Atohl activators include, for example, β-Catenin or β- catenin pathway agonists, e.g., Wnt ligands, DSH/DVL1 , 2, 3, LRP65N, WNT3A, WNT5A, and
WNT3 A, 5A. Additional Wnt/ β -catenin pathway activators and inhibitors are reviewed in the art (Moon et al, Nature Reviews Genetics, 5:689-699, 2004). In some embodiments, suitable Wnt/ -catenin pathway agonists can include antibodies and antigen binding fragments thereof, and peptides that bind specifically to frizzled (Fzd) family of receptors.
Kinase inhibitors, e.g., casein kinase 1 (CK1) and glycogen synthase kinase 3 β (GSK3) inhibitors can also act as β-Catenin or β- catenin pathway agonists to activate Atohl .
GSK3 β inhibitors include, but are not limited to, lithium chloride (LiCl), Purvalanol A, olomoucine, alsterpaullone, kenpaullone, benzyl-2-methyl-l,2,4-thiadiazolidine-3,5-dione (TDZD-8), 2-thio(3-iodobenzyl)-5-(l-pyridyl)-[l,3,4]-oxadiazole (GSK3 inhibitor II), 2,4- dibenzyl-5-oxothiadiazolidine-3-thione (OTDZT), (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO), α-4-Dibromoacetophenone (i.e., Tau Protein Kinase I (TPK I) Inhibitor), 2-Chloro-l-(4,5- dibromo-thiophen-2-yl)-ethanone, N-(4-Methoxybenzyl)-N'-(5-nitro-l,3-thiazol-2-yl)urea (AR- A014418), and indirubins (e.g., indirubin-5 -sulfonamide; indirubin-5-sulfonic acid (2- hydroxyethyl)-amide indirubin-3'-monoxime; 5-iodo-indirubin-3'-monoxime; 5-fluoroindirubin; 5,5'-dibromoindirubin; 5-nitroindirubin; 5-chloroindirubin; 5-methylindirubin, 5- bromoindirubin), 4-Benzyl-2-methyl-l,2,4-thiadiazolidine-3,5-dione (TDZD-8), 2-thio(3- iodobenzyl)-5-(l-pyridyl)-[l,3,4]-oxadiazole (GSK3 inhibitor II), 2,4-Dibenzyl-5- oxothiadiazolidine-3-thione (OTDZT), (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO), a-4- Dibromoacetophenone (i.e., Tau Protein Kinase I (TPK I) Inhibitor), 2-Chloro-l-(4,5-dibromo- thiophen-2-yl)-ethanone, (vi) N-(4-Methoxybenzyl)-N'-(5-nitro-l,3-thiazol-2-yl)urea (AR- AO 14418), and H-KEAPPAPPQSpP-NH2 (L803) or its cell-permeable derivative Myr-N-
GKEAPPAPPQSpP-NH2 (L803-mts). Other GSK3p inhibitors are disclosed in U.S. Patent Nos. 6,417, 185; 6,489,344; and 6,608,063. In some embodiments, suitable kinase inhibitors can include RNAi and siRNA designed to decrease GSK3p and/or CKI protein levels. In some embodiments, useful kinase inhibitors include FGF pathway inhibitors. In some embodiments, FGF pathway inhibitors include, for example, SU5402.
Additional Atohl activators include gamma secretase inhibitors (e.g.,
arylsulfonamides, dibenzazepines, benzodiazepines, N-[N-(3,5-difluorophenacetyl)-L-alanyl]- (S)-phenylglycine t-butyl ester (DAPT; EMD Biosciences, San Diego, CA, USA), L-685,458, or MK0752ho, in addition to those listed above under Notch inhibitors), gentamycin, and the combination of transcription factors Eyal and Sixl (and optionally Sox2), as described in Ahmed et al (2012) Dev. Cell. 22(2):377-390.
Additional Atohl activators are described in U.S. Patent No. 8,188, 131, including a compound represented by Formula Γ.
(I) wherein:
each of Rug, R1 19, Ri20, and RI2I is, independently selected from H, halo, OH, CN, N02, C]-C3 alkyl, C1-C3 haloalkyl, alkoxy, and Ci-C8 haloalkoxy;
R122 is hydrogen or— Z— Ra; wherein:
Z is O or a bond; and
Ra is:
(i) Ci-C6 alkyl or Ci-C6 haloalkyl, each of which is optionally substituted with from 1 -3 Rb; or
(ii) C3-C(o cycloalkyl, C3-Cio cycloalkenyl, each of which is optionally substituted with from 1-5 Rc; or
(iii) C7-C1 1 aralkyl, or heteroaralkyl including 6-1 1 atoms, each of which is optionally substituted with from 1 -5 Rc;
(iv) C6-Cio aryl or heteroaryl including 5-10 atoms, each of which is optionally substituted with from 1 -5 Rd;
(i) hydrogen; or
(ii) Ci-C6 alkyl or Ci-C6 haloalkyl, each of which is optionally substituted with from 1-3 Rb; or
(iii) C6-Cio aryl or heteroaryl including 5- 10 atoms, each of which is optionally substituted with from 1-5 Rd; or
(iv) C7-C11 aralkyl, or heteroaralkyl including 6-1 1 atoms, each of which is optionally substituted with from 1 -5 Rc; or
(v)— (C,-C6 alky -Z1— (C6-C10 aryl), wherein Z1 is O, S, NH, or N(CH3); the alkyl portion is optionally substituted with from 1-3 Rb; and the aryl portion is optionally substituted with from 1 -5 Rd; or
(vi)— (Ci-C6 alkyl)-Z2-(heteroaryl including 5- 10 atoms), wherein Z2 is O, S, NH, or N(CH3); the alkyl portion is optionally substituted with from 1-3 Rb; and the heteroaryl portion is optionally substituted with from 1 -5 Rd; or
(vii)— (C,-C6 alkyl)-Z3— (C3-C,0 cycloalkyl), wherein Z3 is O, S, NH, or N(CH3); the alkyl portion is optionally substituted with from 1 -3 Rb; and the cycloalkyl portion is optionally substituted with from 1-5 Rc;
R at each occurrence is, independently:
(i) NH2; NH(C,-C3 alkyl); N(C,-C3 alkyl)2; hydroxy; C,-C6 alkoxy or C,-C6 haloalkoxy; or
(ii) C3-C7 cycloalkyl optionally substituted with from 1-3 substituents independently selected from C,-C6 alkyl, NH2; NH(Ci-C3 alkyl); N(CrC3 alkyl)2; hydroxy; C C6 alkoxy or Ci-C6 haloalkoxy;
Rc at each occurrence is, independently:
(i) halo; NH2; NH(C,-C3 alkyl); N(C,-C3 alkyl)2; hydroxy; Cj-C6 alkoxy; C,-C6 haloalkoxy; or oxo; or
(ii) CpC6 alkyl or Ci-C6 haloalkyl; and
Rd at each occurrence is, independently:
(i) halo; NH2; NH(C,-C3 alkyl); N(C,-C3 alkyl)2; hydroxy; CrC6 alkoxy or d-C6 haloalkoxy; nitro;— NHC(0)( Ci-C3 alkyl); or cyano; or
(ii) Ci-C6 alkyl or C|-C6 haloalkyl; or a pharmaceutically acceptable salt thereof.
Other exemplary Atohl activators described in U.S. Patent No. 8,188, 131 include 4-(4-chlorophenyl)- 1 -(5H-pyrimido [5,4-b] indol-4-yl)- 1 H-pyrazol-3 -amine; 6-chloro- 1 -(2- chlorobenzyloxy)-2-phenyl- lH-benzo[d]imidazole; 6-chloro- 1 -(2-chlorobenzyloxy)-2-(4- methoxyphenyl)-lH-benzo[d] imidazole; 6-chloro-2-(4-methoxyphenyl)-l-(4-methylbenzyloxy)- lH-benzo[d] imidazole; 6-chloro- 1 -(3,5-dimethylbenzyloxy)-2-(4-methoxyphenyl)- 1 H-benzo [d] imidazole; 6-chloro- 1 -(4-methoxybenzyloxy)-2-(4-methoxyphenyl)- 1 H-benzo [d] imidazole; 1 -(4-methylbenzyloxy)-6-nitro-2 -phenyl- 1 H-benzo[d] imidazole; 4-(lH-benzo[d] imidazol-2-yl)phenol; 2,5-dichloro-N-((l -methyl- lH-benzo[d]imidazol-2-yl)methyl)aniline; 4- (2-(l-methyl-lH-benzo[d]imidazol-2-yl)ethyl)aniline; 2-((2-methoxyphenoxy)methyl)-lH- benzo[d]imidazole; 2-((4-fluorophenoxy)methyl)-l-methyl- 1 H-benzo [d] imidazole; 2-
(phenylthiomethyl)- 1 H-benzo [d] imidazole; 3-(6-methyl- 1 H-benzo[d]imidazole-2-yl)-2H-
chromen-2-imine; N-(2-(lH-benzo[d]imidazole-2-yl)phenyl)isobutyramide; 2-(o- tolyloxymethyl)- lH-benzo[d]imidazole; 2-(4-methoxyphenyl)-l -phenethyl- 1H- benzo[d] imidazole; N-(6-bromobenzo[d]thiazole-2-yl)thiophene-2-carboxamide; N- (benzo[d]thiazole-2-yl)-l-methyl-lH-pyrazole-5-carboxamide; 2-(4- fluorobenzylthio)benzo[d]thiazole; 5-chloro-N-methylbenzo[d]thiazole-2-amine; N-(6- acetamidobenzo[d]thiazol-2-yl)furan-2-carboxamide; N-(6-fluorobenzo[d]thiazole-2-yl)-3- methoxybenzamide; 2-(benzo[d]oxazol-2-ylthio)-N-(2-chlorophenyl)acetamide; 5-chloro-2- phenylbenzo[d]oxazole; 5-methyl-2-m-tolylbenzo[d]oxazole; 2-(4-isobutoxyphenyl)-3- (naphthalen-2-yl)-2,3-dihydroquinazolin-4(lH)-one; N-(2-(2-(4-fluorophenyl)-2-oxoethylthio)-4- oxoquinazolin-3(4H)-yl)benzamide; 2-(4-chlorophenyl)-4-(4-methoxyphenyl)-l,4- dihydrobenzo[4,5]imidazo [l,2-a]pyrimidine; 2-(3-pyridyl)-4-(4-bromophenyl)-l,4- dihydrobenzo[4,5]imidazo [l,2-a]pyrimidine; N-sec -butyl- l,7,7-trimethyl-9-oxo-8,9-dihydro- 7H-furo[3,2-f]chromene-2-carboxamide; N-(3-carbamoyl-5,6-dihydro-4H- cyclopenta[b]thiophen-2-yl)benzofuran-2-carboxamide; 3-chloro-N-(5-chloropyridin-2- yl)benzo[b]thiophene-2-carboxamide; 3-chloro-N-((tetrahydrofuran-2- yl)methyl)benzo[b]thiophene-2-carboxamide; N-(3-(5-chloro-3-methylbenzo[b]thiopen-2-yl)-lH- pyrazol-5-yl)acetamide; 2-(naphthalen-2-yl)-lH-indole; 2-(pyridin-2-yl)-lH-indole; N-(2- chlorophenyl)-2-(lH-indole-3-yl)-2-oxoacetamide; 2-m-tolylquinoline; 2-(4-(2-methoxyphenyl) piperazin- 1 -yl)quinolone; 2-(lH- benzo[d][ 1,2,3 ]triazol-l -yl)-N-(2,3-dihy dro-1 H-inden-2- yl)acetamide; 1 -phenethyl- 1 H-benzo[d] [ 1 ,2,3]triazole; 7-(4-fluorobenzyloxy)-2H-chromen- 2-one; N-(2,4-dichlorophenyl)-8-methoxy-2H-chromene-3-carboxamide; N-(3-chlorophenyl)-8- methyl-3,4-dihydroquinoline-l(2H)-carbothioamide; 7-methoxy-5-methyl-2-phenyl-4H- chromen-4- one; 2-(3,4-dimethylphenyl)quinoxaline; 4-bromo-N-(5-chloropyridin-2- yl)benzamide; 3-amino-6,7,8,9-tetrahydro-5H-cyclohepta[e]thieno[2,3-b]pyridine-2- carboxamide; (Z)-3-methyl-N'-(nicotinoyloxy)benzimidamide; N,N-diethyl-6- methoxythieno[2,3-b]quinoline-2-carboxamide; 6-(4-methoxyphenyl)-l,2,3,4-tetrahydro-l,5- naphthyridine; 5-bromo-N-(2-(phenylthio)ethyl) nicotinamide; N-(6-methylpyridin-2-yl)-2,3- dihydrobenzo[b][l,4]dioxine-6-carboxamide; 2-(4-methylbenzylthio)oxazolo [4,5-b]pyridine; N- (2-methoxyethyl)-5-p-tolylpyrimidin-2-amine; 4-(5-(benzo[b]thiophen-2-yl)pyrimidin-2- yl)morpholino; 4-(5-(4-fluorophenyl)pyrimidin-2-yl)morpholino; N-(4-bromo-3- methylphenyl)quinazoline-4-amine; N-(4-methoxyphenyl)quinazolin-4-amine; N-(3-
methoxyphenyl)-9H-purin-6-amine; Ν,Ν-diethyl- 1 -m-tolyl- 1 H-pyrazolo [3 ,4-d] pyrimidin-4- amine; (5-(4-bromophenyl)furan-2-yl)(mo holino)methanone; (Z)-4-bromo-N'-(furan-2- carbonyloxy)benzimidamide; N-(4-iodophenyl)furan-2-carboxamide; 5-(5-(2,4- difluorophenyl)furan-2-yl)- 1 -(methylsulfonyl)- 1 H-pyrazole; 1 -(3 -amino-5-(4-tert- butylphenyl)thiophen-2-yl)ethanone; N-(3-cayano-4,5,6,7-tetrahydrobenzo[b]tmophen-2-yl)-2- fluorobenzamide; N-(5-chloropyridin-2-yl)thiophene-2-carboxamide; N-(2-(4- fluorophenoxy)ethyl)thiophene-2-carboxamide; 2,5-dimethyl-N-phenyl-l-(thiophen-2-ylmethyl)- lH-pyrrole-3 -carboxamide; N-(3-cyanothiophen-2-yl)-4-isopropoxybenzamide; 2-(4- methoxyphenoxy)-N-(thiazol-2-yl)acetamide; 4-(4-methoxyphenyl)-N-(3-methylpyridin-2- yl)thiazol-2-amine; 4-(biphenyl-4-yl)thiazol-2-amine; 4-(4-(4-methoxyphenyl)thiazol-2-yl)-3- methylisoxazol-5-araine; N-(2-methoxyphenyl)-4-phenylthiazol-2-amine; l-(4-amino-2-(m- tolylamino)thiazol-5-yl)-2-methylpropan-l-one; 4-(4-chlorophenyl)-l-(5H-pyrimido[5,4-b]indol- 4-yl)-lH-pyrazol-3-amine; 2-(4-chlorophenyl)-6-ethyl-5-methylpyrazolo[l,5-a]pyrimidin-7(4H)- one; 5-methoxy-2-(5-phenyl- lH-pyrazol-3-yl)phenol; (3-(4-bromophenyl)-l -phenyl- 1 H- pyrazol-4-yl)methanol; N-(2,5-dichlorophenyl)- 1 -ethyl- lH-pyrazole-3 -carboxamide; 4-chloro- l-methyl-N-(2-oxo-2-phenylethyl)-lH-pyrazole-3-carboxamide; N-(3-(5-tert-butyl-2- methylfuran-3-yl)-lH- pyrazole-5-yl)benzamide; N-(5-methylisoxazol-3-yl)benzo [d] [ 1 ,3 ] dioxole-5-carboxamide; (5 -(4- bromophenyl)isoxazole-3 -yl)(morpholino)methanone; N-(4- bromophenyl)-5-isopropylisoxazole-3-carboxamide; 5-((4-chloro-2-methylphenoxy)methyl)-3- (pyridin-4-yl)-l,2,4-oxadiazole; 5-(2-methoxyphenyl)-3-p-tolyl-l,2,4-oxadiazole; 5-
(phenoxymethyl)-3-(pyridin-3-yl)-l,2,4-oxadiazole; 5-(2-chloro-4-methylphenyl)-3-(pyridin-3- yl)-l,2,4-oxadiazole; 3-(2-chlorophenyl)-5-p-tolyl-l,2,4-oxadiazole; 5-(piperidin-l-ylmethyl)-3-p- toyl-l,2,4-oxadiazole;5-(4-bromophenyl)-3-(pyridin-3-yl)-l,2,4-oxadiazole; 5-(2-bromophenyl)- 3-(4-bromophenyl)-l,2,4-oxadiazole; 5-(2-bromo- 5- methoxyphenyl)-3-(thiophenyl-2-yl)-l,2,4- oxadiazole; 3-(2-fluorophenyl)-N-(3-(piperidin-l-yl)propyl)-l,2,4-oxadiazol-5-amine; 2-(2- chlorobenzoyl)-N-(4-fluorophenyl)hydrazinecarbothioamide; 2-(methylamino)-N- phenethylbenzamide; 4-tert-butyl-N-((tetrahydrofuran-2-yl)methyl)benzamide; 2-phenyl-5-o- tolyl-l,3,4-oxadiazole;4-(3-(4-chlorophenyl)-4,5-dihydro-lH-l,2,4-triazole-5-yl)-N,N- dimethylaniline; 7-methoxy-2-(4-methoxyphenyl)- 1 , 10b-dihydrospiro[benzo[e]pyrazolo[ 1 ,5- c] [ 1 ,3 ]oxazine-5, 1 '-cyclohexane]; 6- oxo-2-(4-(3-(trifluoromethyl)phenoxy)phenyl)-l,4,5,6- tetrahydropyridine-3- carbonitrile; 6-(4-methoxyphenyl)imidazo[2, l-b]thiazole; 2-(2-
bromophenoxy)-N-(4H-l,2,4-triazol-3-yl)acetamide; l-(indolin-l-yl)-2-phenoxyethanone; 2-(4- chlorophenyl)-6,7,8,9-tetrahydrobenzo[e]imidazo [l,2-b][l,2,4]triazine; and pharmaceutically acceptable salts thereof.
Delivery of Agents for Modulating Myc, Notch andAtohl: The method of delivery of modulators of Myc, Notch or Atohl activity will depend, in part, upon whether the hair cells or supporting cells are being contacted with the agents of interest in vivo or ex vivo. In the in vivo approach, the agents are delivered into the inner ear of a mammal. In the ex vivo approach, cells are contacted with the agents ex vivo. The resulting hair cells can then be transplanted into the inner ear of a recipient using techniques known and used in the art. In certain embodiments, Myc activity is increased by administering Myc protein or a Myc activator in the inner ear of a recipient to give, for example, a final concentration of greater than about 30 μΜ, for example, in the range of about 30 μΜ to about 1000 μΜ. In certain embodiments, the Myc protein or Myc activator can be administered in an amount sufficient to give a final concentration of greater than about 30 μΜ. For example, the Myc protein or Myc activator may be administered in an amount sufficient to give a final concentration in the range from about 30 μΜ to about 1000 μΜ, 50 μΜ to about 1000 μΜ, 80 μΜ to about 1000 μΜ, about 100 μΜ to about 1000 μΜ, about 150 μΜ to about 1000 μΜ, from about 200 μΜ to about 800 μΜ, or from about 200 μΜ to about 600 μΜ.
In other embodiments, Myc protein or a Myc activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Myc protein or Myc activator can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Myc protein or Myc activator is administered locally to the inner ear. In certain other embodiments, from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Myc protein or Myc activator can be administered locally to the inner ear of a mammal.
In certain embodiments, Notch activity is increased by administering a Notch protein, a NICD protein or a Notch activator to an inner ear of a recipient to give a final concentration of greater than about 30 μΜ, for example, in the range of about 30 μΜ to about
1000 μΜ. In certain embodiments, a Notch protein, NICD protein or Notch activator can be administered in an amount sufficient to give a final concentration of greater than about 30 μΜ. For example, the Notch protein, NICD protein or Notch activator may be administered in an amount sufficient to give a final concentration in the range from about 30 μΜ to about 1000 μΜ, 50 μΜ to about 1000 μΜ, 80 μΜ to about 1000 μΜ, about 100 μΜ to about 1000 μΜ, about 150 μΜ to about 1000 μΜ, from about 200 μΜ to about 800 μΜ, or from about 200 μΜ to about 600 μΜ.
In other embodiments, Notch protein, NICD protein or Notch activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Notch protein, NICD protein or Notch activator can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Notch protein, NICD protein or Notch activator is administered locally to the inner ear of a mammal. In certain other embodiments, from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Notch protein, NICD protein or Notch activator can be administered locally to the inner ear of a mammal.
In certain embodiments, after cell proliferation has occurred, Notch activity is inhibited by administering a Notch inhibitor. A Notch inhibitor can be administered to give a final concentration of greater than about 30 μΜ, for example, in the range of about 30 μΜ to about 1000 μΜ. In certain embodiments, a Notch inhibitor can be administered in an amount sufficient to give a final concentration of greater than about 30 μΜ. For example, the Notch inhibitor may be administered in an amount sufficient to give a final concentration in the range from about 30 μΜ to about 1000 μΜ, 50 μΜ to about 1000 μΜ, 80 μΜ to about 1000 μΜ, about 100 μΜ to about 1000 μΜ, about 150 μΜ to about 1000 μΜ, from about 200 μΜ to about 800 μΜ, or from about 200 μΜ to about 600 μΜ. In certain embodiments, the Notch inhibitor is administered in an amount sufficient to give a final concentration of about 400 μΜ.
In other embodiments, a Notch inhibitor is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0.1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to
about 0.8 mg of the Notch inhibitor can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Notch inhibitor is administered locally to the inner ear of a mammal. In certain other embodiments, from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0.15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Notch inhibitor can be administered locally to the inner ear of a mammal. In certain embodiments, about 0.7 mg Notch inhibitor is administered locally to the inner ear of a mammal.
In certain embodiments, Atohl activity is increased by administering Atohl protein or an Atohl activator in the inner ear of a recipient to give, for example, a final concentration of greater than about 30 μΜ, for example, in the range of about 30 μΜ to about
1000 μΜ. In certain embodiments, the Atohlprotein or Atohl activator can be administered in an amount sufficient to give a final concentration of greater than about 30 μΜ. For example, the Atohlprotein or Atohl activator may be administered in an amount sufficient to give a final concentration in the range from about 30 μΜ to about 1000 μΜ, 50 μΜ to about 1000 μΜ, 80 μΜ to about 1000 μΜ, about 100 μΜ to about 1000 μΜ, about 150 μΜ to about 1000 μΜ, from about 200 μΜ to about 800 μΜ, or from about 200 μΜ to about 600 μΜ.
In other embodiments, Atohl protein or a Atohl activator is administered at a dose from about 0.025 mg to about 4 mg, from about 0.035 mg to about 2 mg, from about 0.05 mg to about 2 mg, from about 0. 1 mg to about 2 mg, from about 0.2 mg to about 1 mg, or from about 0.2 mg to about 0.8 mg of the Atohl protein or Atohl activator can be administered locally to the inner ear of a mammal. In one embodiment, 0.5 mg of Atohl protein or Atohl activator is administered locally to the inner ear. In certain other embodiments, from about 0.05 mg to about 2 mg, from about 0.2 mg to about 2 mg, from about 0.05 mg to about 1.5 mg, from about 0. 15 mg to about 1.5 mg, from about 0.4 mg to about 1 mg, or from about 0.5 mg to about 0.8 mg of Atohl protein or Atohl activator can be administered locally to the inner ear of a mammal.
Alternative methods for Delivery of DNA
In some aspects, the activity of Myc, Notch or Atohl can be increased in a target cell using expression constructs known in the art, e.g., naked DNA constructs, DNA vector based constructs, and/or viral vector and/or viral based constructs to express nucleic acids encoding a desired Myc, Notch or Atohl protein. In certain embodiments, a single DNA construct
expressing Myc and Notch or NICD as two separate genes can be delivered into the inner ear of a subject. In certain embodiments, a single DNA construct expressing Myc and Notch or NICD and Atohl as three separate genes can be delivered into the inner ear of a subject.
Exemplary expression constructs can be formulated as a pharmaceutical composition, e.g., for administration to a subject. DNA constructs and the therapeutic use of such constructs are well known to those of skill in the art (see, e.g. Chiarella et al. (2008) Recent Patents Anti-Infect. Drug Disc. 3: 93- 101 ; Gray et al. (2008) Expert Opin. Biol. Ther. 8:91 1- 922; Melman et al. (2008) Hum. Gene Ther. 17: 1165- 1 176). Naked DNA constructs typically include one or more therapeutic nucleic acids (e.g., DNA encoding Myc and/or Notch) and a promoter sequence. A naked DNA construct can be a DNA vector, commonly referred to as pDNA. Naked DNA typically does not integrate into chromosomal DNA. Generally, naked DNA constructs do not require, or are not used in conjunction with, the presence of lipids, polymers, or viral proteins. Such constructs may also include one or more of the non-therapeutic components described herein. DNA vectors are known in the art and typically are circular double stranded DNA molecules. DNA vectors usually range in size from three to five kilo-base pairs (e.g., including inserted therapeutic nucleic acids). Like naked DNA, DNA vectors can be used to deliver and express one or more therapeutic proteins in target cells. DNA vectors do not integrate into chromosomal DNA. Generally, DNA vectors include at least one promoter sequence that allows for replication in a target cell. Uptake of a DNA vector may be facilitated by combining the DNA vector with, for example, a cationic lipid, and forming a DNA complex. Typically, viral vectors are double stranded circular DNA molecules that are derived from a virus. Viral vectors typically are larger in size than naked DNA and DNA vector constructs and have a greater capacity for the introduction of foreign (i.e., not virally encoded) genes. Like naked DNA and DNA vectors, viral vectors can be used to deliver and express one or more therapeutic nucleic acids in target cells. Unlike naked DNA and DNA vectors, certain viral vectors stably incorporate themselves into chromosomal DNA. Typically, viral vectors include at least one promoter sequence that allows for replication of one or more vector encoded nucleic acids, e.g., a therapeutic nucleic acid, in a host cell. Viral vectors may optionally include one or more non-therapeutic components
described herein. Advantageously, uptake of a viral vector into a target cell does not require additional components, e.g., cationic lipids. Rather, viral vectors transfect or infect cells directly upon contact with a target cell.
The approaches described herein include the use of retroviral vectors, adenovirus- derived vectors, and/or adeno-associated viral vectors as recombinant gene delivery systems for the transfer of exogenous genes in vivo, particularly into humans. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F. M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14, and other standard laboratory manuals. Viruses that are used as transduction agents of DNA vectors and viral vectors such as adenoviruses, retroviruses, and lentiviruses may be used in practicing the present invention. Illustrative retroviruses include, but are not limited to: Moloney murine leukemia virus (M- MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus
(MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus. As used herein, the term "lentivirus" refers to a group (or genus) of complex retroviruses. Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna- maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
In certain embodiments, an adenovirus can be used in accordance with the methods described herein. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells. Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of
infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situ where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors.
Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. It is also one of the few viruses that may integrate its DNA into non- dividing cells, and exhibits a high frequency of stable integration.
In various embodiments, one or more viral vectors that expresses a therapeutic transgene or transgenes encoding a polypeptide or polypeptides of the invention (e.g., Atohl , Notch, Myc) is administered by direct injection to a cell, tissue, or organ of a subject, in vivo.
In some embodiments of the invention, it may be desirable to use a cell, cell type, cell lineage or tissue specific expression control sequence to achieve cell type specific, lineage specific, or tissue specific expression of a desired polynucleotide sequence, for example, to express a particular nucleic acid encoding a polypeptide in only a subset of cell types, cell lineages, or tissues, or during specific stages of development. Illustrative examples of cell, cell type, cell lineage or tissue specific expression control sequences include, but are not limited to: an Atohl enhancer for all hair cells; a Pou4f3 promoter for all hair cell; a Myo7a promoter for all hair cells; a Hes5 promoter for vestibular supporting cells and cochlear inner phalangeal cells, Deiters cells and Pillar cells; and GFAP promoter for vestibular supporting cells and cochlear inner phalangeal cells, Deiters cells and Pillar cells.
Certain embodiments of the invention provide conditional expression of a polynucleotide of interest. For example, expression is controlled by subjecting a cell, tissue, organism, etc., to a treatment or condition that causes the polynucleotide to be expressed or that causes an increase or decrease in expression of the polynucleotide encoded by the polynucleotide of interest. Illustrative examples of inducible promoters/systems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter
(inducible by treatment with various heavy metals), MX- 1 promoter (inducible by interferon), the "GeneSwitch" mifepristone-regulatable system (Sirin et al, 2003, Gene, 323:67), the cumate inducible gene switch (WO 2002/088346), tetracycline-dependent regulatory systems, etc.
In certain embodiments, vectors comprise a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, hygromycin, methotrexate, Zeocin, Blastocidin, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli. Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler et al, (1977) Cell, 1 1 :223-232) and adenine phosphoribosyltransferase (Lowy et al, (1990) Cell, 22:817-823) genes which can be employed in tk- or aprt- cells, respectively.
In certain embodiments, DNA delivery may occur by use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, optionally mixing with cell penetrating polypeptides, and the like, for the introduction of the compositions of the present invention into suitable host cells. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, a nanoparticle or the like. The formulation and use of such delivery vehicles can be carried out using known and conventional techniques. Duration of Delivery
The duration of Myc, Notch and Atohl activation can be varied to achieve a desired result. For example, it may be beneficial to expose a target cell to a Myc protein or Myc activator and a Notch protein, NICD protein, or a Notch activator for one to six days, one week, two weeks, three weeks, one month, three months, six months, nine months, one year, two years or more. Alternatively, when Myc is increased by constitutive activation (e.g., using an adenovirus to overexpress Myc), the duration of increased Myc activity can be controlled by administering a Myc inhibitor following administration of a myc protein or a myc activator. Inhibiting Myc activity after a period of increased Myc activity can be used to control proliferation, promote cell survival, and avoid tumorigenesis.
Similarly, the duration of increased Notch activity can be controlled by administering a Notch inhibitor, as discussed above, following administration of a Notch protein, NICD protein, or a Notch activator.
Route of Administration and Formulation
The route of administration will vary depending on the disease being treated. Hair cell loss, sensorineural hearing loss, and vestibular disorders can be treated using direct therapy using systemic administration and/or local administration. In certain embodiments, the route of administration can be determined by a subject's health care provider or clinician, for example following an evaluation of the subject.
The invention provides (i) a composition for use in proliferating or regenerating a cochlear or a utricular hair cell, (ii) a composition for use in proliferating or regenerating a cochlear or a utricular supporting cell, (iii) a composition for use in reducing the loss of, maintaining, or promoting hearing in a subject, and (iv) a composition for use in reducing the loss of, maintaining, or promoting vestibular function in a subject. Accordingly, the invention provides a first composition comprising an agent, for example, each of the agents discussed hereinabove, for example, an agent that increases Myc activity and/or an agent that increases Notch activity within a hair or supporting cell, either alone or in combination with a
pharmaceutically acceptable carrier for use in each of the foregoing approaches. In addition, the invention provides a second composition comprising an agent, for each of the agents discussed hereinabove, for example, an agent that reduces or inhibits Myc activity and/or an agent that reduces or inhibits Notch activity within a hair or supporting cell, either alone or in combination with in a pharmaceutically acceptable carrier for use in each of the foregoing approaches. When supporting cells are regenerated, the invention provides a third composition comprising an agent, for example, an agent for increasing Atohl activity, to induce trans differentiation of a proliferated supporting cell into a hair cell.
In addition, it is contemplated that the Myc protein or activator and/or the Notch protein, NICD protein, or Notch activator, and/or Atohl protein or activator can be formulated so as to permit release of one or more proteins and/or activators over a prolonged period of time. A release system can include a matrix of a biodegradable material or a material, which releases the incorporated active agents. The active agents can be homogeneously or heterogeneously
distributed within a release system. A variety of release systems may be useful in the practice of the invention, however, the choice of the appropriate system will depend upon the rate of release required by a particular drug regime. Both non-degradable and degradable release systems can be used. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar (for example, trehalose). Release systems may be natural or synthetic.
In certain embodiments, the agents can be administered to a subject, e.g., a subject identified as being in need of treatment for hair cell loss, using a systemic route of
administration. Systemic routes of administration can include, but are not limited to, parenteral routes of administration, e.g., intravenous injection, intramuscular injection, and intraperitoneal injection; enteral routes of administration, e.g., administration by the oral route, lozenges, compressed tablets, pills, tablets, capsules, drops (e.g., ear drops), syrups, suspensions and emulsions; rectal administration, e.g., a rectal suppository or enema; a vaginal suppository; a urethral suppository; transdermal routes of administration; and inhalation (e.g., nasal sprays). Alternatively or in addition, the agents can be administered to a subject, e.g., a subject identified as being in need of treatment for hair cell loss, using a local route of administration. Such local routes of administration include administering one or more
compounds into the ear of a subject and/or the inner ear of a subject, for example, by injection and/or using a pump. In certain embodiments, the agents may be injected into the ear (e.g., auricular administration), such as into the luminae of the cochlea (e.g., the Scala media, Sc vestibulae, and Sc tympani). For example, the agents can be administered by intratympanic injection (e.g., into the middle ear), and/or injections into the outer, middle, and/or inner ear. Such methods are routinely used in the art, for example, for the administration of steroids and antibiotics into human ears. Injection can be, for example, through the round window of the ear or through the cochlea capsule.
In other embodiments, the agents can be delivered via nanoparticles, for example, protein-coated nanoparticles. Nanoparticles can be targeted to cells of interest based on cell-type specific receptor affinity for ligands coating the nanoparticles. The dosage of the agent can be modulated by regulating the number of nanoparticles administered per dose.
Alternatively, the agent may be administered to the inner ear using a catheter or pump. A catheter or pump can, for example, direct the agent into the cochlea luminae or the round window of the ear. Exemplary drug delivery systems suitable for administering one or more compounds into an ear, e.g., a human ear, are described in U.S. Patent Publication No. 2006/0030837 and U.S. Patent No. 7,206,639. In certain embodiments, a catheter or pump can be positioned, e.g., in the ear (e.g., the outer, middle, and/or inner ear) of a subject during a surgical procedure.
Alternatively or in addition, the agents can be delivered in combination with a mechanical device such as a cochlea implant or a hearing aid, which is worn in the outer ear.
In certain embodiments, the modes of administration described above may be combined in any order and can be simultaneous or interspersed. For example, the agents may be administered to a subject simultaneously or sequentially. It will be appreciated that when administered simultaneously, the agents may be in the same pharmaceutically acceptable carrier (e.g., solubilized in the same viscoelastic carrier that is introduced into the inner ear) or the two agents may be dissolved or dispersed in separate pharmaceutical carriers, which are administered at the same time. Alternatively, the agents may be provided in separate dosage forms and administered sequentially.
Delivery of Agents to Hair Cells and Supporting Cells Ex vivo
It is understood that the concepts for delivering agents of interest to hair cells and supporting cells in vivo can also apply to the delivery of the agents of interest to hair cells and supporting cells ex vivo. The hair cells and supporting cells can be harvested and cultured using techniques known and used in the art. The agents (protein expression vectors, activators and inhibitors (for example, as discussed above)) can then be contacted with the cultured hair cells or supporting cells to induce the cells to reenter the cell cycle, and proliferate. Thereafter, once the cells have proliferated, the Myc and Notch activities can be inhibited using appropriate inhibitors, for example, those discussed above. The resulting hair cells can then be maintained in culture for any number of uses, including, for example, to study the biological, biophysical, physiological and pharmacological characteristics of hair cells and/or supporting cells.
Alternatively, the resulting hair cells can then be implanted in to the inner ear of a recipient using standard surgical procedures.
In certain embodiments, suitable cells can be derived from a mammal, such as a human, mouse, rat, pig, sheep, goat, or non-human primate. In certain embodiments, the cells can be harvested from the inner ear of a subject, and cells can be obtained from the cochlea organ of Corti, the modiolus (center) of the cochlea, the spiral ganglion of the cochlea, the vestibular sensory epithelia of the saccular macula, the utricular macula, or the cristae of the semicircular canals. Alternatively or in addition, methods include obtaining tissue from the inner ear of the animal, where the tissue includes at least a portion of the utricular maculae.
Tissue isolated from a subject can be suspended in a neutral buffer, such as phosphate buffered saline (PBS), and subsequently exposed to a tissue-digesting enzyme (e.g., trypsin, leupeptin, chymotrypsin, and the like) or a combination of enzymes, or a mechanical (e.g., physical) force, such as trituration, to break the tissue into smaller pieces. Alternatively, or in addition, both mechanisms of tissue disruption can be used. For example, the tissue can be incubated in about 0.05% enzyme (e.g., about 0.001 %, 0.01 %, 0.03%, 0.07%, or 1.0% of enzyme) for about 5, 10, 15, 20, or 30 minutes, and following incubation, the cells can be mechanically disrupted. The disrupted tissue can be passed through a device, such as a filter or bore pipette, that separates a stem cell or progenitor cell from a differentiated cell or cellular debris. The separation of the cells can include the passage of cells through a series of filters having progressively smaller pore size. For example, the filter pore size can range from about 80 μπι or less, about 70 μηι or less, about 60 μιτι or less, about 50 μιη or less, about 40 μπι or less, about 30 μηι or less, about 35 μπι or less, or about 20 μπι or less.
Partially and/or fully differentiated cells, e.g., generated by the methods described above, can be maintained in culture for a variety of uses, including, for example, to study the biological, biophysical, physiological and pharmacological characteristics of hair cells and/or supporting cells. Cell cultures can be established using inner ear cells from subjects with hearing loss and/or loss in vestibular function to develop potential treatments (e.g., to screen for drugs effective in treating the hearing loss and/or loss in vestibular function). Further, the methods of the present invention can be used in combination with induced pluripotent stem (iPS) cell technology to establish cell lines (e.g., hair cell lines and/or supporting cell lines). For example, fibroblasts from a subject with hearing loss can be induced to form iPS cells using known techniques (see, for example, Oshima et al. (2010) Cell, 141(4):704-716).
However, because the numbers of cells generated using iPS cell technology is limited, the methods provided herein can be used in combination with iPS cell technology to produce sufficient numbers of cells to establish cell lines (e.g., hair cell lines and/or supporting cell lines). Partially and/or fully differentiated cells, e.g., generated by the methods described above, can be transplanted or implanted, such as in the form of a cell suspension, into the ear by injection, such as into the luminae of the cochlea. Injection can be, for example, through the round window of the ear or through the bony capsule surrounding the cochlea. The cells can be injected through the round window into the auditory nerve trunk in the internal auditory meatus or into the scala tympani. In certain embodiments, the cells described herein can be used in a cochlea implant, for example, as described in U.S. Patent Publication No. 2007/0093878.
To improve the ability of transplanted or implanted cells to engraft, cells can be modified prior to differentiation. For example, the cells can be engineered to overexpress one or more anti-apoptotic genes. The Fak tyrosine kinase or Akt genes are candidate anti-apoptotic genes that can be used for this purpose; overexpression of FAK or Akt can prevent cell death in spiral ganglion cells and encourage engraftment when transplanted into another tissue, such as an explanted organ of Corti (see, for example, Mangi et al, (2003) Nat. Med. 9: 1195-201). Neural progenitor cells overexpressing ανβ3 integrin may have an enhanced ability to extend neurites into a tissue explant, as the integrin has been shown to mediate neurite extension from spiral ganglion neurons on laminin substrates (Aletsee et al., (2001) Audiol. Neu. Ootol. 6:57-65). In another example, ephrinB2 and ephrinB3 expression can be altered, such as by silencing with RNAi or overexpression with an exogenously expressed cDNA, to modify EphA4 signaling events. Spiral ganglion neurons have been shown to be guided by signals from EphA4 that are mediated by cell surface expression of ephrin-B2 and -B3 (Brors et al., (2003) J. Comp. Neurol. 462:90-100). Inactivation of this guidance signal may enhance the number of neurons that reach their target in an adult inner ear. Exogenous factors such as the neurotrophins BDNF and NT3, and LIF can be added to tissue transplants to enhance the extension of neurites and their growth towards a target tissue in vivo and in ex vivo tissue cultures. Neurite extension of sensory neurons can be enhanced by the addition of neurotrophins (BDNF, NT3) and LIF (Gillespie et al. (2010) Neuro. Report 12:275-279).
Measurement ofMyc, Notch or Atohl Activity in Target Cells
The methods and compositions described herein can be used to induce cells, e.g., adult mammalian inner ear cells, to reenter the cell cycle and proliferate. For example, the number of hair cells can be increased about 2-, 3-, 4-, 6-, 8-, or 10-fold, or more, as compared to the number of hair cells before treatment. The hair cell can be induced to reenter the cell cycle in vivo or ex vivo. It is contemplated that using these approaches it may be possible to improve the hearing of a recipient. For example, using the methods and compositions described herein, it may be possible to improve the hearing of a recipient by at least about 5, 10, 15, 20, 40, 60, 80, or 90% relative to the hearing prior to the treatment. Tests of auditory or vestibular function also can be performed to measure hearing improvement.
Cells that have been contacted with (i) a Myc protein or Myc activator and/or (ii) a Notch protein, NICD protein or Notch activator, can be assayed for markers indicative of cell cycle reentry and proliferation. In one example, a cell can be assayed for incorporation of EdU (5-ethynyl-2'-deoxyuridine) followed sequentially by BrdU (5-bromo-2'-deoxyuridine) by using, for example, an anti-EdU antibody and an anti-BrdU antibody. Labelling by EdU and/or BrdU is indicative of cell proliferation. In addition, double labeling of EdU and BrdU can be used to demonstrate that a cell has undergone division at least two times. Alternatively or in addition, a cell can be assayed for the presence of phosphorylated histone H3 (Ph3) or aurora B, which are indicative of a cell that has reentered the cell cycle and is undergoing metaphase and cytokinesis. Cell markers can also be used to determine whether a target cell, e.g., a hair cell or a supporting cell, has entered the cell cycle. Exemplary markers indicative of hair cells include Myo7a, Myo6, Prestin, Lhx3, Dner, espin, parvalbumin, and calretinin. Exemplary markers indicative of supporting cells include Sox2, SlOOal, Proxl, Rps6, and Jagl . Double labeling of a cell cycle and/or proliferation marker and a cell-type molecule can be used to determine which cells have reentered the cell cycle and are proliferating.
In addition, neuronal markers, e.g., acetylated tubulin, neurofilament and CtBP2, can be used to detect neuronal structure, to determine whether proliferating hair cells are in contact with neurons. The presence of neuronal markers adjacent to or in contact with hair cells suggests that newly-generated hair cells have formed synapses with neurons (e.g., ganglion neurons) and that the hair cells are differentiated.
Where appropriate, following treatment, the subject, for example, a human subject, can be tested for an improvement in hearing or in other symptoms related to inner ear disorders. Methods for measuring hearing are well-known and include pure tone audiometry, air conduction, auditory brainstem response (ABR) and bone conduction tests. These exams measure the limits of loudness (intensity) and pitch (frequency) that a human can hear. Hearing tests in humans include behavioral observation audiometry (for infants to seven months), visual reinforcement orientation audiometry (for children 7 months to 3 years) and play audiometry for children older than 3 years. Oto-acoustic emission testing can be used to test the functioning of the cochlea hair cells, and electro-cochleography provides information about the functioning of the cochlea and the first part of the nerve pathway to the brain. In certain embodiments, treatment can be continued with or without modification or can be stopped.
Compositions
In some embodiments, a composition comprises a cationic lipid encapsulating one or more chimeric molecules. These chimeric molecules comprise one or more proteins or peptides fused, complexed or linked to one or more anionic molecules. The anionic molecules can vary as long as they comprise one or more anionic domains or bind to an anionic nucleic acid domain. It is preferred that the anionic molecules confer an overall net negative charge to the chimeric molecule. Without wishing to be bound by theory, it was hypothesized that proteins that are engineered to be highly negatively charged or that are naturally highly anionic may be able to take advantage of the same electrostatics-driven complexation and encapsulation used by cationic liposomal reagents for nucleic acid delivery. While few proteins natively possess the density of negative charges found in the phosphate backbone of nucleic acids, it was speculated that translational fusion to, or non-covalent complexation with, a polyanionic molecule may render the resulting protein or protein complex sufficiently anionic to be efficiently complexed by common cationic lipid reagents.
Accordingly, in some embodiments, the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. In some embodiments, the oligonucleotides or
polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA),
short guide RNA (sgRNA), a short interfering RNA (siRNA), a micro, interfering RNA (miRNA), a small, temporal RNA (stRNA), a short, hairpin RNA (shRNA), mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
The one or more proteins or peptides of the chimeric or anionic molecule can possess any charge as long as the overall net charge of the chimeric molecule is anionic.
Accordingly, in embodiments, the proteins or peptides are cationic, anionic or are neutrally charged. Examples of proteins or peptides of the chimeric molecule which can be complexed or linked to the polyanionic molecule or domain comprise: enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, gene editing agents, synthetic molecules or combinations thereof.
In some embodiments, the protein or peptide is a therapeutic agent for delivery to a specific target. The target can be any desired intracellular target. In some embodiments, the target is a nucleic acid sequence or gene. In embodiments where it is desired to manipulate, modulate or edit a gene, the protein or peptide is a gene or genome editing agent. In some embodiments, the gene editing agents comprise: transcriptional activators, transcriptional repressors, transcription factors, enhancer modulating molecules, recombinases, nucleases, nucleic acid binding-proteins, nucleic acid binding-polynucleotides or oligonucleotides, DNA- binding proteins or DNA -binding nucleic acids, or combinations thereof. In some embodiments, the target is a protein or peptide. Accordingly, in some embodiments, the chimeric or anionic molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
In other embodiments, the chimeric molecule optionally comprises one or more detectable labels, anions, radiolabels, tags, targeting agents, negatively charged proteins or peptides, or combinations thereof. These molecules can be selected based on the user's desired goal, e.g. for diagnostic or research purposes, or to increase the anionic charge, targeting signals and the like. Accordingly, a liposomal formulation for complexing protein and nucleic acid (e.g. transcription factors with their target binding region as oligonucleotides) for inner ear cell types delivery in vivo, is used to treat deafness or associated disorders thereof as the chimeric molecule can be tailored for regeneration (e.g. hair cell and auditory neuron regeneration), repair (e.g. re-
establishment of connections between hair cells and neurons for hearing recovery) and prevention (e.g. by protein function of isll that prevents hair cell death during aging and noise exposure, thus preserving hearing).
In other embodiments, a chimeric molecule comprises at least one protein or peptide fused, complexed or linked to one or more anionic molecules. Preferably, the one or more anionic molecules comprise one or more anionic domains or bind to an anionic nucleic acid domain. In embodiments, the chimeric molecule comprises an overall net negative charge. In some embodiments, the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. In some embodiments, the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), a short interfering RNA (siRNA), a micro, interfering RNA (miRNA), a small, temporal RNA (stRNA), a short, hairpin RNA (shRNA), mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof. The chimeric molecule also comprises one or more proteins or peptides which are cationic, anionic or are neutrally charged. Examples of proteins include without limitation: enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, genome or gene editing agents, synthetic molecules or combinations thereof. The gene or genome editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof. In other embodiments, the chimeric molecule optionally comprises one or more detectable labels, radiolabels, tags, anions, targeting agents or combinations thereof.
In other embodiments, a cationic liposome encapsulates an anionic molecule comprising a protein or peptide complexed, fused or linked to a negatively charged molecule. In some embodiments, the negatively charged molecule comprises oligonucleotides,
polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof. In other embodiments, the polynucleotide or oligonucleotide is a guide RNA. In some embodiments, the protein or peptide is a negatively charged fluorescent protein. In yet other embodiments, the one or more proteins or peptides are cationic, anionic or are neutrally charged. In yet another embodiment, the negatively charged protein is fused or linked to one or more protems or peptides. In some embodiments, the protein or peptide comprises:
enzymes, hormones, chemotherapeutic agents, immunotherapeutic agents, gene editing agents, synthetic molecules or combinations thereof. In some embodiments, the gene editing agents comprise: transcriptional activators, transcriptional repressors, transcription factors, enhancer modulating molecules, recombinases, nucleases, nucleic acid binding-proteins, nucleic acid binding-polynucleotides or oligonucleotides, DNA-binding proteins or DNA-binding nucleic acids, or combinations thereof.
In other embodiments, the liposome comprises one or more cationic lipids, modified lipids or combinations thereof.
In some embodiments, a liposome encapsulating one or more molecules embodied herein comprises a liposome, a nanoliposome, a niosome, a microsphere, a
nanosphere, a nanoparticle, a micelle, or an archaeosome.
Modified Proteins or Peptides: Hybrid proteins comprising a polypeptide or fragment thereof may be linked to other types of polypeptides, for example, a negatively supercharged green fluorescent protein in addition to a reporter polypeptide, or in lieu of a reporter polypeptide. These additional polypeptides may be any amino acid sequence useful for the purification, identification, overall charge of the protein or peptide, and/or therapeutic or prophylactic application of the peptide. In addition, the additional polypeptide can be a signal peptide, or targeting peptide, etc.
In some cases, the other additions, substitutions or deletions may increase the stability (including but not limited to, resistance to proteolytic degradation) of the polypeptide or increase affinity of the polypeptide for its appropriate receptor, ligand and/or binding proteins. In some cases, the other additions, substitutions or deletions may increase the solubility of the polypeptide. In some embodiments sites are selected for substitution with a naturally encoded or non-natural amino acid in addition to another site for incorporation of a non-natural amino acid for the purpose of increasing the polypeptide solubility following expression in recombinant host cells. In some embodiments, the polypeptides comprise another addition, substitution, or deletion that modulates affinity for the associated ligand, binding proteins, and/or receptor, modulates (including but not limited to, increases or decreases) receptor dimerization, stabilizes receptor dimers, modulates circulating half-life, modulates release or bio-availability, facilitates purification, or improves or alters a particular route of administration. Similarly, the non-natural
amino acid polypeptide can comprise chemical or enzyme cleavage sequences, protease cleavage sequences, reactive groups, antibody-binding domains (including but not limited to, FLAG or poly-His) or other affinity based sequences (including but not limited to, FLAG, poly-His, GST, etc.) or linked molecules (including but not limited to, biotin) that improve detection (including but not limited to, GFP), purification, transport through tissues or cell membranes, prodrug release or activation, size reduction, or other traits of the polypeptide.
The methods and compositions described herein include incorporation of one or more non-natural amino acids into a polypeptide. One or more non-natural amino acids may be incorporated at one or more particular positions which does not disrupt activity of the polypeptide. This can be achieved by making "conservative" substitutions, including but not limited to, substituting hydrophobic amino acids with non-natural or natural hydrophobic amino acids, bulky amino acids with non-natural or natural bulky amino acids, hydrophilic amino acids with non-natural or natural hydrophilic amino acids) and/or inserting the non-natural amino acid in a location that is not required for activity. A variety of biochemical and structural approaches can be employed to select the desired sites for substitution with a non-natural amino acid within the polypeptide. Any position of the polypeptide chain is suitable for selection to incorporate a non-natural amino acid, and selection may be based on rational design or by random selection for any or no particular desired purpose. Selection of desired sites may be based on producing a non-natural amino acid polypeptide (which may be further modified or remain unmodified) having any desired property or activity, including but not limited to agonists, super-agonists, partial agonists, inverse agonists, antagonists, receptor binding modulators, receptor activity modulators, modulators of binding to binder partners, binding partner activity modulators, binding partner conformation modulators, dimer or multimer formation, no change to activity or property compared to the native molecule, or manipulating any physical or chemical property of the polypeptide such as solubility, aggregation, or stability. For example, locations in the polypeptide required for biological activity of a polypeptide can be identified using methods including, but not limited to, point mutation analysis, alanine scanning or homolog scanning methods. Residues other than those identified as critical to biological activity by methods including, but not limited to, alanine or homolog scanning mutagenesis may be good candidates for substitution with a non-natural amino acid depending on the desired activity sought for the polypeptide. Alternatively, the sites
identified as critical to biological activity may also be good candidates for substitution with a non-natural amino acid, again depending on the desired activity sought for the polypeptide. Another alternative would be to make serial substitutions in each position on the polypeptide chain with a non-natural amino acid and observe the effect on the activities of the polypeptide. Any means, technique, or method for selecting a position for substitution with a non-natural amino acid into any polypeptide is suitable for use in the methods, techniques and compositions described herein.
Modified Oligonucleotides: Examples of some oligonucleotides envisioned for this invention include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. In some embodiments, modified oligonucleotides comprise those with phosphorothioate backbones and those with heteroatom backbones, CH2 ~NH~0~CH2, CH,-N(CH3)-0-CH2 [known as a methyl ene(methylimino) or MMI backbone], CH2 -O-N (CH3)-CH2, CH2 -N (CH3)-N (CH3)-CH2 and O-N (CH3)~CH2 — CH2 backbones, wherein the native phosphodiester backbone is represented as O— P— O— CH). The amide backbones disclosed by De Mesmaeker et al. Acc. Chem. Res. 1995, 28:366-374) are also embodied herein. In some embodiments, the oligonucleotides having morphohno backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506), peptide nucleic acid (PNA) backbone wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleobases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen et al. Science 1991, 254, 1497). Oligonucleotides may also comprise one or more substituted sugar moieties. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.
Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein,
"unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimi dines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleobases, e.g., 2-aminoadenine, 2-(methylamino)adenine, 2-
(imidazolylalkyl)adenine, 2-(aminoalklyamino)adenine or other heterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7- deazaguanine, N6 (6-aminohexyl)adenine and 2,6-diaminopurine. Kornberg, A., DNA
Replication, W. H. Freeman & Co., San Francisco, 1980, pp75-77; Gebeyehu, G., et al. Nucl. Acids Res. 1987, 15:4513). A "universal" base known in the art, e.g., inosine, may be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., in Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions.
Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA 1989, 86, 6553), cholic acid (Manoharan et al. Bioorg. Med. Chem. Let. 1994, 4, 1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al. Ann. N Y. Acad. Sci. 1992, 660, 306;
Manoharan et al. Bioorg. Med. Chem. Let. 1993, 3, 2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res. 1992, 20, 533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al. EMBO J. 1991 , 10, 1 1 1 ; Kabanov et al. FEBS Lett. 1990, 259, 327; Svinarchuk et al. Biochimie 1993, 75, 49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l ,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.
Tetrahedron Lett. 1995, 36, 3651 ; Shea et al. Nucl. Acids Res. 1990, 18, 3777), a polyamine or a polyethylene glycol chain (Manoharan et al. Nucleosides & Nucleotides 1995, 14, 969), or adamantane acetic acid (Manoharan et al. Tetrahedron Lett. 1995, 36, 3651). Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides are known in the art, for example, U.S. Pat. Nos. 5,138,045, 5,218,105 and 5,459,255. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide. The present invention also includes oligonucleotides which are chimeric oligonucleotides as hereinbefore defined.
Labeled Molecules: In another preferred embodiment, the chimeric molecules can be labeled. Uses include therapeutic and imaging for diagnostic and prognostic purposes. The label may be a radioactive atom, an enzyme, or a chromophore moiety. Methods for labeling antibodies have been described, for example, by Hunter and Greenwood, Nature, 144:945 (1962) and by David et al. Biochemistry 13: 1014-1021 (1974). Additional methods for labeling antibodies have been described in U.S. Pat. Nos. 3,940,475 and 3,645,090. Methods for labeling oligonucleotide probes have been described, for example, by Leary et al. Proc. Natl. Acad. Sci. USA (1983) 80:4045; Renz and Kurz, Nucl. Acids Res. (1984) 12:3435; Richardson and
Gumport, Nucl. Acids Res. (1983) 1 1 :6167; Smith ei a/. Nucl. Acids Res. (1985) 13:2399; and Meinkoth and Wahl, Anal. Biochem. (1984) 138:267.
The label may be radioactive. Some examples of useful radioactive labels include 32P, 125I, 131I, and 3H. Use of radioactive labels have been described in U.K. 2,034,323, U.S. Pat. No. 4,358,535, and U.S. Pat. No. 4,302,204.
Some examples of non-radioactive labels include enzymes, chromophores, atoms and molecules detectable by electron microscopy, and metal ions detectable by their magnetic properties.
Some useful enzymatic labels include enzymes that cause a detectable change in a substrate. Some useful enzymes and their substrates include, for example, horseradish peroxidase (pyrogallol and o-phenylenediamine), β-galactosidase (fluorescein β-D- galactopyranoside), and alkaline phosphatase (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium). The use of enzymatic labels has been described in U.K. 2,019,404, EP 63,879, and by Rotman, Proc. Natl. Acad. Sci. USA, 47, 1981-1991 (1961).
Useful chromophores include, for example, fluorescent, chemiluminescent, and bioluminescent molecules, as well as dyes. Some specific chromophores useful in the present invention include, for example, fluorescein, rhodamine, Texas red, phycoerythrin, umbelliferone, luminol.
The labels may be conjugated to the chimeric molecule by methods that are well known in the art. The labels may be directly attached through a functional group on the probe. The probe either contains or can be caused to contain such a functional group. Some examples of suitable functional groups include, for example, amino, carboxyl, sulfhydryl, maleimide,
isocyanate, isothiocyanate. Alternatively, labels such as enzymes and chromophores may be conjugated to the antibodies or nucleotides by means of coupling agents, such as dialdehydes, carbodiimides, dimaleimides, and the like.
In another preferred embodiment, the chimeric fusion molecules of the invention can be used for imaging. In imaging uses, the complexes are labeled so that they can be detected outside the body. Typical labels are radioisotopes, usually ones with short half-lives. The usual imaging radioisotopes, such as 123I, 124I, 125I, 1311, 99mTC, 186Re, 188Re, 64Cu, 67Cu, 2,2Bi, 2 l3Bi, 67Ga, 90Y, 1 1 'in, 18F, 3H, 14C, 35S or 32P can be used. Nuclear magnetic resonance (NMR) imaging enhancers, such as gadolinium- 153, can also be used to label the complex for detection by NMR. Methods and reagents for performing the labeling, either in the polynucleotide or in the protein moiety, are considered known in the art.
Reporter genes useful in the present invention include acetohydroxy acid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), and derivatives thereof. Multiple selectable markers are available that confer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin, and tetracycline. Methods to determine modulation of a reporter gene are well known in the art, and include, but are not limited to, fluorometric methods (e.g. fluorescence spectroscopy, Fluorescence Activated Cell Sorting (FACS), fluorescence microscopy), antibiotic resistance determination.
Kits
In yet another aspect, the invention provides kits for targeting nucleic acid sequences of cells and molecules associated with modulation of the target molecule. For example, the kits can be used to target any desired nucleic sequence and as such, have many applications.
In one embodiment, a kit comprises: (a) a cationic lipid, and a chimeric molecule or an encapsulated chimeric molecule, or a protein and a separate polyanionic molecule, or any combinations thereof, and (b) instructions to administer to cells or an individual a therapeutically
effective amount of the composition. In some embodiments, the kit may comprise
pharmaceutically acceptable salts or solutions for administering the composition. Optionally, the kit can further comprise instructions for suitable operational parameters in the form of a label or a separate insert. For example, the kit may have standard instructions informing a physician or laboratory technician to prepare a dose of chimeric molecule.
Optionally, the kit may further comprise a standard or control information so that a patient sample can be compared with the control information standard to determine if the test amount of chimeric molecule is a therapeutic amount consistent with for example, treating deafness in a patient. While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. Numerous changes to the disclosed embodiments can be made in accordance with the disclosure herein without departing from the spirit or scope of the invention. Thus, the breadth and scope of the present invention should not be limited by any of the above described embodiments.
All documents mentioned herein are incorporated herein by reference. All publications and patent documents cited in this application are incorporated by reference for all purposes to the same extent as if each individual publication or patent document were so individually denoted. By their citation of various references in this document, applicants do not admit any particular reference is "prior art" to their invention. Embodiments of inventive compositions and methods are illustrated in the following examples.
EXAMPLES
The following non-limiting Examples serve to illustrate selected embodiments of the invention. It will be appreciated that variations in proportions and alternatives in elements of the components shown will be apparent to those skilled in the art and are within the scope of embodiments of the present invention.
Example 1: Efficient Delivery of Proteins In vitro and In vivo.
One of the goals is to develop a protein-based hair cell regeneration paradigm by delivering functional Myc/NICD proteins to adult guinea pig inner ear to induce supporting cell
proliferation, and to transdifferentiate them to hair cells. The approach is to restore hearing in deafened guinea pig models exposed to noise and treated by ototoxic drugs. The protein based- therapy is to be applied to adult human inner ear ex vivo for induction of proliferation and hair cell regeneration. Development of protein delivery into adult guinea pig inner ear for induction of proliferation: The guinea pig model was chosen for the study due to the fact it is non-transgenic, with an inner ear that is about ten times larger than the mouse inner ear, and with well- understood hearing and deafness characteristics. This makes it possible to develop a procedure (biological and surgical) applicable to humans. A protein-based therapy was chosen as it delivers biological molecules with specific and transient function. With this approach, the dose, duration and relative ratio of proteins to be delivered can be optimized in vitro and in vivo.
The protein-based therapy is delivered using a modified supercharged GFP protein that is linked to aurein (s-GFP-aurein or alternatively referred to, herein, as aurein- +36GFP), a peptide with antibacterial function secreted by frog. When linked with s-GFP- aurein, Cre recombinase is taken up by inner ear supporting cells in vivo after being directly injected into the inner ears of neonatal and adult mice. Cre recombinase delivered was translocated into nuclei, leading to the cleavage of the floxP sites and expression of a reporter gene tdTomato. s-GFP-aurein is fused with Myc and NICD and delivery to the supporting cells of adult guinea pig inner ears is tested. Production of fusion proteins including s-GFP-aurein, s-GFP-aurein-NICD and s-GFP -aurein- Atohl : The respective proteins are purified at micro molar (μηι) concentrations and tested for inner ear delivery. s-GFP-aurein- Atohl is used for the study.
Testing of the combined Myc/NICD proteins for adult mouse inner ear delivery to induce proliferation in vivo. As adult mouse supporting cells proliferate in response to
Myc NICD activation, and take up s-GFP-aurein, the adult mouse inner ear is used for a proof- of-principle experiment testing the ability of s-GFP-aurein carrying the transcription factors Myc and NICD to induce the proliferation of supporting cells.
Test Myc/NICD protein delivery to induce proliferation in the adult guinea pig inner ear in vivo. Combinations of s-GFP-aurein-Myc/s-GFP-aurein-NICD are injected into adult guinea pig inner ears. Induction of proliferation is evaluated by doses, the ratios between
the two proteins, the duration of effects and single vs. multiple injections. The conditions under which limited proliferation is induced in the inner ear sensory epithelial region that is suitable for transdifferentiation into hair cells are to be identified. Further attention will be paid to any sign of tumor formation. In the current study by continuous expression of Myc/NICD through viral infection or by induced Myc NICD trans gene expression for over 30 days, tumors were not observed. The transient nature of protein-based therapy, with an estimated protein half-life of less than 24 hours, should further dramatically reduce the risk of tumor formation. It is important to note that human inner ear is one of the organs in which no endogenous tumor has been identified, making it a better organ for renewed proliferation without associated tumorigenesis.
Optimization of route of delivery in adult guinea pig inner ear. Guinea pigs serve as an excellent model to optimize the surgical procedure for protein delivery that should be applicable to humans. The cochlea is a snail-shaped structure that senses sounds ranging from high frequency at the base to low frequency at the apex. It is critical to regenerate hair cells along the length of the cochlea so hearing can be recovered in most frequencies. Ways to reach different cochlear regions will be evaluated, including single injection of fluorophore-labeled s- GFP-aurein (which itself does not have fluorescence due to modifications to GFP) to the middle turn, multiple injections to different turns, and injections to different chambers of the cochlea (scala tympani vs. scala media). The goal is to identify a simple procedure that optimizes therapeutic effects while avoiding damage to the inner ear.
Example 2: Hair cell regeneration in adult guinea pig in vivo
Two approaches are used to transdifferentiate supporting cells into hair cells in the adult mouse inner ear: overexpression of Atohl and blockade of the Notch pathway by inhibitors.
Hair cell regeneration by Atohl overexpression. Delivery of s-GFP-aurein- Atohl into supporting cells is evaluated for hair cell induction. This is performed three to five days after Myc/NICD induced proliferation, as Myc/NICD activity is required for proliferation and their downregulation is important to Atohl induced hair cell transdifferentiation. Due to the relatively short half-life of the delivered proteins, downregulation of Myc/NICD is thus achieved by slightly delayed Atohl delivery. Following the protein-delivery of Atohl, hair cell production at different time points is examined. The shortest period within which differentiated and functional
hair cells are regenerated is to be identified. Interestingly by adenovirus-mediated delivery of Atohl into adult mammalian cochlea including mouse, rat and guinea pig, no convincing hair cell regeneration has been observed by various labs, which demonstrate that it is highly unlikely hair cells can be induced by Atohl alone in adult inner ear. However with the activation of Myc NICD, the inventors routinely achieve hair cell regeneration by Ad-Atohl in adult mouse inner ear in vivo.
Hair cell regeneration by blocking Notch pathway by DAPT and LY411575. The advantage of using Notch inhibitors is that they are well characterized and there are multiple forms, some of which have been approved for clinical use, including Eli Lilly's Alzheimer drug (gamma-secretase inhibitor LY411575). Local delivery of DAPT and LY411575 is tested by placing PEG400 or gelform containing different concentrations of DAPT and LY411575 in the round window niche (just outside the membrane of the inner ear that separates middle and inner ear). Two to four weeks later, hair cell regeneration will be evaluated. The shortest period within which differentiated hair cells can be regenerated is determined. Example 3: Hair cell regeneration to restore hearing
Hearing loss in guinea pigs can be induced by noise exposure or ototoxic drug treatment (e.g. gentamicin). The functional test following hair cell regeneration is hearing restoration. By auditory brainstem response (ABR), hearing recovery can be precisely measured.
Hearing restoration in noise-induced deaf guinea pig model: Guinea pigs are subjected to noise to create profound (complete) hearing loss across different frequencies that are associated with major hair cell loss. Supporting cell proliferation is induced by protein delivery and hair cell regeneration by Atohl protein and by application of Notch inhibitors in one ear; whereas the contralateral uninjected ear serves as a control. ABR is performed 1-4 months following injection, to study hearing recovery. In control ear, no ABR or significantly elevated ABR thresholds are detected at any frequencies. In the injected inner ear, ABR will ascertain hearing recovery (by dB) across different frequencies. For instance detection by ABR at 50 dB at 16 kHz is a demonstration of hearing in the middle frequency with a threshold at 50 dB (i.e. the animal can hear the sound at 50 dB or above at this frequency). This study will demonstrate precisely how much hearing has recovered and at what frequencies.
ABR identifies whether or not regenerated hair cells are functional and the effect on hearing recovery. It will provide information regarding the procedure that produces the best outcome. For instance by correlating the surgical and delivery procedure with ABR, it can be determined how effective the approach is on hearing restoration at different frequencies, which has a direct relevance in human study.
Hearing restoration in deaf guinea pig treated with ototoxic drugs: Ototoxic drugs (aminoglycoside antibiotics neomycin and gentamicin, and anti-cancer drug Cisplatin) preferentially kill hair cells to cause hearing loss. Guinea pigs will be treated with gentamicin to create permanent deafness. Protein delivery of Myc NICD followed by Atohl and Notch inhibitors will be similarly studied. ABR will be performed to analyze hearing recovery in the injected inner ears vs. uninfected control inner ears. Detection of ABR will be a demonstration of hearing recovery following delivery of key molecules.
Hearing recovery between the above two models is compared to determine which recovery is more prominent. This information would be useful in determining the type of patients to enroll in clinical study.
Example 4: Induction of proliferation and hair cell regeneration in adult human cochlea ex vivo.
Protein delivery of Myc/NICD is performed for proliferation and Atohl and Notch inhibitor for hair cell regeneration using cultured human inner ear. This study will evaluate the similarity and difference in protein-based therapy in guinea pig and human inner ears, providing important information that is relevant to clinical study. Due to extreme conservation between mammalian inner ear, it is expected to see a highly similar outcome in human inner ear explant study as in the guinea pig.
Example 5: Protein Delivery Into the Inner Ear The goal of this study was to use protein-mediated delivery system to deliver the biological proteins directly inner ear cell types with functional consequences. With this method, the proteins delivered have specific functions, and the effect is transient. Further, delivery of native protein lessens any potential immune response.
As cell surface is cationic (positively charged), it has been demonstrated that, by changing amino acids, GFP (green fluorescent protein) can be modified to be highly charged (both positively and negatively, named supercharged protein), which enables the supercharged GFP to enter cells. As a result, the super-charged GFP (s-GFP) can be used as vehicle to link and deliver other proteins into cells with biological effect in vitro and in vivo. This was demonstrated in mouse retina in which s-GFP carrying Cre recombinase (s-GFP-Cre) was delivered that resulted in expression of reporter gene in retinal cells. The s-GFP used as (-30)-GFP, a negatively charged GFP protein.
The use of (-30)-GFP protein and a new positively charged (+36)-GFP protein to carry Cre, (-30)-GFP-Cre and (+36)-GFP-Cre, was tested for injection into mouse cochlea in vivo. The mouse used was Rosa-tdTomatof/ in which functional Cre activity in the nuclei results in cells being labeled with tdT (red). It was shown that both (-30)-GFP-Cre and (+36)-GFP-Cre injections led to tdT expression in the cochlear hair cells. Near the injection site (base turn of cochlea), -30% of hair cells became tdT-labeled (Figures 1 A, IB), The study demonstrated that supercharged GFP proteins can be used to delivery protein directly into inner ear hair cells with biological effect in nuclei.
It was next tested whether aurein, an antimicrobial peptide, in combination with s- GFP, can serve as an effective carrier to deliver functional proteins into mouse inner ear cell types with high efficiency. (+36)-GFP-aurein-Cre was injected with different concentrations into P3 PvOsa-tdT mouse inner ear by cochleostomy in vivo. The tissues were harvested 5 days later for immunolabeling to identify tdT+ inner ear cell types. Overall it was found that cochlear hair cells were primarily labeled with tdT, with additional tdT labeling in supporting cells. At low concentrations of 5μΜ, few IHC and some supporting cells (SC) were tdT+. At 22.5μΜ, 58% of OHC and 75% of IHC, as well as 8% of SC were tdT+. At the highest 50μΜ, 96% of OHC, 88% of IHC and 19% of SC were tdT+. There was slight cell toxicity associated with the highest concentration of 50μΜ. It was found that 20% of IHC loss 8% of OHC in the injected animals, whereas at lower concentrations of 5 and 22.5μΜ no cell loss was detected.
The study demonstrated that functional proteins including nuclear proteins can be conjugated with supercharged protein (+36)GFP fused with aurein. The protein complex can be directly injected into mammalian inner ear that leads to uptake by a wide range of inner ear cell
types. The protein delivered was properly localized in the nuclei and had the specific biological function in cleaving floxP sites on the DNA sequence, to activate tdTomato in the inner ear cells with high efficiency.
The delivery system can be used to study protein functions, inner ear regeneration for hearing recovery, hearing protection, etc.
Example 6: Delivery of functional NICD by aurein in the inner ear.
In addition to the in vivo delivery of Cre recombinase by aurein that leads to reporter (tdTomato) expression, aurein linked with NICD was prepared for inner ear delivery in vitro. Cultured mouse cochlea were treated with aurein-NICD without lipofectamine2000. Five days after the treatment, tissues were harvested for qRT-PCR, to determine the level Notch and its two downstream targets Hesl and Hes5. qRT-PCR showed overall that there was an increase in the level for all three genes, judging by qRT-PCR. 40%, 70% and 15% of upregulation were observed for Hesl , hes5 and Notch respectively. The level increase in Notch is smaller, which may be a reflection of degradation of Notch. Example 7: Supporting cells reprogrammed by Myc/NICD combination can
transdifferentiate to hair cells without going through proliferation
Myc/NICD co-activation leads to renewed proliferation of many cell types including supporting cells, hair cells, stria vascularis and fibrocytes. Proliferating supporting cells react to Atohl over expression robustly and transdifferentiate to hair cells. Further upon Myc/NICD c-activation, even without cell cycle re-entry, the supporting cells can still be reprogrammed by Myc NICD and transdifferentiate to hair cells by Atohl over expression (Figures6A-6H). Thus the Myc and NICD dosage is likely to play an important role, in which high activity induces proliferation and subsequent transdifferentiation, and low activity induces transdifferentiation. Rejuvenation of adult inner ear stem cells: Inner ear stem cells have been isolated only from neonatal and early postnatal mouse (Oshima, K. et al. Differential distribution of stem cells in the auditory and vestibular organs of the inner ear. J. Assoc. Res. Otolaryngol. 8, 18-31 (2007)). In adult no inner ear stem cells have been isolated, an indication that the stem cells lose their potential to proliferate and regenerate. It was shown by using rtTa tet-Myc/tet-NICD mice,
in which Myc/NICD is induced by doxycycline, adult inner ear stem cells can be isolated as spheres. Further the spheres can differentiate to inner ear neurons, supporting cells and hair cells as neonatal mice (Figures 7A-7I). Thus Myc/NICD activation can be used to re-activate dormant adult inner ear stem cells, for regeneration of inner ear cell types for hearing recovery.
Claims
1. A method of regenerating inner ear cells in vitro or in vivo comprising: contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a chimeric protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl ), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear.
2. The method of claim 1, wherein the chimeric protein comprises a supercharged protein or variants thereof.
3. The method of claim 2, wherein the supercharged protein is green fluorescent protein (s- GFP), or variants thereof.
4. The method of claim 1 , wherein the chimeric protein comprises green fluorescent protein (s-GFP) linked to one or more proteins or peptides, or modified variants thereof, comprising: antimicrobial or membrane destabilizing peptides, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
5. The method of claim 1 , wherein activation of Myc and/or Notch activity induces proliferation of the hair cells and supporting cells.
6. The method of claim 1, wherein inhibition of Myc activity, Notch activity, NICD activity or combinations thereof, in supporting cells induces transdifferentiation of the supporting cells into functional hair cells.
7. The method of claim 1 , wherein the supporting cells are induced to transdifferentiate into hair cells by administration of an effective amount of inhibitors of Myc, Notch, NICD, or combinations thereof.
8. The method of claim 1 , wherein after inhibition of Myc activity and/or Notch activity, a composition comprising activators of Atohl is administered to the inner ear, wherein activation of Atohl induces transdifferentiation of the supporting cells into functional hair cells.
9. The method of claim 1, wherein Myc activity is increased by administering an effective amount of Myc protein, Myc peptides or Myc activators linked to GFP or variants thereof.
10. The method of claim 9, wherein after Myc activity is increased, Myc activity is inhibited, or Myc activity decreases as the Myc activator degrades.
1 1. The method of claim 1, wherein Notch activity is increased by administering an effective amount of Notch protein, Notch peptides, Notch activators, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof, linked to GFP or variants thereof.
12. The method of claim 11 , wherein the Notch activity is inhibited by administering one or more inhibitors of Notch activity, or Notch activity decreases as the Notch activator degrades.
13. A method of regenerating inner ear cells in vitro or in vivo comprising: contacting a cell in vitro or administering to an inner ear of patient in need of such treatment, a composition comprising an effective amount of a chimeric protein comprising one or more proteins, peptides or variants thereof, which increase expression of or activate Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD), or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear.
14. The method of claim 13, wherein the chimeric protein comprises a supercharged domain comprising a fluorescent protein or variants thereof.
15. The method of claim 14, wherein the fluorescent protein is green fluorescent protein (s- GFP), or variants thereof.
16. The method of claim 13, wherein the chimeric protein comprises green fluorescent protein (s-GFP) linked to one or more proteins or peptides, or variants thereof, comprising: antimicrobial or membrane destabilizing peptides, Myc, Notch, Notch Intracellular domain (NICD), transcription factors, transcription modulators, modulators of activity, or combinations thereof.
17. The method of claim 13, wherein the chimeric protein comprising activators of Myc, Notch, and/or NICD activators is administered to a patient to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear.
18. The method of claim 13, wherein after Myc activity is increased, Myc activity is inhibited, or Myc activity decreases as the Myc activator degrades.
19. The method of claim 13, wherein after Notch activity is increased, Notch activity is inhibited, or Notch activity decreases as the Notch activator degrades.
20. The method of any one of claims 18-19, wherein after Myc and/or Notch activity is inhibited, the method further comprises contacting the supporting cells with a composition comprising Atohl modulators or variants thereof, wherein the Atohl modulators induce transdifferentiation of the supporting cells into functional hair cells.
21. The method of claim 20, wherein the composition comprises a chimeric protein linked to one or polypeptides or variants thereof comprising: antimicrobial or membrane destabilizing peptides, aurein, Atohl proteins, Atohl peptides, activators of Atohl , variants or combinations thereof.
22. The method of claim 20, wherein the composition comprises a vector encoding for Atohl proteins, Atohl peptides, activators of Atohl , variants or combinations thereof.
23. A method of inducing proliferation and transdifferentiation of inner ear cells, in vivo or in vitro, comprising contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; administering inhibitors to inhibit Notch and Myc activity; and, administering a composition which activates Atohl in the supporting cells, inducing the transdifferentiation of the supporting cells to hair cells.
24. The method of claim 23, wherein the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof, an antimicrobial or membrane destabilizing peptide, one or more Myc protein or peptides, Myc modulators, Notch
protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
25. A method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprising contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein the composition comprises a supercharged domain, an antimicrobial or membrane destabilizing domain and one or more therapeutic molecules which modulate the activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides; administering inhibitors to inhibit Notch and Myc activity; and, administering an activator of Atohl, wherein the Atohl activator induces the transdifferentiation of the supporting cells to hair cells.
26. A method of inducing proliferation and transdifferentiation of inner ear cells, in vivo or in vitro, comprising contacting inner ear cells comprising, strial vascularis, hair cells, or supporting cells of the inner ear with a composition which increases expression or activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl, to induce the transdifferentiation of the supporting cells to hair cells.
27. The method of claim 26, wherein the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof, an antimicrobial or membrane destabilizing peptide, one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
28. A method of preventing or treating deafness or disorders thereof, in a patient in need of such treatment comprising contacting inner ear cells comprising, strial vascularis, hair cells, stem cells or supporting cells of the inner ear with a composition which increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in hair and supporting cells of the inner ear; wherein after Notch and/or Myc activity is decreased or inhibited, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
29. The method of claim 28, wherein the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof, an antimicrobial or membrane destabilizing peptide, one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
30. A method of delivering a therapeutic molecule to cells of an inner ear of a patient, comprising: administering to the inner ear of a patient a chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules.
31. The method of claim 30, wherein the cells or the inner ear cells comprising, strial vascularis, hair cells, supporting cells, or combinations thereof.
32. The method of claim 30, wherein the chimeric molecule comprises one or more gene editing agents, transcriptional modulators, translational modulators, post-translational modulators, and/or modulators that regulate protein expression, function, activity or combinations thereof.
33. The method of claim 32, wherein the gene editing agents comprise: transcriptional activators, transcriptional repressors, recombinases, nucleases, DNA-binding proteins or nucleic acids, or combinations thereof.
34. The method of claim 30, wherein the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
35. The method of claim 34, wherein the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
36. The method of claim 30, wherein the chimeric molecule further comprises a supercharged protein or variants thereof.
37. The method of claim 36, wherein the supercharged protein is a fluorescent protein, or variants thereof.
38. The method of claim 30, wherein the chimeric molecule further comprises antimicrobial or membrane destabilizing peptides or variants thereof.
39. The method of claim 30, wherein the chimeric molecule is optionally encapsulated in a cationic lipid formulation.
40. A method of inducing transdifferentiation of inner ear cells comprising contacting an inner ear cell in vitro or in vivo with a composition which transiently increases activity of Myc proteins or peptides, Notch proteins or peptides, Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, variants or combinations thereof within a cell, to induce transdifferentiation of supporting cells of the inner ear without proliferation; wherein after Notch activity is decreased or inhibited by a Notch inhibitor, optionally, administering an activator of Atohl , to induce the transdifferentiation of the supporting cells to hair cells.
41. The method of claim 40, wherein the composition comprises an effective amount of a chimeric protein comprising a supercharged protein or variants thereof, linked to an antimicrobial or membrane destabilizing peptide, and the antimicrobial or membrane destabilizing peptide being linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
42. A method of regenerating inner ear cells comprising inducing proliferation or cell cycle reentry of inner ear cells in vitro or in vivo, the method comprising contacting a cell in vitro or
administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising: a supercharged protein or peptide, an antimicrobial or membrane destabilizing peptide and one or more proteins, peptides or variants thereof, which modulate activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce proliferation or cell cycle re-entry in inner ear cells.
43. A method protecting and/or treating hearing loss in a patient in need of such treatment, comprising: contacting a cell in vitro or administering to an inner ear of a patient in need of such treatment, a composition comprising an effective amount of a supercharged protein comprising one or more proteins, peptides or variants thereof, which modulate expression or activity of Myc, Notch, Atonal Homolog 1 (Atohl), Notch Intracellular domain (NICD) proteins, Notch Intracellular domain (NICD) peptides, or combinations thereof within a cell, to induce neurite growth, proliferation or cell cycle re-entry of inner ear cells, proliferation of hair cells, proliferation of supporting cells, and/or transdifferentiation of supporting cells.
44. A chimeric molecule comprising at least one protein or peptide fused, complexed or linked to one or more anionic molecules, wherein the at least one protein or peptides comprise Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof; and, the one or more anionic molecules comprise one or more anionic domains or bind to an anionic nucleic acid domain.
45. The chimeric molecule of claim 44, wherein the anionic molecules comprise: oligonucleotides, polynucleotides, proteins, peptides, peptide nucleic acids (PNA), synthetic molecules or combinations thereof.
46. The chimeric molecule of claim 45, wherein the oligonucleotides or polynucleotides comprise: ribonucleic acids (RNA), deoxyribonucleic acids (DNA), synthetic RNA or DNA sequences, modified RNA or DNA sequences, complementary DNA (cDNA), short guide RNA (sgRNA), interference RNA, mRNA, nucleic acid sequences comprising one or more modified nucleobases or backbones, or combinations thereof.
47. The chimeric molecule of claim 44, wherein the one or more proteins or peptides are cationic, anionic or are neutrally charged.
48. The chimeric molecule of claim 44, wherein the one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof, are fused, complexed or linked to antimicrobial or membrane destabilizing peptides, supercharged proteins, or combinations thereof.
49. A chimeric molecule comprising: a supercharged protein, an antimicrobial or membrane destabilizing peptide, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
50. A chimeric molecule comprising at least one supercharged protein linked to at least one antimicrobial or membrane destabilizing peptide, and at least one molecule selected from the group consisting of: Myc protein or peptides, Myc modulators Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
51. A chimeric molecule comprising any two or more proteins, peptides or variants thereof, said proteins, peptides or variants thereof comprising: a supercharged protein or peptide, an antimicrobial or membrane destabilizing peptide, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch modulators, Notch Intracellular domain (NICD) proteins or peptides, Notch Intracellular domain (NICD), Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
52. The chimeric molecule of claim 51 , wherein the two or more proteins, peptides or variants thereof, comprise an antimicrobial or membrane destabilizing peptide and a protein or peptide selected from the group consisting of: Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch modulators, Notch Intracellular domain (NICD) proteins or peptides, Notch Intracellular domain (NICD), Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
53. A chimeric nucleic acid molecule encoding any two or more proteins, peptides or variants thereof, said proteins, peptides or variants thereof comprising: a supercharged protein or peptide, antimicrobial or membrane destabilizing peptide, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch modulators, Notch Intracellular domain (NICD) proteins or
peptides, Notch Intracellular domain (NICD), Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
54. The chimeric molecule of claim 53, wherein a supercharged protein or peptide is fused or linked to an antimicrobial or membrane destabilizing peptide, the antimicrobial or membrane destabilizing peptide being fused or linked to one or more proteins or peptides comprising Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch modulators, Notch Intracellular domain (NICD) proteins or peptides, Notch Intracellular domain (NICD), Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
55. A chimeric molecule comprising a supercharged domain, an antimicrobial or membrane destabilizing domain, Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
56. The chimeric molecule of claim 55, wherein the antimicrobial or membrane destabilizing domain is fused or linked to one or more Myc protein or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof
57. A chimeric molecule comprising an antimicrobial or membrane destabilizing domain, and one or more Myc proteins or peptides, Myc modulators, Notch protein or peptides, Notch Intracellular domain (NICD) proteins or peptides, Atonal Homolog 1 (Atohl), Atohl modulators, transcription factors, transcription modulators, or combinations thereof.
58. A pharmaceutical composition of any one of claims 44, 49, 50, 51 , 53, 55 or 57.
59. A cationic liposome encapsulating a composition of any one of claims 44, 49, 50, 51, 53, 55 or 57.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15855303.2A EP3212773B1 (en) | 2014-10-29 | 2015-10-29 | Efficient delivery of therapeutic molecules to cells of the inner ear |
US15/523,317 US11370823B2 (en) | 2014-10-29 | 2015-10-29 | Efficient delivery of therapeutic molecules to cells of the inner ear |
US17/750,530 US12043653B2 (en) | 2014-10-29 | 2022-05-23 | Efficient delivery of therapeutic molecules to cells of the inner ear |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072220P | 2014-10-29 | 2014-10-29 | |
US62/072,220 | 2014-10-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/523,317 A-371-Of-International US11370823B2 (en) | 2014-10-29 | 2015-10-29 | Efficient delivery of therapeutic molecules to cells of the inner ear |
US17/750,530 Division US12043653B2 (en) | 2014-10-29 | 2022-05-23 | Efficient delivery of therapeutic molecules to cells of the inner ear |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016069906A1 true WO2016069906A1 (en) | 2016-05-06 |
Family
ID=55858345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/058081 WO2016069906A1 (en) | 2014-10-29 | 2015-10-29 | Efficient delivery of therapeutic molecules to cells of the inner ear |
Country Status (3)
Country | Link |
---|---|
US (2) | US11370823B2 (en) |
EP (1) | EP3212773B1 (en) |
WO (1) | WO2016069906A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106692989A (en) * | 2017-03-07 | 2017-05-24 | 大连民族大学 | Drug liposome/p53 gene compound and preparation method and application thereof |
WO2017210553A1 (en) | 2016-06-03 | 2017-12-07 | Hough Ear Institute | Combination therapies for inner ear sensory hair cell regeneration/replacement |
CN110981943A (en) * | 2019-12-02 | 2020-04-10 | 清华大学 | Polypeptide, application thereof in preparation of medicine and medicine |
US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11883491B2 (en) * | 2017-05-03 | 2024-01-30 | St. Jude Children's Research Hospital, Inc. | Compositions and methods for prevention and treatment of hearing loss |
US11911416B2 (en) | 2018-08-01 | 2024-02-27 | University Of Iowa Research Foundation | Compositions and methods to restore hearing loss and balance through embryonic ear transplant |
CN113365603A (en) * | 2018-10-11 | 2021-09-07 | 分贝治疗公司 | AAV1 vectors and their use for treating otic indications |
CN114981298B (en) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | Compositions and methods for preventing and treating hearing loss |
US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
EP4397750A1 (en) * | 2021-09-03 | 2024-07-10 | The Kitasato Institute | Method for producing inner ear stria vascularis marginal cells, chemical agent assessment method, and cell culture for assessing chemical agent |
Citations (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US131A (en) | 1837-02-24 | Machine foe cutting eur fedm skins | ||
US8188A (en) | 1851-07-01 | Htkstaht | ||
US3645090A (en) | 1969-06-19 | 1972-02-29 | Citizen Watch Co Ltd | Day-date quick-adjuster for calender timepiece |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
GB2019404A (en) | 1978-03-31 | 1979-10-31 | Chevron Res | N-haloacetylphenylamino carbonyl oximes |
GB2034323A (en) | 1978-12-18 | 1980-06-04 | Inst Nat Sante Rech Med | Production of DNA Comprising B Hepatitis Viral Genome |
US4302204A (en) | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
EP0063879A2 (en) | 1981-04-17 | 1982-11-03 | Yale University | Modified nucleotides and methods of preparing and using same |
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
WO1998028268A2 (en) | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS |
US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
WO2002047671A2 (en) | 2000-11-17 | 2002-06-20 | Eli Lilly And Company | Lactam compound to inhibit beta-amyloid peptide release or synthesis |
US6417185B1 (en) | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
US6541466B2 (en) | 1996-12-23 | 2003-04-01 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6608063B2 (en) | 1999-12-17 | 2003-08-19 | Chiron Corporation | Pyrazine based inhibitors of glycogen synthase kinase 3 |
RU38486U1 (en) | 2003-11-03 | 2004-06-20 | Закрытое акционерное общество "Пермский проектно-конструкторский и экспериментальный институт горного и нефтяного машиностроения" | HYDRAULIC DRINKING MACHINE |
WO2004090110A2 (en) | 2003-03-31 | 2004-10-21 | Bresagen Inc. | Compositions and methods for the control, differentiation and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
US20040237127A1 (en) | 1999-06-01 | 2004-11-25 | Zoghbi Huda Y. | Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation |
US20060030837A1 (en) | 2004-01-29 | 2006-02-09 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US7026343B2 (en) | 2002-06-12 | 2006-04-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pharmacologic inhibition of Myc function |
US7206639B2 (en) | 2002-03-15 | 2007-04-17 | Sarcos Investments Lc | Cochlear drug delivery system and method |
US20070093878A1 (en) | 2005-09-08 | 2007-04-26 | Albert Edge | Cochlear implants containing biological cells and uses thereof |
US7300951B2 (en) | 2003-03-31 | 2007-11-27 | Wyeth | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
WO2009040423A1 (en) | 2007-09-26 | 2009-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tocopherol derivatives as inhibitors of the notch signalling pathway |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
US20090232780A1 (en) | 2008-02-07 | 2009-09-17 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh1 expression |
US20090258026A2 (en) | 2007-06-04 | 2009-10-15 | Genentech, Inc. | Anti-notch1 nrr antibodies and methods using same |
US7872027B2 (en) | 2006-02-17 | 2011-01-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Low molecular weight Myc-max inhibitors |
EP1949916B1 (en) | 2005-08-31 | 2011-08-10 | LifeScan, Inc. | Chromatin remodeling agents for increasing expression of PDX-1 and promoting cell differentiation |
US20110251120A1 (en) | 2006-10-26 | 2011-10-13 | Wang Guangshun | Antimicrobial Peptides and Methods of Identifying the Same |
US20110263580A1 (en) | 2008-12-11 | 2011-10-27 | Thomas Miller | Method for treating alzheimer's disease and related conditions |
US20110275719A1 (en) | 2009-02-06 | 2011-11-10 | Matthew Daniels | Novel trifluoromethylsulfonamide gamma secretase inhibitor |
WO2011149762A2 (en) | 2010-05-25 | 2011-12-01 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiantion of human embryonic stem cells and uses thereof |
US20110305674A1 (en) | 2008-11-24 | 2011-12-15 | Massachusetts Eye & Ear Infirmary | Pathways to Generate Hair Cells |
US8114422B2 (en) | 2005-07-29 | 2012-02-14 | The General Hospital Corporation | Methods and compositions for reducing skin damage |
US20120100569A1 (en) | 2009-04-28 | 2012-04-26 | Liu David R | Supercharged proteins for cell penetration |
US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
US8188069B2 (en) | 2007-08-14 | 2012-05-29 | Eli Lilly And Company | Azepine derivatives as gamma-secretase inhibitors |
WO2012080926A2 (en) | 2010-12-15 | 2012-06-21 | Wyeth Llc | Anti-notch1 antibodies |
US8226943B2 (en) | 2008-07-08 | 2012-07-24 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2487156A1 (en) | 2003-12-11 | 2012-08-15 | Board Of Regents The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US8338482B2 (en) | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
WO2014039908A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737604B2 (en) * | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
WO2016069906A1 (en) | 2014-10-29 | 2016-05-06 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
-
2015
- 2015-10-29 WO PCT/US2015/058081 patent/WO2016069906A1/en active Application Filing
- 2015-10-29 US US15/523,317 patent/US11370823B2/en active Active
- 2015-10-29 EP EP15855303.2A patent/EP3212773B1/en active Active
-
2022
- 2022-05-23 US US17/750,530 patent/US12043653B2/en active Active
Patent Citations (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US131A (en) | 1837-02-24 | Machine foe cutting eur fedm skins | ||
US8188A (en) | 1851-07-01 | Htkstaht | ||
US3645090A (en) | 1969-06-19 | 1972-02-29 | Citizen Watch Co Ltd | Day-date quick-adjuster for calender timepiece |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
GB2019404A (en) | 1978-03-31 | 1979-10-31 | Chevron Res | N-haloacetylphenylamino carbonyl oximes |
GB2034323A (en) | 1978-12-18 | 1980-06-04 | Inst Nat Sante Rech Med | Production of DNA Comprising B Hepatitis Viral Genome |
US4302204A (en) | 1979-07-02 | 1981-11-24 | The Board Of Trustees Of Leland Stanford Junior University | Transfer and detection of nucleic acids |
US4358535A (en) | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
US4358535B1 (en) | 1980-12-08 | 1986-05-13 | ||
EP0063879A2 (en) | 1981-04-17 | 1982-11-03 | Yale University | Modified nucleotides and methods of preparing and using same |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
WO1998028268A2 (en) | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS |
US6541466B2 (en) | 1996-12-23 | 2003-04-01 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
US6417185B1 (en) | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US6489344B1 (en) | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
US20040237127A1 (en) | 1999-06-01 | 2004-11-25 | Zoghbi Huda Y. | Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation |
US6608063B2 (en) | 1999-12-17 | 2003-08-19 | Chiron Corporation | Pyrazine based inhibitors of glycogen synthase kinase 3 |
WO2002047671A2 (en) | 2000-11-17 | 2002-06-20 | Eli Lilly And Company | Lactam compound to inhibit beta-amyloid peptide release or synthesis |
US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
US7206639B2 (en) | 2002-03-15 | 2007-04-17 | Sarcos Investments Lc | Cochlear drug delivery system and method |
US7026343B2 (en) | 2002-06-12 | 2006-04-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Pharmacologic inhibition of Myc function |
US7300951B2 (en) | 2003-03-31 | 2007-11-27 | Wyeth | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof |
WO2004090110A2 (en) | 2003-03-31 | 2004-10-21 | Bresagen Inc. | Compositions and methods for the control, differentiation and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
RU38486U1 (en) | 2003-11-03 | 2004-06-20 | Закрытое акционерное общество "Пермский проектно-конструкторский и экспериментальный институт горного и нефтяного машиностроения" | HYDRAULIC DRINKING MACHINE |
EP2487156A1 (en) | 2003-12-11 | 2012-08-15 | Board Of Regents The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US20060030837A1 (en) | 2004-01-29 | 2006-02-09 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US8114422B2 (en) | 2005-07-29 | 2012-02-14 | The General Hospital Corporation | Methods and compositions for reducing skin damage |
EP1949916B1 (en) | 2005-08-31 | 2011-08-10 | LifeScan, Inc. | Chromatin remodeling agents for increasing expression of PDX-1 and promoting cell differentiation |
US20070093878A1 (en) | 2005-09-08 | 2007-04-26 | Albert Edge | Cochlear implants containing biological cells and uses thereof |
US7872027B2 (en) | 2006-02-17 | 2011-01-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Low molecular weight Myc-max inhibitors |
US8338482B2 (en) | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
US20110251120A1 (en) | 2006-10-26 | 2011-10-13 | Wang Guangshun | Antimicrobial Peptides and Methods of Identifying the Same |
US20090258026A2 (en) | 2007-06-04 | 2009-10-15 | Genentech, Inc. | Anti-notch1 nrr antibodies and methods using same |
WO2009005688A2 (en) | 2007-06-29 | 2009-01-08 | Trustees Of Columbia University In The City Of New York | Activating mutations in notch-1 |
US8188069B2 (en) | 2007-08-14 | 2012-05-29 | Eli Lilly And Company | Azepine derivatives as gamma-secretase inhibitors |
WO2009040423A1 (en) | 2007-09-26 | 2009-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of tocopherol derivatives as inhibitors of the notch signalling pathway |
US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
US20090232780A1 (en) | 2008-02-07 | 2009-09-17 | Massachusetts Eye & Ear Infirmary | Compounds that enhance atoh1 expression |
US8188131B2 (en) | 2008-02-07 | 2012-05-29 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh1 expression |
US8226943B2 (en) | 2008-07-08 | 2012-07-24 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
US20110305674A1 (en) | 2008-11-24 | 2011-12-15 | Massachusetts Eye & Ear Infirmary | Pathways to Generate Hair Cells |
US20110263580A1 (en) | 2008-12-11 | 2011-10-27 | Thomas Miller | Method for treating alzheimer's disease and related conditions |
US20110275719A1 (en) | 2009-02-06 | 2011-11-10 | Matthew Daniels | Novel trifluoromethylsulfonamide gamma secretase inhibitor |
US20120100569A1 (en) | 2009-04-28 | 2012-04-26 | Liu David R | Supercharged proteins for cell penetration |
WO2011149762A2 (en) | 2010-05-25 | 2011-12-01 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiantion of human embryonic stem cells and uses thereof |
US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
WO2012080926A2 (en) | 2010-12-15 | 2012-06-21 | Wyeth Llc | Anti-notch1 antibodies |
WO2014039908A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye And Ear Infirmary | Methods and compositions for regenerating hair cells and/or supporting cells |
Non-Patent Citations (93)
Title |
---|
"Short Protocols in Molecular Biology", 1999, JOHN WILEY & SONS |
AGGARWAL ET AL., CLIN. CANCER RES., vol. 1 1, no. 20, 2005, pages 7490 - 8 |
AHMED ET AL., DEV. CELL, vol. 22, no. 2, 2012, pages 377 - 390 |
ALETSEE ET AL., AUDIOL. NEU. OOTOL., vol. 6, 2001, pages 507 - 511 |
AS, FUWA ET AL., BIOORG. MED. CHEM. LETT., vol. 16, no. 16, 2006, pages 4184 - 4189 |
ASHIZAWA ET AL., INT. J. ONCOL., vol. 38, no. 5, 2011, pages 1245 - 52 |
BEST ET AL., J. PHARMACOL. EXP. THER., vol. 317, no. 2, 2006, pages 786 - 90 |
BOLLAG ET AL.: "Protein Methods", 1996, JOHN WILEY & SONS |
BRISTOL MYERS SQUIBB, ALBRIGHT ET AL., J PHARMACOL. EXP. THER., vol. 344, no. 3, 2013, pages 686 - 695 |
BRORS ET AL., J. COMP. NEUROL., vol. 462, 2003, pages 90 - 100 |
CHIARELLA ET AL.: "Recent Patents Anti-Infect", DRUG DISC., vol. 3, 2008, pages 93 - 101 |
CHUNG ET AL., J. CLIN. INVEST., vol. 122, no. 6, 2012, pages 2257 - 2266 |
CHURCHER ET AL., J. MED. CHEM., vol. 46, no. 12, 2003, pages 2275 - 8 |
CLAUSEN DM ET AL., J. PHARMACOL. EXP. THER., vol. 335, no. 3, 2010, pages 715 - 27 |
DAUDET, DEV. BIO., vol. 326, 2009, pages 86 - 100 |
DAVID B. THOMPSON ET AL.: "Engineering and identifying Supercharged Proteins for Macromolecule Delivery into Mammalian Cells", PROTEIN ENGINEERING FOR THERAPEUTICS, vol. 503, 1 January 2012 (2012-01-01), pages 293 - 319, XP055044980, ISBN: 978-0-12-396962-0, DOI: 10.1016/B978-0-12-396962-0.00012-4 |
DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014 - 1021 |
DE MESMAEKER ET AL., ACC. CHEM. RES., vol. 28, 1995, pages 366 - 374 |
ELI LILLY, FAUQ ET AL., BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 6392 - 5 |
ENGELHARD ET AL., J. NEUROONCOL., vol. 37, no. 2, 1998, pages 97 - 108 |
EWAN ET AL., PLOS ONE, vol. 7, no. 1 1, 2012, pages e 9160 |
FERNANDEZ, D. I. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1788, no. 8, August 2009 (2009-08-01), pages 1630 - 8 |
FREIER S. M., NUCLEIC ACID RESEARCH, vol. 25, 1997, pages 4429 - 4443 |
FREIERALTMANN, NUCL. ACID. RES., vol. 25, no. 22, 1997, pages 4429 - 4443 |
GEBEYEHU, G. ET AL., NUCL. ACIDS RES., vol. 15, 1987, pages 4513 |
GILLESPIE ET AL., NEURO. REPORT, vol. 12, 2010, pages 275 - 279 |
GRAY ET AL., EXPERT OPIN. BIOL. THER., vol. 8, 2008, pages 911 - 922 |
HENIKOFF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919 |
HERDEWIN P., ANTISENSE & NUCLEIC ACIDDRUGDEV., vol. 10, 2000, pages 297 - 310 |
HU ET AL., LEUK. LYMPHOMA, vol. 10, no. 1-2, 1993, pages 135 - 42 |
HUANG ET AL., EXP. HEMATOL., vol. 34, no. 1 1, 2006, pages 1480 - 9 |
HUNTERGREENWOOD, NATURE, vol. 144, 1962, pages 945 |
HURLEY ET AL., J. VASE. RES., vol. 47, no. 1, 2010, pages 80 - 90 |
IMBIMBO BP, CURR. TOP. MED. CHEM., vol. 8, no. 1, 2008, pages 54 - 61 |
ISHIKAWA Y ET AL., ONCOGENE, 4 June 2012 (2012-06-04) |
JOSEPH C. BURNS ET AL.: "Myc Gene Delivery to Adult Mouse Utricles stimulates Proliferation of Postmitotic Supporting Cells in vitro", PLOS ONE, vol. 7, no. 10, 30 October 2012 (2012-10-30), pages e48704, XP055472838, DOI: 10.1371/journal.pone.0048704 |
KABANOV ET AL., FEBS LETT., vol. 259, 1990, pages 327 |
KALTENBACH ET AL., J. NEUROPHYSIOL., vol. 88, no. 2, 2002, pages 699 - 714s |
KARAGIANNIS E D ET AL.: "ACS NANO 20131022", vol. 7, 22 October 2013, AMERICAN CHEMICAL SOCIETY, article "Rational design of a biomimetic cell penetrating peptide library", pages: 8616 - 8626 |
KORNBERG, A.: "Nucleotide Analogs", 1980, W. H. FREEMAN & CO., pages: 75 - 77 |
KUJAWA ET AL., J. NEUROSCI., vol. 29, no. 45, 2009, pages 14077 - 14085 |
KWAN ET AL.: "Int'l Symposium on Olfaction and Taste", ANN. N.Y. ACAD. SCI., vol. 170, 2009, pages 28 - 33 |
LAUBER ET AL., CARCINOGENESIS, vol. 25, no. 12, 2004, pages 2509 - 17 |
LEARY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 4045 |
LETSINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6553 |
LIN CP ET AL., ANTICANCER DRUGS, vol. 18, no. 2, 2007, pages 161 - 70 |
LOWY ET AL., CELL, vol. 22, 1990, pages 817 - 823 |
M. V. WILES: "Embryonic Stem Cell Differentiation in vitro", METH. ENZYMOL., vol. 225, 1993, pages 900, XP009097134, DOI: 10.1016/0076-6879(93)25057-9 |
MANGI ET AL., NAT. MED., vol. 9, 2003, pages 1195 - 201 |
MANOHARAN ET AL., ANN. N.Y. ACAD. SCI., vol. 660, 1992, pages 306 |
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 3, 1993, pages 2765 - 278 |
MANOHARAN ET AL., BIOORG. MED. CHEM. LET., vol. 4, 1994, pages 1053 |
MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, vol. 14, 1995, pages 969 |
MANOHARAN ET AL., TETRAHEDRON LETT., vol. 36, 1995, pages 3651 |
MANOHARAN M., BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1489, 1999, pages 117 - 139 |
MEINKOTHWAHL, ANAL. BIOCHEM., vol. 138, 1984, pages 267 |
MELMAN ET AL., HUM. GENE THER., vol. 17, 2008, pages 1165 - 1176 |
MERCK, MIZUMA ET AL., MOL. CANCER THER., vol. 11, no. 9, 2012, pages 1999 - 2009 |
MOON ET AL., NATURE REVIEWS GENETICS, vol. 5, 2004, pages 689 - 699 |
MORI ET AL., J. CELL. BIOCHEM. SUPPL., vol. 27, 1997, pages 35 - 41 |
N.K CHRISTIENSEN. ET AL., J. AM. CHEM. SOC., vol. 120, 1998, pages 5458 - 5463 |
NIELSEN ET AL., SCIENCE, vol. 254, 1991, pages 1497 |
OBERHAUSER ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 533 |
OSHIMA ET AL., CELL, vol. 141, no. 4, 2010, pages 704 - 716 |
OSHIMA, K. ET AL.: "Differential distribution of stem cells in the auditory and vestibular organs of the inner ear", J. ASSOC. RES. OTOLARYNGOL., vol. 8, 2007, pages 18 - 31, XP019476063 |
P. D. RATHJEN ET AL.: "Properties and uses of Embryonic Stem Cells: Prospects for Application to Human Biology and Gene Therapy", REPROD. FERTIL. DEV., vol. 10, 1998, pages 31, XP000916997, DOI: 10.1071/R98041 |
PAGE ET AL., J. MED. CHEM., vol. 55, no. 3, 2012, pages 1047 - 55 |
PARK S ET AL., J. CELL. BIOCHEM., vol. 91, no. 5, 2004, pages 973 - 86 |
PUROW B., ADV. EXP. MED. BIOL., vol. 727, 2012, pages 305 - 19 |
RENZKURZ, NUCL. ACIDS RES., vol. 12, 1984, pages 3435 |
RICHARDSONGUMPORT, NUCL. ACIDS RES., vol. 11, 1983, pages 6167 |
ROTMAN, PROC. NATL. ACAD. SCI. USA, vol. 47, 1961, pages 1981 - 1991 |
S. SIDE ET AL., J. BIOL. CHEM., vol. 278, no. 20, 2003, pages 18664 - 70 |
SAI ET AL., J. NEUROONCOL., vol. 107, no. 3, 2012, pages 487 - 501 |
SAISON-BEHMOARAS ET AL., EMBO J., vol. 10, 1991, pages 111 |
SHANNON KRAFT ET AL.: "Atohl induces auditory hair cell recovery in mice after ototoxic injury", THE LARYNGOSCOPE, vol. 123, no. 4, 11 March 2013 (2013-03-11), pages 992 - 999, XP055277861, DOI: 10.1002/lary.22171 |
SHEA ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 3777 |
SHEARMEN ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 8698 - 8704 |
SHIH ET AL., CANCER RES., vol. 67, 2007, pages 1879 - 1882 |
SIRIN ET AL., GENE, vol. 323, 2003, pages 67 |
SMETANINA ET AL., TOXICOL. APPL. PHARMACOL., vol. 255, no. l, 2011, pages 76 - 85 |
SMITH ET AL., NUCL. ACIDS RES., vol. 13, 1985, pages 2399 |
SVINARCHUK ET AL., BIOCHIMIE, vol. 75, 1993, pages 49 |
TAKEBAYASHI ET AL., DEV. BIO., vol. 307, 2007, pages 165 - 178 |
TOLCHER ET AL.: "J. Clin. Oncol.", vol. 30, 2012, HOFFMAN-LA ROCHE INC., pages: 2348 - 2353 |
TOULME, J.J., NATURE BIOTECHNOLOGY, vol. 19, 2001, pages 17 - 18 |
UHLMAN, E., DRUG DISCOVERY & DEVELOPMENT, vol. 3, 2000, pages 203 - 213 |
WEIHOFEN ET AL., SCIENCE, vol. 296, 2002, pages 2215 - 2218 |
WIGLER ET AL., CELL, vol. 11, 1977, pages 223 - 232 |
WOLFE ET AL., J. MED. CHEM., vol. 41, no. 6, 1998 |
ZASLOFF, M., NATURE, vol. 415, 2002, pages 389 |
ZHANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 109, no. 24, 2012, pages 9623 - 8 |
ZHENG ET AL., XENOBIOTICA, vol. 39, no. 7, 2009, pages 544 - 55 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
US12043653B2 (en) | 2014-10-29 | 2024-07-23 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
WO2017210553A1 (en) | 2016-06-03 | 2017-12-07 | Hough Ear Institute | Combination therapies for inner ear sensory hair cell regeneration/replacement |
CN109562140A (en) * | 2016-06-03 | 2019-04-02 | 霍夫耳科研究所 | For inner ear sensory hair cell regeneration/replacement conjoint therapy |
US11013752B2 (en) | 2016-06-03 | 2021-05-25 | Hough Ear Institute | Combination therapies for inner ear sensory hair cell regeneration/replacement |
CN109562140B (en) * | 2016-06-03 | 2023-01-03 | 霍夫耳科研究所 | Combination therapy for inner ear sensory hair cell regeneration/replacement |
CN115814097A (en) * | 2016-06-03 | 2023-03-21 | 霍夫耳科研究所 | Combination therapy for inner ear sensory hair cell regeneration/replacement |
CN106692989A (en) * | 2017-03-07 | 2017-05-24 | 大连民族大学 | Drug liposome/p53 gene compound and preparation method and application thereof |
CN110981943A (en) * | 2019-12-02 | 2020-04-10 | 清华大学 | Polypeptide, application thereof in preparation of medicine and medicine |
CN110981943B (en) * | 2019-12-02 | 2021-08-03 | 清华大学 | Polypeptide, application thereof in preparation of medicine and medicine |
Also Published As
Publication number | Publication date |
---|---|
EP3212773A1 (en) | 2017-09-06 |
EP3212773B1 (en) | 2021-09-15 |
US20170327557A1 (en) | 2017-11-16 |
US12043653B2 (en) | 2024-07-23 |
US20220281941A1 (en) | 2022-09-08 |
US11370823B2 (en) | 2022-06-28 |
EP3212773A4 (en) | 2018-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12043653B2 (en) | Efficient delivery of therapeutic molecules to cells of the inner ear | |
AU2020217408B2 (en) | Methods and compositions for regenerating hair cells and/or supporting cells | |
US11963968B2 (en) | Treatment of hearing loss | |
EP2381936B1 (en) | Pathways to generate auditory hair cells | |
US20170189477A1 (en) | Methods and Compositions of P27KIP1 Transcriptional Modulators | |
WO2022169881A1 (en) | Methods and compositions for regenerating hair cells in the inner ear of adult mammals | |
Shoda et al. | Inhibition of hypoxia-inducible factors suppresses subretinal fibrosis | |
Suthon | The Molecular Mechanisms of Estrogen Receptor α on Two Single Nucleotide Polymorphisms to Regulate WNT Signaling in Osteoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15855303 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015855303 Country of ref document: EP |